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CHAPTER 1 
GENERAL INTRODUCTION 

Chapter 1 
A INTRODUCTION 
Infection of the abdominal cavity is a serious and potentially life-threatening condition. 
When untreated, about 90% of all patients with intra-abdominal infection die from sepsis1. 
The conventional approach to manage intra-abdominal infection is elimination of the 
source of peritoneal contamination, removal of purulent material, parenteral administration 
of antibiotics and haemodynamic and respiratory support. This approach results in 
complete recovery of most patients with intra-abdominal infection. However, this combined 
treatment may fail in patients with severe intra-abdominal infection, caused for example 
by perforation of the colon, leakage of intestinal anastomosis and pancreatic necrosis. 
Mortality rate of patients with these conditions is still high, varying from 20% to 60%2'5. 
Many patients have persistent or recurrent intra-abdominal infection and eventually 
died due to multiple organ dysfunction syndrome56. 
The disappointing outcome in patients with these severe forms of intra-abdominal infection 
has stimulated the search, in the past 20 years, for alternative treatment. At least three 
new operative methods have been proposed in an attempt to reduce high mortality 
in this group of patients7. Common purpose of these new operative methods was early 
aggressive removal of all intra-abdominal material, such as fibrin, tissue necrosis, and 
visceral content, that would potentiate intra-abdominal infection. 
The first new operative method was radical peritoneal debridement e.g. elimination 
of all adherent fibrinous deposits on peritoneal surfaces. In the original nonrandomized 
trial of peritoneal debridement, mortality was extremely low8. A subsequent randomized 
study did not show benefit from extensive debridement of fibrinous deposits9. 
The second development was continuous postoperative peritoneal lavage10'14. In this 
technique, the problem inciting intra-abdominal infection is corrected, the abdomen 
is washed with normal saline solution, and drains are placed in the paracolic gutters 
and other accessible areas for infusion of peritoneal dialysis solution. The dialysis 
solution is evacuated from the abdomen through strategically positioned drains with 
the aid of gentle suction. The aim is to wash out infectious material, including bacteria, 
to prevent further intra-abdominal pus collections. One half of the studies reported 
in the literature indicates improved survival with this technique; the other half refutes 
such a benefit15. 
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The third technique involved variations of the "open abdomen" approach for treatment 
of intra-abdominal infection16"22. In the "open" treatment of intra-abdominal infection, 
the abdominal cavity is treated as if it is an abscess cavity. After elimination of the 
source of infection, the abdominal incision is left open, providing free drainage of exudates 
and free access to the peritoneal cavity. Variations of this technique are the "semi-open" 
treatment and the method of "planned relaparotomy". In the "semi-open" treatment, 
the abdomen is temporarily closed without tension by artificial material, such as Marlex® 
mesh, Ethizip®, or Velcro® analogue, to prevent evisceration21"26. In the method of 
"planned relaparotomy", the abdominal cavity is re-explored at regular intervals (24 
to 48 hours) to remove fibrin, necrotic tissue and other material that potentiate infection26" 
32
. Several authors have demonstrated reduced mortality associated with the "open 
abdomen" approach or its variations. However, evaluation of these studies is difficult 
since they were nonrandomized, and heterogeneous patients groups were 
examined7,21,22,32. 
Although all these new operative methods were promising initially, they failed to gain 
wide acceptance, because improved outcome was not evident. Furthermore, these 
procedures were accompanied by serious intra-abdominal complications, such as 
haemorrhage, fistula formation and abdominal wall hernia26,31,33"36. 
Analogous to new operative methods, newer antibiotics, such as third generation 
cephalosporins or imipenem, monoclonal antibodies, such as human monoclonal antibody 
against endotoxin (HA-1A), and improvements in cardiovascular, respiratory, and renal 
support, have initially shown promising results, but have not evidently improved prognosis 
of patients with severe intra-abdominal infection in the past 10 to 20 years7,37"41. 
So, a new search for alternatives or adjuvants to the present treatment seems warranted. 
A T H E ROLE OF FIBRIN AND FIBRINOLYSIS IN INTRAABDOMINAL INFECTION 
It is generally accepted that residual or recurrent intra-abdominal infection promotes 
the development and progression of organ dysfunction5·642"45. Progressive organ 
dysfunction, induced by intra-abdominal infection, has a poor prognosis5,6. Delayed 
treatment of intra-abdominal infection often does not reverse organ dysfunction, whereas 
early intervention is more successful646"52. Prevention of residual or recurrent intra-
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abdominal infection most likely improves prognosis. 
Fibrin plays a crucial role in localizing infection in the abdominal cavity53"55. Thereby, 
fibrin protects the host from overwhelming bacteraemia54. However, fibrin also protects 
bacteria against host defense and antibiotics, and thereby favours residual or recurrent 
intra-abdominal infection53. 
Prevention of intra-abdominal fibrin formation may prevent residual or recurrent infection, 
which in turn may improve prognosis, particularly of patients initially operated on for 
severe intra-abdominal infection. Mechanical removal of fibrin during the initial operation 
has not evidently shown to increase survival in patients with intra-abdominal infection9. 
This may be due to intra-abdominal complications, such as bleeding and fistula formation, 
introduced by this technique. Furthermore, immediate recurrence of intra-abdominal 
fibrin deposition after operation may be expected. Repeated mechanical removal of 
fibrin deposits, as in the method of "planned relaparotomy", has decreased the rate 
of residual intra-abdominal abscesses30,32. However, this method introduces marked 
morbidity, which may adversely effect patient prognosis32,56. The complications of this 
surgical technique, applied in patients with severe intra-abdominal infection, due to 
colonic perforation or anastomotic leakage, or infected pancreatic necrosis, are outlined 
in more detail in Chapter 6 and 7. 
An alternative to mechanical removal is enzymatical removal of fibrin. The enzymatic 
degradation of fibrin is carried out by the natural fibrinolytic system. During intra-
abdominal infection the fibrinolytic system seems to be impaired57,58. Impaired fibrinolysis 
may be responsible for persistence of intra-abdominal fibrin and thereby development 
of residual intra-abdominal infection. Conceivably, enhancement of fibrinolysis in the 
abdominal cavity may prevent development of residual infection59. 
In this thesis, we focused on fibrin formation and fibrinolysis in the abdominal cavity 
during intra-abdominal infection and the effect of enhancement of intra-abdominal 
fibrinolysis on residual intra-abdominal infection. The following objectives of study were 
formulated. 
¿OBJECTIVES 
1. What is the effect of intra-abdominal infection on fibrin formation and 
fibrinolysis in the abdominal fluid and plasma and how does the fibrinolytic 
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activity relate to peritoneal injury (Chapter 8 and 9)? 
2 Does human recombinant tissue-type plasminogen activator (rtPA) -a 
fibrinolytic agent- effect the rat fibrinolytic system (Chapter 10)? What 
are the pharmacokinetics of human rtPA administered into the abdominal 
cavity of rats with intra-abdominal infection (Chapter 11 )? 
3 What are the effects of human rtPA on mortality and intra-abdominal 
abscess formation in rats with intra-abdominal infection (Chapter 12)? 
4 Does combined treatment of human rtPA and gentamicin improve outcome 
in rats with intra-abdominal infection (Chapter 13)? 
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Chapter 2 
AANATOMY A N D PHYSIOLOGY OF T H E ABDOMINAL CAVITY 
The abdominal cavity is the largest preformed extravascular space in the body. Normally 
the viscera within the abdominal cavity are in contact along their serosal surfaces. 
Therefore, the abdominal cavity contains less than 50 ml of clear yellow fluid. This 
fluid is normally sterile and has a specific gravity of less than 1.016 and a protein level 
of less than 30 g/l, most of which is albumin. The peritoneal fluid contains fewer than 
3,000 cells/mm3, with 50 percent macrophages, 40 percent lymphocytes, a few 
eosinophils and mast cells, and an occasional mesothelial cell1. 
The peritoneum lines the abdominal cavity as the parietal peritoneum and reflects 
onto the abdominal viscera as the visceral peritoneum. In adults, the area of peritoneal 
surface approximates that of the cutaneous surface, which is about 1.7 m2. The 
peritoneum consists of a single layer of flat mesothelial cells, that resides on a basement 
membrane, which, in turn, overlies a bed of connective tissue consisting of fat cells, 
macrophages, fibroblasts, lymphocytes, a few mast cells, and collagen and elastic 
fibres2. The peritoneum is a smooth, translucent membrane. Most of this membrane 
behaves as a passive, semipermeable barrier to the bidirectional diffusion of water 
and low molecular weight solutes. Studies of dialysis patients have shown that the 
functional exchange surface of the abdominal cavity is approximately one square meter*. 
Factors that alter the fluid exchange are changes in the membrane area, in the splanchnic 
blood flow, and in the peritoneal membrane permeability4 5. 
Although the entire peritoneal surface participates in fluid and low molecular weight 
solute exchange, particulate material is cleared through stornata between specialised 
peritoneal mesothelial cells that overlie lymphatic channels on the diaphragmatic surface 
of the abdominal cavity2,6"8. These intercellular stornata correspond with fenestrations 
in the basement membrane, and together they serve as channels leading from the 
abdominal cavity to the underlying specialised diaphragmatic lymphatic vessels called 
lacunae (Figure 1)7B. 
Fluid flows rapidly through the stornata into the lacunae with relaxation of the diaphragm, 
e.g. during expiration. Contraction of the diaphragm, during inspiration, empties the 
lymphatics into efferent ducts, aided by the simultaneous drop in intrathoracic pressure. 
One-way valves in the thoracic lymphatics prevent reversed flow. Injection of contrast 
material into the abdominal cavity has demonstrated a cephalad flow into the upper 
abdomen (suprahepatic and intrahepatic spaces), as well as into the pelvis and paracolic 
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gutters10. Movements into the upper abdomen probably represent flow into a region 
of low pressure produced by absorption of fluid and material by the diaphragmatic 
lymphatics and a suction effect caused by the pull of gravity on the upper abdominal 
viscera, particularly the liver, away from the diaphragm (Figure 2)11. Flow into the pelvis 
and the paracolic gutters is likely the effect of gravity in the prone or semi-upright position. 
PERITONEAL 
STOMATA 
Figure 1. Schematic view of peritoneal stornata and underlying lymphatic tissue. Over the 
lymphatics, mesothelial cells are small, with stornata between the cells. Through these 
stornata and corresponding fenestrations of the basement membrane, the abdominal cavity 
communicates with lymphatic lacunae, which are lined by lymphatic endothelium. 
(Modified from Allen L2) 
The size of the stornata (8 to 12 μτη) determines the maximum size of particles that 
are readily absorbed from the abdominal cavity. Bacteria, which average 0.5 to 2 μτη, 
pass easily through these stornata. After inoculation in the abdominal cavity, bacteria 
26 
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are recoverable from the right thoracic lymph duct of dogs within six minutes and from 
the blood within 12 minutes12. Bacteria are not absorbed to any extent from 
nondiaphragmatic peritoneal surfaces. 
Figure 2. Circulation of fluid and particles in the abdominal cavity. Solid arrows indicate 
the direction of flow, generated by diaphragmatic movement and absorption of material 
from the diaphragmatic lymphatics. Dashed arrows demonstrate the effect of gravity in 
the upright position. 
(Modified from Autio Vм) 
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Various factors can affect peritoneal clearance of particulate matter, such as bacteria 
(Table 1)12"17. Already in 1900, Fowler used the semi-upright position in nine patients 
with intra-abdominal infection to prevent the rapid absorption of "toxins" from the 
abdominal cavity13. In 1944, Steinberg showed that absorption of bacteria from the 
abdominal cavity was delayed by the upright position and accelerated by the head-down 
position12. In dogs, laparotomy with manipulation of the viscera, leading to ileus, causes 
a delayed clearance time of peritoneal graphite particles14. Phrenic neurectomy, with 
resultant diaphragmatic paralysis, initially delays absorption on the denervated site; 
the absorption is later accelerated as the muscles atrophy14. Increased intraperitoneal 
pressure accelerates the clearance of material from the abdominal cavity15. Depression 
of spontaneous respiration and increased intrathoracic pressure decrease efferent 
lymph flow and bacterial clearance from the abdominal cavity16,17- All these mechanical 
factors may greatly influence the ability of the abdominal cavity to handle bacterial 
inocula. 
Table 1. Factors impairing mechanical clearance of fluid and particles from the abdominal 
cavity. 
Factor 
Posture (head up/pelvis down) 
Hypoventilation (general anaesthetics, 
phrenic neurectomy) 
Mechanical ventilation, especially with 
positive end-expiratory pressure 
Ileus 
Ascites 
Effect 
Impaired gravitational drainage 
Altered diaphragmatic pumping action 
Constant positive intrathoracic 
pressure 
Impaired intra-abdominal circulation 
Overwhelmed lymphatics 
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ж HOST RESPONSE TO INTRAABDOMINAL INFECTION 
Local response 
After bacterial contamination of the abdominal cavity, a complex series of events is 
initiated by the host in order to eradicate invading bacteria. These local host defense 
mechanisms are: (1) mechanical clearance of fluid and bacteria via the diaphragmatic 
lymphatics, (2) phagocytosis and destruction of bacteria by phagocytic cells, and (3) 
sequestration of bacteria. 
(1) After intra-abdominal inoculation, bacteria begin to disappear from the abdominal 
cavity immediately, even before the influx of phagocytic cells18. As mentioned before, 
bacteria are recoverable from the right thoracic lymph duct within six minutes and 
from the blood within 12 minutes after intra-abdominal inoculation12. Bacteria are 
transported by the abdominal fluid circulation via the paracolic gutters to the left and 
right subdiaphragmatic spaces (Figure 2)10·19. These observations suggest that the 
first line of defense in the abdominal cavity is physical removal, whereby bacteria are 
carried cephalad by the abdominal fluid circulation, absorbed into the diaphragmatic 
lymphatics, and then carried to the bloodstream. 
(2) The second line of defense is phagocytosis and killing of bacteria by phagocytic 
cells. Influx of phagocytic cells into the abdominal cavity is part of the initial peritoneal 
response to bacterial contamination, which is further characterized by vasodilatation 
and fluid exudation20. Peritoneal macrophages predominate in the abdominal cavity 
in the first four hours of infection. Thereafter, neutrophils are the most important 
phagocytic cells for 48 to 72 hours18. After about 48 to 72 hours macrophages again 
predominate in the inflammatory process. Influx of phagocytes into the abdominal cavity 
is mediated by bacterial cell products (e.g. lipopolysaccharide), complement cleavage 
products (specifically C5a), inflammatory proteins (kinins, histamine) and cytokines 
such as tumor necrosis factor (TNF) and interleukins (IL-1, IL-6, IL-8)20"31. Many of 
these cytokines are released by macrophages. Lipopolysaccharide, derived from gram-
negative enteric bacteria, is a particularly strong stimulus for release of cytokines by 
peritoneal macrophages. These enteric bacteria are most commonly found in intra­
abdominal infectious processes. 
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After Chemotaxis, invading organisms must be ingested and destroyed Particularly, 
encapsulated micro-organisms, are able to resist ingestion by human phagocytes and 
must be opsonized with a sufficient amount of specific antibody to be ingested32 Activated 
C3 and IgG are the best-characterized and most important opsonins On contact of 
the opsonized bacteria with the phagocyte, fusion processes are initiated, followed 
by degranulation of antimicrobial products, that eventually kill the bacteria3336 
(3) The third line of defense is sequestration of bacteria Fibrin plays a crucial role 
in walling off infection by incorporating bacteria in its matrix and by creating a physical 
barrier against dissemination through formation of intra-abdominal adhesions1923373* 
The entrapment of bacteria during the clotting process is highly effective Fibrin also 
impairs the clearance of bacteria from the abdominal cavity by occluding the diaphragmai 
stornata39 Furthermore, local fibrin deposition seems to stimulate the inflammatory 
response by increasing vascular permeability and Chemotaxis of neutrophils and 
monocytes40'42 By all these actions, fibrin protects the host against early systemic 
spread of bacteria and subsequent death37 
If these peritoneal defense mechanisms fail in controlling intra-abdominal infection, 
the peritoneal cavity is flooded with infectious material Under these circumstances, 
the peritoneal defense mechanisms may have detrimental effects on the host Five 
interacting mechanisms are responsible for the failure to control infection (1) fluid 
exudation into the abdominal cavity, (2) impairment of the immunological defense 
mechanisms, (3) adjuvant substances, (4) bacterial synergism, and (5) fibrin 
(1 ) The influx of large amounts of protein-nch exudate into the abdominal cavity produces 
massive third-space fluid shifts These exudates impair bactenal opsonization by diluting 
opsonins and reduce the ability of phagocytic cells to reach and to phagocytose the 
bacteria43 Absorption of these intraperitoneal exudates and bacteria is disturbed by 
occlusion of the diaphragmai stornata 
(2) The immunological defense mechanisms are impaired by dilution of chemotaxic 
factors and opsonins, by adjuvant substances, and by fibrin Adjuvant substances, 
such as bile salts, gastric mucin, faeces, barium sulphate, necrotic tissue, blood 
components, and foreign bodies, inhibit the migration and killing capacity of neutrophils 
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and result in premature release of oxygen radicals by these cells18,44"54. It has been 
demonstrated that fibrin inhibits phagocytic killing of Escherichia coli (E. coli) by 
neutrophils and impedes macrophage migration55,56. This inhibition is related to impairment 
of phagocytosis rather than irreversible damage to the killing system of the neutrophiP5. 
Impairment of phagocytosis might be due (i) to the physical entrapment of neutrophils 
preventing locomotion, (ii) to reduced opsonization of bacteria in a fibrinous environment, 
and (iii) to premature release of lysosomal enzymes in the presence of activated 
complement components along fibrin strands. 
(3) Adjuvant substances not only impair immunological defense mechanisms, but promote 
bacterial growth. Haemoglobin, for example, enhances bacterial growth and increases 
bacterial virulence8. In vitro addition of iron to a culture medium enhances growth of 
E coli*9. 
(4) More so than a monomicrobial infection, a polymicrobial intra-abdominal infection 
enhances lethality and the formation of residual abscesses. Herein, synergism between 
anaerobic and aerobic bacteria plays an important role. Especially the synergism between 
Bacteroides fragilis and E coli has been studied in vitro and in vivo57"62. The possible 
mechanisms of their synergy are: (i) the ability of one species to provide growth nutrients 
for its bacterial partner, (ii) the ability of one species to impair host defenses, permitting 
its co-pathogen to survive and exert its intrinsic virulence, and (iii) the ability of the 
species to optimize local environment, thereby enhancing bacterial proliferation. 
(5) Fibrin entraps bacteria and provides a protected environment, in which bacteria 
may proliferate almost unaffected by neutrophils. As mentioned, fibrin also impairs 
neutrophil function55. Fibrin blocks diaphragmai stornata and thereby prevents absorption 
of intra-abdominal fluid and bacteria39. 
Impairment of function of neutrophils due to bacteria, fibrin, and adjuvant substances, 
is accompanied by premature extracellular release of neutrophil enzymes63. During 
intra-abdominal infection, these enzymes are present in such concentrations in the 
peritoneal fluid, that the neutralizing activity of inhibitors of these enzymes, such as 
alpha-1 protease inhibitor (complexing leukocyte elastase), is insufficient64. Neutrophil 
enzymes are capable of damaging viable tissue, resulting in necrosis. In addition to 
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the enzymes liberated by neutrophils, bacteria themselves produce a number of 
exoenzymes, such as hyaluronidase and lipase, that cause tissue destruction65. In 
such an environment, characterized by hypoxia and a low pH, neutrophil function is 
further impaired and bacterial growth is stimulated66"74. Tissue necrosis, fibrin and bacteria 
augment the severity of the inflammatory process with continuous influx of neutrophils 
and macrophages. This process may readily become self-perpetuating, even in the 
absence of bacteria. 
Systemic response 
The systemic response to intra-abdominal infection mimics the body's response to 
trauma in general and includes the rapid release of catecholamines, increased secretion 
of adrenocortical hormones and secretion of aldosterone and antidiuretic hormone11. 
Of particular importance are the haemodynamic and cytokine responses to intra-
abdominal infection. 
The haemodynamic alterations observed in patients with intra-abdominal infection 
are mainly due to hypovoiaemia. Diffuse intra-abdominal infection has been likened 
to a total burn surface of 50 percent in terms of its effect on fluid shifts. A massive 
fluid shift into the peritoneal tissues and cavity produces hypovolaemic shock with 
a reduced cardiac index, elevated peripheral vascular resistance, and increased 
peripheral oxygen extraction. After fluid resuscitation, patients with severe intra-abdominal 
infection demonstrate the more classic "septic" (hyperdynamic) response: elevated 
cardiac output, reduced peripheral vascular resistance, and a narrowing arterio-venous 
02 content difference75,76. 
As proposed for the local response to infection in the abdominal cavity, the stimulated 
release of products of cells of the monocyte-macrophage lineage also appears to be 
responsible for the characteristic systemic host response observed in patients with 
intra-abdominal infection. Intravenous infusion of TNF into experimental animals mimics 
the haemodynamic alterations and lactate acidosis that follow the administration of 
bacterial endotoxin77. Both TNF and IL-1 cause fever and neutrophilia, and IL-6 initiates 
the acute-phase protein response characteristic of infection77"79. The central role of 
these cytokines in mediating the systemic host response is further illustrated by the 
ability of antibodies directed against either TNF or IL-6 to abrogate the adverse effects 
of endotoxaemia8061. 
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д INTRAABDOMINAL INFECTION 
Intra-abdominal infection or intra-abdominal sepsis is defined as an inflammatory process 
of bacterial origin in the abdominal cavity. 
There are two major manifestations of intra-abdominal infection: bacterial peritonitis 
or infection of the peritoneum, and intra-abdominal abscess, in which infection has 
become walled off from the remainder of the abdominal cavity1. 
APERITONITIS 
Peritonitis is defined as an inflammation of (part of) the peritoneum. Peritonitis may 
be divided in bacterial, chemical, ischaemic or mechanical peritonitis, based on the 
type of peritoneal injury. Another classification is that of a local or a generalized (diffuse) 
peritonitis, based on the extent of peritoneal inflammation. Other terms as severe, 
suppurative or fulminant peritonitis often refer to serious forms of generalized peritonitis, 
in which the abdomen is flooded with pus, and patients are critically ill. 
The classification into (1) primary peritonitis, (2) secondary peritonitis, and (3) tertiary 
peritonitis, based on aetiology, is most commonly used1"3. 
(1) Primary peritonitis is defined as a diffuse bacterial infection of the abdominal cavity 
in which there is no obvious source, such as a perforated viscus. 
Primary peritonitis classically occurs in young girls and is caused by Streptococcus 
pneumoniae*·5. The incidence of primary peritonitis in children has decreased after 
antibiotics became available56. This form of peritonitis is being recognised with increasing 
frequency in the adult population. In adults, the presence of alcoholic cirrhosis and 
ascites is the most frequent underlying risk factor78. Cirrhotic ascites predisposes to 
infection because of reduced total protein and complement levels, which result in impaired 
bacterial opsonization9. In patients with cirrhosis, monomicrobial infections with enteric 
bacteria, particularly Escherichia coli (E. coli), predominate, whereas a polymicrobial 
flora is present in less than 10 percent of the cases10. 
Rare forms of primary peritonitis are tuberculous peritonitis (caused by Mycobacterium 
species), abdominal actinomycosis and amoebic peritonitis. 
41 
Intra-abdominal infections 
(2) Secondary peritonitis is defined as a peritoneal inflammation due to perforation 
of a hollow viscus or transmural necrosis of the gastrointestinal tract. Common causes 
of secondary peritonitis are perforated appendix, perforated duodenal ulcer, perforated 
sigmoid colon due to diverticulitis, volvulus or cancer, strangulation obstruction of the 
small intestine, and postoperative peritonitis due to anastomotic leakage. Pancreatic 
necrosis is also considered as a cause of secondary peritonitis. 
The spectrum of microorganisms inoculating the peritoneum after perforation of the 
gastrointestinal tract depends on the level of perforation as well as the pathologic process 
leading to the perforation. Stone et al. did not find bacteria in the abdominal cavity 
when a normal human duodenum was perforated11. Gram-positive bacteria are 
predominantly released in perforations of the upper gastrointestinal tract. However, 
patients who have been taken antacids or H2-receptor blockers have greater numbers 
of gram-negative bacteria in their stomach before perforation12,1Э. Bacterial peritonitis 
due to a perforation of the distal small intestine or the colon is almost always 
polymicrobial, containing a mixture of aerobic and anaerobic bacteria14. Most common 
aerobic and anaerobic species, that are found in the abdominal cavity of patients with 
secondary bacterial peritonitis, are E. coli and Bacteroides fragilis (B. fragilis), 
respectively14,15. 
A special form of secondary bacterial peritonitis, that often is categorized as primary 
peritonitis, is peritonitis in patients on continuous ambulatory peritoneal dialysis. The 
infection is commonly from exogenous sources, usually by Staphylococcus epidermidis 
(St. epidermidis)i/t6. Treatment differs from other forms of secondary peritonitis as 
to the elimination of the source of infection, i.e. the dialysis catheter. Primarily, antibiotics 
are administered, while the catheter remains in situ. 
(3) Tertiary peritonitis is defined as a persistent inflammation of the abdominal cavity, 
associated with multiple organ dysfunction and general depression of the immune 
system. Patients with tertiary peritonitis are unable to localize infection, whether due 
to impaired host defense mechanisms or overwhelming infection11. 
St. epidermidis, Pseudomonas species and Candida species are the predominant 
microorganisms recovered from these patients17,18. The common microorganisms isolated 
from patients with secondary bacterial peritonitis, E. coli and B. fragilis, are only 
occasionally found in these patients. In a number of patients with tertiary peritonitis, 
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no bacteria are isolated from the abdominal cavity. The bacteria comprising the flora 
of tertiary peritonitis have classically been considered innocuous colonizers rather 
than true pathogens. However, the fact that these bacteria are true invasive pathogens 
rather than merely colonising bacteria is clearly demonstrated by their ability to become 
blood-bome. It is therefore likely that a relatively immunocompromised host contributes 
to their pathogenicity. 
Several lines of evidence suggest that the bacteria found in the abdominal cavity of 
patients with tertiary peritonitis originate from the gastrointestinal tract19·20. In experimental 
models, the migration of enteric bacteria through the intestinal wall, a process called 
bacterial translocation, into sterile inflammatory processes in the abdominal cavity 
has been shown19,21. A study in patients with multiple organ dysfunction has demonstrated 
a correlation between upper gastrointestinal tract flora and invasive infection with the 
same organisms17. Moreover, it has been reported that small intestinal bacterial 
overgrowth, which is an important cause of bacterial translocation, depresses the immune 
system2223. This event may then initiate a vicious circle leading to further bacterial 
translocation and a worsening of the immune-compromised state of the host. 
* INTRAABDOMINAL ABSCESS 
Intra-abdominal abscesses are well-defined collections of pus which are walled off 
from the rest of the peritoneal cavity by inflammatory adhesions, loops of intestine 
and their mesentery, the greater omentum, or other abdominal viscera. Intra-abdominal 
abscesses represent the successful result of normal host defense mechanisms in the 
abdominal cavity. These abscesses arise in two situations: (i) after resolution of diffuse 
intra-abdominal infection in which a loculated area of infection persists and evolves 
into an abscess, and (ii) after perforation of a viscus or an anastomotic breakdown 
that is successfully walled off by peritoneal defense mechanisms. 
Intra-abdominal abscesses almost always consist of both aerobic and anaerobic 
bacteria15,2". As in secondary bacterial peritonitis, most common bacteria isolated from 
the abscess cavity are E. coli and 8. rrag///s15. The abscess cavity is a microenvironment, 
characterized by hypoxia, low pH, large numbers of bacteria in the stationary phase, 
and high concentrations of bacterial toxins and proteases12,25. In such an environment 
host defense mechanisms are impaired and antibiotic efficacy is reduced 2β"2β. 
43 
Intra-abdominal infections 
AREFERENCES 
1 Rotstein OD Peritonitis and intra-abdominal abscesses In Surgical Infections diagnosis and 
treatment Meakms JL (Ed) New York, Scientific American Ine, 1994 329-51 
2 Wittmann DH Intra-abdominal infections-Introduction World J Surg 1990,14 145-7 
3 Pollock AV Nonoperative anb-infective treatment of intra-abdominal infectons World J Surg 
1990,14 227-30 
4 Harken AH, Shochat S J Gram-positive pentonitis in children Am J Surg 1973,125 769-72 
5 McDougal WS, Izant RJ Jr, Zollinger RM Jr Pnmary pentonitis in infancy and childhood Ann 
Surg 1975,181 310-3 
6 Golden GT, Shaw A Pnmary pentonitis Surg Gynecol Obstet 1972,135 513-6 
7 Conn HO, Fessel JM Spontaneous bactenal peritonitis in cirrhosis vanatrons on a theme Mediane, 
Baltimore 1971,50161-97 
8 Wyke RJ Problems of bactenal infection in patients with liver disease Gut 1987,28 623-41 
9 Akalin HE, Laleli Y, Telatar H Bactencidal and opsonic activity of ascitic fluid from cirrhotic and 
noncirrhotic patients J Infect Dis 1983,147 1011-7 
10 Correla JP, Conn HO Spontaneous bactenal pentonitis in cirrhosis endemic or epidemic? Med 
Clin North Am 1075,59 963-81 
11 Stone H, Kolb LD, Geheber CE, et al Incidence and significance of intraperitoneal anaerobic bacteria 
Ann Surg 1975,181 705-15 
12 Rotstein OD, Meakms JL Diagnostic and therapeutic challenges of intra-abdominal infections 
World J Surg 1990,14 159-66 
13 Ruddell WJS, Axon AT, Findlay JM Effect of Cimetidine on the gastnc flora Lancet 1980,1 672-4 
14 Lortoer B, Swenson RM The bactenology of intra-abdominal infections Surg Clin North Am 
1975,55 1349-54 
15 Hau Τ, Haaga JR, Aeder Ml Pathophysiology, diagnosis, and treatment of abdominal abscesses 
Curr Probi Surg 1984,21 1-82 
16 Vas SI Pentonitis dunng CAPD a mixed bag Pent Dial Bull 1982,1 47 
17 Marshall JC, Chnstou NV, Horn R The microbiology of multiple organ failure The proximal 
gastrointestinal tract as a reservoir of pathogens Arch Surg 1988,123 309-15 
18 Rotstein OD, Pruett TL Simmons RL Microbiologic features and treatment of persistent pentonitis 
in patients in the intensive care unit Can J Surg 1986,29 247-50 
19 Schweinburg FB, Seligman AM, Fine J Transmural migration of intestinal bactena a study based 
on the use of radioactive Escherichia coll N Engl J Med 1950,242 747-51 
20 Wells CL, Maddeus MA, Simmons RL Proposed mechanisms for the translocation of intestinal 
bactena Rev Infect Dis 1988,10 958-79 
21 Wells CL, Rotstem OD, Pruett TL Intestinal bactena translocate into expenmental intra-abdominal 
abscesses Arch Surg 1986,121 102-7 
22 Marshall JC, Chnstou NV, Meakms JL Small bowel bactenal overgrowth and systemic 
immunosuppression in expenmental pentonitis Surgery 1988,102 404-11 
44 
Chapter 3 
23 Marshall JC, Chnstou NV, Meakins JL Immunomodulation by altered gastrointestinal tract flora 
Arch Surg 1988,123 1465-9 
24 Wang SM, Wilson SE Subfrenic abscesses The new epidemiology Arch Surg 1977,112 934-6 
25 Bartlett JG, Sullivan-Sigler N, Louis TJ, et al Anaerobes survive in clinical specimens despite 
delayed processing J Clin Microbiol 1976,3 133-6 
26 O'Keefe JP, Tally FP, Barza M, et al Inactivation of penicillin G in experimental anaerobic infections 
J Infect Dis 1978,137 437-42 
27 Hau Τ, Nishikawa RA, Phuangsab A The effect of bacterial trapping by fibnn on the efficacy of 
systemic antibiotics in experimental peritonitis Surg Gynecol Obstet 1983,157 252-6 
28 Klempner MS, Styrt В Alkalmizing the mtralyposomal pH inhibits degranulation of human neutrophils 
J Clin Invest 1983,72 1793-800 
45 

CHAPTER 4 
SURGICAL TREATMENT OF INTRAABDOMINAL INFECTION 

Chapter 4 
•INTRODUCTION 
Surgery is the primary treatment modality to manage intra-abdominal infection, caused 
by perforation of a hollow viscus or transmural necrosis of the gastrointestinal tract, 
or caused by pancreatic necrosis. In 1926, the operative management of intra-abdominal 
infection has been defined by Kirschner as 'Ausshaltung der Infektionsquelle, Beseitigung 
des Exsudates, Behandlung der Bauchhölle mit Desinfektionsmitteln und Ableitung 
des Exsudates'1. Nowadays the elimination or control of the infectious source, and 
the reduction of peritoneal contamination by debridement and lavage are still the 
cornerstones of primary operative treatment2. 
•SOURCE OF INFECTION 
In general the source of infection is eliminated, avoiding continuous peritoneal soiling, 
by resection or closing the perforated viscus, or resection of necrosis. 
For pathology located in the large intestine, resection is usually performed, followed 
by creation of a proximal enterostomy (Hartmann's procedure). In this location, primary 
anastomosis is avoided because of the high risk of anastomotic dehiscence3. 
The risk associated with primary anastomosis of the small intestine, following resection 
of a diseased segment, is considered much lower. However, if peritoneal soiling is 
particularly extensive, resection plus proximal and distal enterostomy is advocated4,5. 
Suturing a perforation is mainly performed today for perforated peptic ulcer. Additionally, 
it may be considered for single, small, foreign body or traumatic perforations of the 
small intestine, diagnosed early5. 
• DEBRIDEMENT AND LAVAGE 
Reduction of peritoneal contamination by debridement and intraoperative lavage is 
intended to prevent residual infection. As discussed in Chapter 2, adjuvant substances 
as foreign material, necrotic tissue, fibrin, bile, blood or intestinal content enhance 
the severity of the infectious process by stimulation of bacterial growth and impairment 
of neutrophil and macrophage function. 
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"Radical debridement" -eliminating all ad herent fibrinous deposits on peritoneal surfaces-
was advocated by Hudspeth6. In his series of 92 patients with peritonitis treated by 
"radical debridement", only one intra-abdominal abscess developed, and all patients 
recovered. However, in a prospective randomized trial of 46 patients with diffuse 
peritonitis, receiving either standard surgical therapy or "radical debridement", Polk 
and Fry did not find better results from the radical operation7. On the contrary, excessive 
bleeding from serosal surfaces and intestinal perforations was more often encountered 
attributed to mechanical removal of fibrin. 
Intraoperative lavage has become a standard procedure2 8. However, in clinical studies 
the efficacy of intraoperative lavage has not well been documented89. Intraoperative 
lavage is applied to reduce the quantity of bacteria and to remove adjuvant substances, 
thus supporting the local host defense mechanisms10,11. The fear of disseminating 
bacteria by lavage is probably unfounded, since it has been demonstrated in animal 
experiments that, even without irrigation, locally applied particles spread rapidly 
throughout the peritoneal cavity by the abdominal fluid circulation12. 
The question whether the lavage solution should contain antibiotic or antiseptic 
preparations is still widely discussed. From recent reviews on this subject, it appears 
that intraoperative lavage with antibiotics or antiseptics does not improve outcome 
in patients with intra-abdominal infection, who already receive appropriate systemic 
antibiotics8·8. 
There is a great variance in surgical strategies to be followed after elimination of the 
source, debridement and intraoperative lavage, especially in patients with severe intra-
abdominal infection. These strategies vary from a conservative "wait and see" policy 
to the most aggressive method of "planned relaparotomy". Four strategies may be 
distinguished: (1) "wait and see" policy with or without tube drainage, (2) continuous 
postoperative peritoneal lavage, (3) "open" drainage (laparostomy), and (4) "planned 
relaparotomy"2. 
(1) In the "wait and see" policy surgeons rely on host defenses, eradicating bacteria 
and adjuvant substances, that remain intraperitoneally after the first operation. However, 
in severe forms of intra-abdominal infection, host defenses are not likely to eradicate 
remaining bacteria and adjuvant substances. This is illustrated by the high incidence 
of residual intra-abdominal infection in patients with diffuse peritonitis, treated according 
50 
Chapter 4 
to the "wait and see" policy13"16. 
In the "wait and see" policy, surgeons also rely on clinical signs of residual or recurrent 
intra-abdominal infection for the decision whether or not to re-explore the abdominal 
cavity (i.e. "on demand" relaparotomy). 
Clinical signs of residual intra-abdominal infection are often blunted in patients, who 
are critically ill and cared for in intensive care units. Furthermore, diagnostic 
investigations, such as ultrasound or computed tomography, for the detection of residual 
infection are often not conclusive or impossible to perform. Therefore, most "on demand" 
relaparotomies are performed on the basis of, otherwise unexplained, progressive 
organ dysfunction or bacteraemia17'22. These relaparotomies are technically difficult 
to perform, have a high morbidity, and often do not reverse organ dysfunction, even 
when infectious foci are encountered and drained18,19,23·24. 
Tubes are meant to drain residual blood, pus, peritoneal fluid, and necrotic material 
in the postoperative period25. In diffuse intra-abdominal infection the rale of tube drainage, 
if any, seems to be a minor one2627. This is predominantly caused by the rapidity in 
which drains will be sealed off by fibrin deposition or in which fibrinous drain tracts 
are formed, that do not communicate with the abdominal cavity as such28'31. Beside 
the fact that drains simply do not work from the beginning, tubes placed intraperitoneally 
may cause visceral and vessel wall erosion with fistula formation and bleeding232. 
Moreover, drains like other foreign bodies impair neutrophil function and potentiate 
infection33. The risk of being an access route for external bacteria into the abdominal 
cavity, although present, should not be overestimated in this situation34,35. The only 
indications for intra-abdominal drains are evacuating well-defined abscesses, and offering 
a preferential pathway for the escape of visceral secretions, such as bowel content, 
pancreatic juice and bile38. 
(2) The concept of continuous postoperative peritoneal lavage is not a new one, but 
has recently received more attention as a means to reduce residual intra-abdominal 
infection37"46. At the time of initial surgery, several peritoneal tubes are placed in "strategic" 
positions to irrigate the abdominal cavity in the postoperative phase37,38. Lavage with 
10 to 20 litres of dialysis solution is advised to ensure dispersion of the solution 
throughout the abdominal cavity and to prevent fluid loculi. Antibiotics added to the 
lavage fluid might increase the therapeutic effect37·4041. Silenas et al., and Beger and 
associates, emphasized the mechanical action of continuous postoperative peritoneal 
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lavage, detaching necrosis, debris, and fibrin from surrounding tissues39,47. 
Despite the potentially beneficial effects of continuous postoperative peritoneal lavage, 
reports on this method show conflicting results42^5. Reduction in postoperative abscess 
formation is reported in only half of the, mainly nonrandomized, comparative studies43. 
The few prospective randomized studies have small numbers of patients in the treatment 
groups, which do not allow for reaching conclusions43,44,46. Only in the treatment of 
necrotizing pancreatitis, continuous postoperative peritoneal lavage was found to be 
a valuable adjunct to debridement of necrotic pancreas47. 
In several reports, the disadvantages of continuous postoperative peritoneal lavage 
are emphasized: drains seal off in short time, bowel perforation, and fluid and electrolyte 
disturbances43"45. 
(3) The third strategy, leaving the abdomen open (laparostomy), was initially applied 
in France48,49. The principle of this technique is to treat the whole abdominal cavity 
as if it is an abscess cavity. The laparostomy should provide for free drainage of exudates 
and simple access to the abdominal cavity after the first operation50"54. In practice, 
free drainage becomes impossible within 1-2 days as a consequence of rapid adhesion 
formation by fibrin deposition. For the same reason safe access to all parts of the 
abdomen will be difficult31,55. 
The main advantage of this technique seems to be decompression of the abdomen. 
The relief of the elevated intra-abdominal pressure improves ventilation, splanchnic 
circulation, bacterial clearance, cardiac output and renal function5"1. Particularly during 
the first postoperative days, abdominal decompression might benefit the patient. 
Leaving the abdomen open causes the risk of evisceration of the abdominal content, 
fistula formation and abdominal wall hernia, which in conjunction with the nursing 
problems, are considered major limitations of this technique5762"66. These drawbacks 
have generated the application of alternative methods combining abdominal 
decompression with covering of intra-abdominal organs by, for example, Marlex® mesh 
or skin closure58,6768. Although these methods diminish complications and provide 
abdominal decompression, drainage of peritoneal fluid is still inadequate due to rapid 
fibrin deposition and adhesion formation. 
(4) The concept of "planned relaparotomy" has evolved from the technique to leave 
the abdomen open5569'72. Re-exploration of the abdominal cavity is performed on a 
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24-48 hour basis to remove residual infectious material, such as necrosis, fibrin, and 
bacteria and to prevent fluid loculi. The abdomen may be left open or temporarily closed 
by means of a Zipper® or Velcro® analogue, to relieve intra-abdominal pressure and 
to facilitate re-explorations73'75. In contrast to the "on demand" relaparotomy, which 
is often complicated because of the firm adhesions encountered, planned relaparotomies 
deal with loose and easy to separate fibrinous attachments, especially in the 
beginning18·55·7176·77. 
The success of this approach has been attributed to improved elimination of the bacterial 
inoculum, necrotic material and fibrin, and the possibility to early detect and correct 
intra-abdominal complications75. Favourable results in terms of mortality and residual 
abscess formation of this aggressive therapy compared to more conventional surgical 
therapies have been reported. However, prospective randomized studies are still 
lacking6266"717A 7e. More recently the disadvantages of this treatment were brought under 
attention: unnecessary re-explorations, bleeding due to frequent manipulation of the 
abdominal content and removing fibrin from serosal surfaces, "spontaneous" fistula 
formation, interference with anastomotic healing by detaching adhesions and removing 
fibrin deposits, excessive fluid and protein losses, and large abdominal wall 
defects42,62,79 80. In two studies of 24 patients with the most severe forms of generalized 
peritonitis (massive faecal peritonitis due to perforation of the colon and postoperative 
anastomotic leakage) and 10 patients with infected pancreatic necrosis, respectively, 
treated by "planned relaparotomy" with meticulous removal of fibrin and necrosis, the 
complications of this treatment modality were analyzed (Chapter 6 and 7)79,80. Only 
one patient developed a residual intra-abdominal abscess, but the number of other 
complications, such as intra-abdominal bleeding, bowel perforation and enteric fistula, 
was high. Intra-abdominal infection was successfully treated after a median number 
of three planned relaparotomies, as assessed by bacterial cultures of the peritoneal 
fluid. The number of intra-abdominal complications was related to the number of planned 
relaparotomies and to patient outcome. Some of these findings are in concordance 
with those of Schein et al.62. In their series of 52 patients with severe intra-abdominal 
infection, none of the patients had residual or recurrent infection, six (12%) had massive 
haemorrhage, 16 (31%) developed gastrointestinal fistulas, and in 12 (23%) an abdominal 
wall defect persisted. In a series of 117 patients, reported by Wittmann and associates, 
10% of the patients had severe haemorrhage, needing laparotomy, and the incidence 
of suture line disruption and bowel perforation was 19%74. 
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It may be concluded that the ideal operative approach for patients with severe forms 
of intra-abdominal infecten has not been established yet More conventional approaches, 
such as the "wait and see" policy or continuous postoperative peritoneal lavage, do 
not seem to prevent residual or recurrent intra-abdominal infection and are associated 
with a high mortality The method of "planned relaparotomy" seems to decrease the 
rate of residual intra-abdominal infection However, this method has a high complication 
rate and improvement in patient survival has thusfar not evidently been demonstrated 
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INTRAADBOMINAL FIBRIN FORMATION AND FIBRINOLYSIS 

Chapter 5 
¿INTRODUCTION 
Every insult to the peritoneal cavity and especially the peritoneum will induce exudation 
of fibrinogen-rich fluid into the peritoneal cavity, which in turn results in intra-abdominal 
fibrin deposition1,2. The formation of fibrin is crucial in processes such as haemostasis, 
inflammation and tissue repair. However, fibrin has only a temporary role and must 
be resolved in order to resume normal tissue function. Degradation of fibrin is regulated 
by the fibrinolytic system. This system can be regarded as the physiological counterpart 
of the coagulation system3. 
In this chapter, the coagulation system, the fibrinolytic system, intra-abdominal coagulation 
and fibrinolysis in peritonitis, and the possibilities to modulate intra-abdominal fibrin 
deposition are outlined. 
ATHE COAGULATION SYSTEM 
The coagulation system comprises two pathways of action, i.e. the extrinsic or tissue 
factor (TF) dependent pathway and the intrinsic pathway. Activation of each of both 
pathways results in the generation of thrombin via the common pathway, which converts 
fibrinogen into fibrin (Figure 1). Fibrin monomers are formed by cleavage of small 
peptides (fibrinopeptides A and B) from the Α-alpha and B-beta chains of fibrinogen 
by thrombin. Factor XIII, activated by thrombin, catalyses a process of cross-linking 
with formation of intermolecular isopeptide bonds of adjacent fibrin monomers. In this 
way, a matrix of fibrin is formed which will be stabilized by the ingrowth of cellular 
elements. 
The extrinsic pathway is activated by complex formation between factor VII and TF, 
a protein, that is expressed at the surface of endothelial cells, mesothelium and 
macrophages upon stimuli, such as endotoxin4"7. Upon binding to TF, factor VII becomes 
highly susceptible to proteolytic activation by trace amounts of factor IXa and Xa, resulting 
in the formation of factor Vlla-TF complex5,7. The factor Vlla-TF complex activates 
factor X, which forms a complex with factor Va, calcium ions and phospholipid, which 
in turn converts prothrombin into thrombin89. 
Activation of the intrinsic pathway proceeds in vitro by interactions between (pre)kallikrein, 
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high molecular weight kininogen (HMWK) and factor XII, respectively10·11. Through 
activation of factor XII and XI, factor IX is activated, which forms a complex with its 
cofactor Villa, calcium ions and phospholipids. This complex cleaves factor X into 
Xa, which subsequently induces thrombin formation12. 
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I 
Tissue Factor 
Factor Vila 
kallikrein kaiiikri 
prekallikrein 
+ HMWK 
Factor ХП 
""i 
Factor XHa . f 
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(prothrombin) 
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(thrombin) 
АПИ 
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(fibrinogen) 
Figure 1. The coagulation cascade. 
^ Factor la 
(fibrin) 
In plasma, the TF-d riven pathway exclusively contributes to the basal level of coagulation 
activation in vivo13. Recent studies in healthy volunteers and non-human primates 
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revealed that, by the administration of endotoxin or tumor necrosis factor (TNF), the 
activation of the coagulation system is completely TF pathway dependent14"16. The 
intrinsic pathway might only play a role in conditions requiring an accelerated level 
of coagulation activity, such as trauma17. 
TF-mediated activation of coagulation is regulated by tissue factor pathway inhibitor 
(TPFI), which binds to the factor VIla-TF-Xa complex, resulting in an inactive complex18'19. 
Activation of the intrinsic pathway is controlled by the protein С system, which is activated 
by thrombomodulin bound thrombin20,21 .Activated protein С (APC) inhibits the process 
of coagulation by degradation of activated factors V and VIII in the presence of its 
cofactor protein S22'25. At the level of factor Xa and thrombin, coagulation activation 
is inhibited by antithrombin III (AT III), which neutralizes factor Xa and thrombin28. 
ATHE FIBRINOLYTIC SYSTEM 
The initiating event in the process of fibrinolysis is the conversion of inactive plasminogen 
into the active protease plasmin, which is able to cleave cross-linked fibrin27. The 
conversion of plasminogen into plasmin is mediated by plasminogen activators, of 
which tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator 
(uPA) are the most important (Figure 2). tPA is a glycoprotein composed of a single 
polypeptide chain (sctPA)28. In the presence of plasmin, or tissue kallikrein, sctPA 
is converted into two-chain tPA (tctPA)29. Although there are several functional differences 
between sctPA and tctPA, both activate plasminogen equally well in the presence 
of fibrin. The main source of tPA is the endothelium. Release of tPA from the endothelial 
cells can be induced by physical exercise, mental stress, venous occlusion, and a 
number of substances, such as epinephrine, nicotine amid, histamine, bradykinin, TNF, 
endotoxin, thrombin, and vasopressin30"32. The mechanism of tPA release, induced 
by these stimuli, is poorly understood. A direct action on these cells has never been 
found. Hypoxia and acidosis result in a significant increase in tPA33. These findings 
suggest that release of tPA is triggered in areas of ischaemia. 
tPA has a high affinity for fibrin and fibrin enhances the affinity of tPA for its substrate 
plasminogen by the formation of a tPA-fibrin-plasminogen tertiary complex34. This implies 
that tPA has the highest activity where it is required, i.e. locally in the presence of 
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fibrin, while systemic activation is prevented35. 
PAI-1 
(PAI-2) 
(PA1-3) 
Plasminogen 
V 
t-PA 
u-PA 
PLASMIN <= oti-antiplasmin 
Fibrin • H ^ F D F ' S 
Figure 2. The fibrinolytic system. 
uPA circulates in the plasma in a single (pro-urokinase) and in a two-chain form 
(urokinase) and is present in high concentration in urine36. Pro-urokinase behaves 
like an enzyme itself and is able to directly activate plasminogen37. However, its activity 
is strongly enhanced upon conversion into urokinase by plasmin and kallikrein. uPA 
is produced by a variety of cells, such as endothelial cells, epithelial cells, macrophages, 
and various tumor cells38"41. Mesothelial cells probably do not release uPA42. In contrast 
to tPA, which is believed to prevent extension of intravascular thrombi, uPA plays a 
role in extracellular proteolytic mechanisms: increased vascular permeability, cellular 
migration, tumor invasion and tissue remodelling41. uPA does not form a tertiary complex 
with fibrin and plasminogen and the relative fibrin specificity of uPA is solely dependent 
on the specific binding of plasminogen to fibrin43. 
Inhibition of fibrinolysis is mediated by plasminogen activator inhibitors and a series 
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of plasmin inhibitors44. Plasminogen activator inhibitor 1 (PAI-1) is the most important 
inhibitor of tPA and uPA45. PAI-1 is mainly present in plasma, endothelial cells and 
the alpha granules of platelets46,47. It is also produced by stimulated mesothelial cells, 
hepatocytes, melanoma cells and human vascular smooth muscle cells48. PAI-1 acts 
as a pseudosubstrate fortPAoruPA, forming inactive tPA/PAl oruPA/PAl complexes, 
respectively49. It is also capable to inhibit thrombin, which indicates a modulating role 
in coagulation as well5051. Production and release of PAI-1 are enhanced by several 
stimuli, such as endotoxin, TNF, interleukin(IL)-1 and corticosteroids48,52. Increased 
levels of PAI-1 have been found in inflammatory processes53'55. 
Two other plasminogen activator inhibitors have been identified: PAI-2 and PAI-3. 
PAI-2, an inhibitor of both tPA and uPA, was originally isolated from the human placenta 
and is detectable in plasma in the last trimester of pregnancy56. PAI-2 probably is released 
by human leukocytes, monocytes and macrophages and has recently been identified 
in inflamed peritoneum57. Human omental mesothelial cells also produce PAI-2 upon 
stimulation with TNF in vitro48. PAI-3 is a glycoprotein that appeared to be identical 
to protein С inhibitor, and inhibits both plasminogen activators and activated protein 
С Its exact role in fibrinolysis and coagulation remains to be clarified58. 
Of the protease inhibitors that inhibit plasmin, o2-antiplasmin is the most prominent, 
because it has a high affinity for plasmin and is fast acting59. During the coagulation 
process, o2-antiplaemin is incorporated in the fibrin clot by thrombin activated factor 
XIII (factor Xllla), thereby preventing premature lysis of the clot60. Beside plasmin, 
o2-antiplasmin inhibits factor Xlla, kallikrein, factor Xla and thrombin. However, these 
actions appear to be of minor importance61. 
Other protease inhibitors, such as a2-macroglobulin and σ,-antitrypsin are relatively 
slow inactivators of plasmin, kallikrein, tPA and uPA. 
Intra-abdominal and intravascular coagulation are probably similar processes. Various 
coagulation factors and their natural inhibitors have been found in the peritoneal fluid 
under normal and pathological conditions, such as peritoneal dialysis, pelvic 
endometriosis and intra-abdominal infection62"68. 
Knowledge of intra-abdominal fibrinolysis is mainly derived from studies on intra­
abdominal adhesion formation3·6970. 
Under normal circumstances, there is a balance between coagulation and fibrinolysis 
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in the abdominal cavity If coagulation is activated, fibrin is formed followed by fibrin 
clot retraction, clot stabilization, and clot destabilization Before retraction, the fibrin 
clot is susceptible to lysis by tPA, which influences the extent of clot formation The 
fibrin clot stabilizes as a result of fibrin cross-linking, incorporation of a2-antiplasmin 
and local release of PAI-1 After these processes, the fibrin deposit is subject to 
destabilization, which is mainly caused by inactivation of plasminogen activator inhibitors 
and plasmin inhibitors At this phase neutrophils invade the clot and promote fibrinolysis 
by inactivation of cr2-antiplasmin through their product elastase Disruption of fibrin 
deposits is further enhanced by macrophages During the destabilization phase, tPA 
may become active again and lyses the fibrin clot The process of fibrinolysis is damped, 
when the stimulative effect of fibrin on tPA is lost, tPA and uPA are blocked by PAI 
and plasmin is inactivated by a2-antiplasmin 
A INTRAABDOMINAL COAGULATION AND FIBRINOLYSIS DURING PERITONITIS 
During peritonitis, coagulation most likely is activated by release of TF (procoagulant 
activity) in the abdominal cavity62 7172 TF is expressed by several peritoneal cells, such 
as mesothelial cells, (submesothehal) endothelial cells and peritoneal macrophages4 73"76 
Cellular expression of TF might be due to cell damage or triggering of intact cells by 
inflammatory stimuli and bacteria From studies on mesothelial and endothelial cells 
seeded on vascular prostheses, it is known that the slightest cell injury (detachments 
of cells during culturmg) causes TF expression76 Macrophages, stimulated in vitro 
by endotoxin, Escherichia coll and Bacteroides fragilis, express TF activity75 77 However, 
inhibition of TF activity due to short-chain fatty acids, produced by anaerobic bacteria, 
has also been demonstrated76 
Most studies on peritonitis and fibrinolysis have been focused on intra-abdominal 
adhesion formation and were directed to the peritoneal fibrinolytic activity, assuming 
that fibrinolysis in the abdominal cavity is controlled by activators and inhibitors present 
in the peritoneum727980 These studies almost consistently demonstrated that peritoneal 
fibrinolytic activity is suppressed by infectionβοβ1 Hau et al demonstrated a marked 
decrease of peritoneal fibrinolytic activity in dogs with bacterial peritonitis, which was 
attributed to a decreased tPA activity72 A decrease in tPA, but an increase in uPA 
has been demonstrated immunohistochemically in biopsies of inflamed appendices42 
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In peritoneal biopsies of patients with appendicitis a reduction of fibrinolytic activity 
was found, which was attributed to an increase of PAI-15S. More recently an inhibitory 
role of PAI-2 in peritonitis has been reported57. 
Reduction of fibrinolytic activity is not a unique feature of infection, since it has been 
found after mechanical, chemical and ischaemic injury to the peritoneum80. A common 
response to these types of injury is the synthesis and release of cytokines by 
inflammatory cells82. In vitro studies have shown that IL-1 and TNF increase the release 
of PAI and uPA by endothelial cells, whereas tPA is unaffected or decreased5283. In 
cultures of human omental mesothelial cells, TNF induces a decrease of fibrinolytic 
activity as a result of a decrease of tPA and an increase of PAI48. In women with pelvic 
inflammatory disease, an increase of tPA, uPA, and PAI antigens has been demonstrated 
in the peritoneal fluid84. Signs of consumption of plasminogen and antiplasmins, and 
formation of plasmin-antiplasmin complexes have been found in the peritoneal fluid 
of both patients with chemical and bacterial peritonitis68. 
All these studies provide evidence that during infection, intra-abdominal coagulation 
is enhanced and fibrinolytic activity in the surrounding peritoneal tissue is depressed, 
which is held responsible for persistence of fibrin deposits in the abdominal cavity. 
AMODULATION OF INTRAABDOMINAL COAGULATION OR FIBRINOLYSIS 
Potential strategies to prevent intra-abdominal fibrin formation include inhibition of 
intra-abdominal coagulation and stimulation of fibrinolysis. The anticoagulant heparin, 
administered both systemically and intraperitoneally, has been studied extensively 
in experimental peritonitis8"8. Hau et al. have shown that heparin, given intraperitoneally, 
is highly effective in the treatment of lethal peritonitis in dogs85. In rats with peritonitis, 
heparin, administered either subcutaneously or intraperitoneally, significantly prolonged 
survival time, and reduced the development of adhesions and abscesses in the peritoneal 
cavity8688. In rabbits with peritonitis after appendiceal ligation, heparin, administered 
intraperitoneally, decreased mortality, whereas heparin, given subcutaneously, did 
not87. In these experiments, heparin did not influence intrinsic fibrinolytic activity of 
the peritoneum, although other studies have demonstrated that heparin can augment 
plasminogen activator induced fibrinolysis89 90. The success of heparin was attributed 
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to reduction of intraperitoneal fibrin formation. However, success has also been attributed 
to the systemic effects of heparin, such as prevention of intravascular coagulation, 
promotion of bacterial clearance by preventing the thrombosis of subperitoneal lymphatics, 
or the observed beneficial effect of heparin on renal function during intraperitoneal 
sepsis8891. A serious drawback of the administration of heparin is haemorrhage, which 
has lessened the enthusiasm to use this anticoagulant in clinical practice. So far, no 
clinical data have been reported on the use of heparin in peritonitis. 
More recent experimental studies have focused on prevention of fibrin deposition and 
intra-abdominal abscesses by plasminogen activators92"95. In a rat model of peritonitis, 
using an infected human fibrin clot, tPA, given intraperitoneal^ simultaneously with 
the inoculum, appeared to be highly effective in preventing intra-abdominal abscess 
formation93. Delayed administration of tPA had no effect on the abscess rate, but did 
reduce abscess size94. In this model, early mortality associated with the use of tPA 
was observed. This mortality was attributed to early bacteraemia93. Increased bleeding 
related to tPA was not found 
Other plasminogen activators, such as urokinase and streptokinase, have only been 
studied in the prevention of adhesions in animal experiments, with conflicting results9697. 
Clinical data on the use of plasminogen activators in peritonitis are not available. 
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Chapter 6 
¿INTRODUCTION 
"Planned relaparotomy" has become an established surgical treatment modality to 
manage patients with generalized peritonitis. Several authors have obtained favourable 
results with this approach, reporting decreased mortality and a low incidence of residual 
abscesses1-4. Furthermore, it was emphasized that "planned relaparotomy" gives the 
opportunity to early diagnose and treat complications like bowel perforation3. However, 
in our experience this approach has a marked morbidity, to which little attention has 
been paid in literature56. 
Therefore, we analyzed the results of "planned relaparotomy" in patients with the most 
severe forms of peritonitis: faecal peritonitis due to colonic perforation and postoperative 
anastomotic leakage, paying special attention to abdominal complications. In addition, 
we made an attempt to define when to stop planned relaparotomies. 
¿PATIENTS AND METHODS 
From 1989 to 1993, 24 consecutive patients underwent "planned relaparotomy" for 
massive faecal peritonitis due to large bowel perforation (n=15) or postoperative anasto-
motic leakage (n=9) in our surgical unit. There were 18 men and 6 women, their mean 
age was 63 years, ranging from 31 to 89 years. Eleven patients were referred from 
other hospitals. 
All patients were admitted at the surgical intensive care unit (ICU). Tobramycin and 
Metronidazole were given as initial antibiotic therapy. If cultures were available, antibiotics 
were adjusted to these. At the first laparotomy management consisted of elimination 
of the source of peritonitis, debridement and intra-operative lavage. The abdomen 
was "closed" with a zipper (Ethizip®), attached to the fascial edges. Planned relaparoto-
mies were performed every 24 to 48 hours. The abdomen was debrided, removing 
fibrinous deposits and septic collections, samples of which were cultured. Finally the 
abdominal cavity was rinsed thoroughly with warm normal saline solution. Planned 
relaparotomies were discontinued when the abdomen was judged to be 'clean' and 
sepsis was subsided. The abdomen was closed whenever possible, preferably without 
the use of foreign material. One author (R.P.B.) personally participated in the surgical 
management of all patients. 
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The following data were extracted from the medical records: number of planned relapa-
rotomies, number and indication for emergency relaparotomy, duration of ICU stay, 
results of cultures taken from the abdominal cavity, (causes of) death during hospital 
stay, time and type of abdominal wall closure, and number and type of abdominal 
complications (intra-abdominal abscess, intra-abdominal haemorrhage for which emer-
gency relaparotomy was needed, gastrointestinal haemorrhage, bowel perforation, 
enterocutaneous fistula, anastomotic dehiscence and stomal necrosis). 
At the day of admittance a modified APACHE II score (no assessment of Glascow 
Coma Scale) was determined for each patient7. During the first 7 days and subsequently 
once a week a modified multiple organ failure (MOF) score (no assessment of central 
nervous system failure) was calculated8. These modifications were necessary because 
a reliable assessment of the neurological state could not be made retrospectively. 
The samples taken from the abdominal cavity were cultured for both aerobes and 
anaerobes according to standard procedures. Growth was determined semiquantitatively 
and expressed in colony forming units (cfu)/ml. 
The statistical tests used are given within the text. When p<0.05, a difference was 
considered significant. 
ARESULTS 
A total of 136 planned relaparotomies and 23 emergency relaparotomies were performed 
in 24 patients during a median ICU stay of 29.5 days, ranging from 9 to 154 days. 
Mean ± SD modified APACHE II score was 18.7 ± 5.6. There was a median number 
of 5 planned relaparotomies per patient, ranging from 2 to 13. All emergency relapa-
rotomies were performed for haemorrhage. 
Mortality 
Seven of 24 patients (29%) died during hospital stay. All these patients were referred 
from other hospitals. Five patients died as a result of a multiple organ dysfunction 
syndrome, one due to an intracerebral bleeding three weeks after the first operation, 
and in one patient treatment was stopped because of disseminated colon cancer. 
In Figure 1 the relation between the modified MOF score and survival is shown. From 
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day 1 on, the score of nonsurvivors was significantly higher than that of survivors. 
MOF score of survivors remained unaltered during the first seven days and decreased 
thereafter (p<0.01; Pitman test), whereas that of nonsurvivors did not change. 
Modified 
MOF-score 
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Figure 1 Relation between the modified M O F score and survival Scores of nonsurvivors 
( · , n=7) were significantly higher (p<0 05, Yates and Cochran test) than those of survivors 
( O , n=17) at all determination points Bars represent median values 
Morbidity 
Major complications were observed in all seven patients who died and in 10 (59%) 
of the 17 surviving patients. The number of complications in nonsurvivors (24 in 7) 
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was significantly higher (p<0 02, Yates and Cochran) than that in survivors (25 in 17) 
A residual intra-abdominal abscess was found in only one patient This abscess was 
drained percutaneously three months after cessation of "planned relaparotomy" 
Intra-abdominal haemorrhage occurred 23 times in 14 patients 14 times in nine of 
the 17 surviving patients and nine times in five of the seven nonsurvivors In most 
cases gauze packing had to be carried out In one patient an iliac artery was ligated 
because of a bleeding mycotic aneurysm 
Six episodes of upper gastrointestinal haemorrhage were documented in five patients 
of whom two died All bleedings were treated conservatively 
Six small bowel perforations were diagnosed in five patients during re-explorations 
In three of these patients an enterostomy was created, of whom in two the enterostomies 
became necrotic and had to be corrected In two patients the bowel was anastomosed 
primarily, no complications of the primary anastomoses were observed 
An end-enterostomy was created in 20 patients at initial surgery and in three of them 
additional enterostomies were made in the course of the planned relaparotomies Six 
of these 20 patients (30%) needed surgical correction of their enterostomy because 
of necrosis and/or perforation Four times in three patients, a small bowel enterostomy 
had to be corrected, three times a colostomy Three patients with necrosis of an 
enterostomy died 
Six small bowel fistulas occurred in four patients In one patient, definitive treatment 
of the fistula was carried out after three months without further complications Three 
patients died with persisting small bowel fistulas 
There was a strong correlation between the number of complications and the number 
of planned relaparotomies (R=0 90, p<0 001, Spearman) (Figure 2) All patients, who 
underwent more than five planned relaparotomies, had complications 
Patients with complications stayed significantly longer (p<0 05, Wilcoxon) in the ICU 
than patients without complications [median (range) 36(14-154)days versus 14(9-
37)days] 
Cultures 
At initial laparotomy the cultures of the abdominal samples revealed more than 103 
cfu/ml in all 24 patients In 96% of the patients a polymicrobial flora was found In 
21 patients the abdomen became "clean" -ι e < 103 cfu/ml- after a median number 
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of 3 relaparotomies (range, 1 to 9). The remaining three patients developed a tertiary 
peritonitis, two with Candida albicans, one with Pseudomonas aeriginosa. At autopsy, 
four patients had a "clean" abdomen, and three a tertiary peritonitis. The abdominal 
cavity of all 17 surviving patients became "clean". Two of these 17 patients were 
successfully treated for a Candida peritonitis during their ICU stay. 
Numbef of 
complications 
8 9 2 10 
Number of relaparotomies 
Figure 2 Correlation between the number of intra-abdominal complications and the number 
of relaparotomies · patients (n=24) R=0 90, p<0 001, Spearman's rank test 
Abdominal wall defects 
In 13 patients (11 survivors, 2 nonsurvivors) the abdomen was closed on an average 
of 14.2 days (range, 5 to 25 days) after admission. Patients in whom fascial closure 
was achieved had undergone a median (range) number of 3 (2-5) relaparotomies, 
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which is significantly less (p<0.05; Wilcoxon) than that in patients without closure; 
8 (5-13). 
A DISCUSSION 
"Planned relaparotomy" has gained wide acceptance among surgeons as the treatment 
of choice for patients with severe forms of peritonitis. However, the indications for 
this treatment are still debatable. The mortality of patients treated by "planned relaparoto­
my" varies between 7 and 67%1β. Most likely this wide variation is a result of patient 
selection. Some surgeons, reporting a low mortality, use this method liberally including 
patients with acute appendicitis and perforated duodenal ulcers, whereas others are 
more restrictive3,6·10·11. Therefore, we have selected those patients in whom the indication 
for "planned relaparotomy" will be accepted by every surgeon who applies this method: 
diffuse suppurative peritonitis due to perforation of the colon or anastomotic dehiscence, 
in which the abdominal cavity remains grossly contaminated after the initial laparotomy. 
Control of the source of contamination is the main goal in patients with generalized 
peritonitis. We reached this goal in all our patients at the initial laparotomy by creating 
an enterostomy, in the majority of cases. However, necrosis of enterostomies occurred 
frequently, which was mainly due to difficulties mobilizing the oedematous bowel with 
its shortened and thickened mesentery. This complication is prevented when a loop-end 
enterostomy is created in stead of an end-enterostomy (Figure 3). Primary anastomosis 
of the bowel might be another good alternative12. 
"Planned relaparotomy" is performed to control infection, to reverse the systemic 
consequences of peritonitis, i.e. multiple organ dysfunction, and to diagnose complications 
in an early stage. Infection was controlled effectively since a residual abscess was 
found in only one patient. Moreover, cultures from the abdominal cavity of 21 patients 
revealed less than 103 cfu/ml in 62% after two, in 76% after three, and in 95% of them 
after four relaparotomies. It is obvious that more relaparotomies were performed than 
necessary for control of infection. In most patients planned relaparotomies were continued 
because of the persistent septic state of the patients. However, in retrospect, "planned 
relaparotomy" had no detectable beneficial influence on organ function. 
Haemorrhage, bowel perforation and bowel fistula were frequent complications, encoun­
tered particularly after more than four relaparotomies, indicating that multiple planned 
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relaparotomies are not harmless. The risk of bleeding and damage to the bowel increases 
in time because firm granulation tissue replaces the initially present loose fibrinous 
serosal attachments. In concert with a decrease of collagen content, the bowel wall 
becomes very vulnerable and perforates following traction, particularly in an "open" 
abdomen13. 
Figure ЗА: End-enterostomy. Because of the oedematous abdominal wall and mesentery, 
the necessary dissection to create an end-enterostomy easily jeopardizes its vascularization, 
especially in circumstances of splanchnic vasoconstriction. 
Figure 3 B: Loop-enterostomy. Mesenterial dissection is not necessary, leaving vascularization 
intact. 
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We, like many authors, used criteria such as a "clean abdomen" or "signs of sepsis 
subsided" for cessation of planned relaparotomies3610. These criteria are not well defined 
and carry the risk of performing too many re-explorations, because sepsis may persist, 
whereas intra-abdominal infection is controlled. 
Based on this study we suggest to use cultures obtained at the time of operation to 
guide the decision for further re-explorations. The seventy of organ dysfunction does 
not play a role in this decision. 
The - < 103 cfu/ml - criteria for cessation of planned relaparotomies needs to be 
confirmed. When we had used this criteria, less planned re-explorations had been 
performed, intra-abdominal infection control had been as effective, less intra-abdominal 
complications might have occurred, and in more patients the abdomen could have 
been closed after cessation of planned relaparotomies. 
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д INTRODUCTION 
The treatment of patients with acute pancreatitis is primarily conservative, as acute 
pancreatitis responds well to supportive treatment in the majority of patients. 15-20% 
of the patients has severe forms of acute pancreatitis with organ failure and/or local 
complications, who may need surgical treatment1"3. Infected (peri)pancreatic necrosis, 
identified by computed tomography (CT)-guided fine needle aspiration biopsy, is the 
main indication for surgical intervention14S, deterioration of the condition of the patient 
despite supportive therapy in the intensive care unit (ICU) might be another6. 
Several surgical approaches such as total or partial pancreatic resection, necrosectomy 
followed by closed drainage or closed continuous lavage, and partial necrosectomy 
followed by planned re-explorations with "open" drainage have been advocated to 
deal with (peri)pancreatic necrosis7"11. 
Pancreatic resection should be avoided because of high mortality and morbidity and 
the risk of diabetes mellitus as a result of removal of viable pancreatic tissue due to 
overestimation of the amount of necrosis7,12. 
In our previous experience with closed drainage after necrosectomy, half of the patients 
died of sepsis and multiple organ dysfunction syndrome (MODS) and 26% had residual 
abscesses due to insufficient drainage8. 
Necrosectomy followed by closed continuous lavage, as strongly recommended by 
the group of Beger, results in low mortality3. However, the reoperation rate due to 
recurrent intra-abdominal sepsis is high. 
Planned re-explorations after initially limited necrosectomy offer the opportunity to 
repeatedly remove necrosis and infected material. Several authors have reported a 
low residual abscess rate and decreased mortality with this treatment modality1,10,11,13. 
Since 1987 we have treated patients with infected pancreatic necrosis by limited 
necrosectomy, planned re-explorations and "open" drainage. It was the aim of this 
study to evaluate the early and long term results of this surgical approach. 
A MATERIALS AND METHODS 
From 1987 to 1990 10 patients with infected (peri)pancreatic necrosis, as diagnosed 
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by CT scan and fine needle aspiration, were treated by limited necrosectomy, planned 
re-explorations and "open" drainage. All patients had extensive (peri)pancreatic necrosis, 
classified as Balthazar D and E, and suffered from MODS14. Twenty-five patients with 
necrotizing pancreatitis, who were treated in the same period, were excluded from 
this study because they had sterile pancreatic necrosis or a (late) pancreatic abscess. 
Access to the peritoneal cavity was obtained via a supra-umbilical transverse laparotomy 
and the lesser sac was opened by dividing the gastrocolic ligament. A limited 
necrosectomy of the (peri)pancreatic area was performed. The abdomen was rinsed 
with several litres of normal saline solution and the lesser sac was packed with gauzes. 
Seven patients received a needle catheter jejunostomy for early enteral feeding. 
Re-explorations were done at least once a day in the operation theatre under general 
anaesthesia. Fluid collections and sequestrated necrotic material were removed. When 
necrosis was replaced by granulation tissue and the inflammatory process had become 
localized, re-explorations were performed in the ICU under sedative medication every 
two days. Explorations were discontinued as the lesser sac had been obliterated. In 
none of the patients the fascia could be closed. 
All patients were treated in the ICU by mechanical ventilation, aggressive fluid 
resuscitation, use of vasopressors, systemic antibiotics and selective bowel 
decontamination15. Five patients needed dialysis due to renal insufficiency. Severity 
of illness was scored following the Ranson criteria16 at admission, and the APACHE 
II score at the day of surgery. Hospital mortality and morbidity were carefully assessed. 
Special attention was paid to complications associated with the surgical technique. 
Surviving patients were examined at least three years after discharge. Long term 
morbidity and return to work or former activities were assessed and patients underwent 
tests to evaluate their pancreatic exocrine and endocrine function. Informed consent 
to perform the pancreatic function tests was given by patients and healthy volunteers. 
Pancreatic exocrine function 
To determine exocrine function, faecal fat excretion was measured on three consecutive 
days with a standard meal, consisting of 70 g/day fat. An average fat excretion lower 
than 7 g/day was considered normal. Faecal fat was measured using a standard 
method17. 
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Pancreatic endocrine function 
An intravenous glucose tolerance test (IVGTT) was performed to assess pancreatic 
endocrine function. After intravenous bolus injection of 25 g/kg glucose, peripheral 
venous blood samples were taken at -15, 0, 5, 10, 20, 30, 40, 50 and 60 minutes for 
determination of glucose, insulin and glucagon levels. For comparison, an IVGTT was 
performed in healthy volunteers, who were matched for age, sex and body weight. 
Assays 
Blood glucose was measured in duplicate using the hexokinase method. 
Insulin and glucagon were determined by radio-immunoassay18'20. 
Statistics 
Mean values and standard error of the mean (SEM) of glucose, insulin, and glucagon 
levels are given. Statistical analysis of these parameters was performed, using ANOVA 
with Duncan's method to correct for multiple comparisons. Glucagon/insulin ratios 
were analyzed after log-transformation. A p-value less than 0.05 was considered 
significant. 
ARESULTS 
The characteristics of the patients are presented in Table 1. There were 6 men and 
4 women. Their mean age was 51.3 years (range, 29-81 years). The median number 
of Ranson criteria was 6 (range, 5-8). The median APACHE II score was 19 (range, 
12-25). The median number of re-explorations in the operation theatre was 13 (range, 
7-28); for survivors 9 (range 7-15) and for nonsurvivors 25 (range, 17-28). 
The median duration of ICU stay was 29 days (range, 21-76 days); for survivors 28 
days (range, 21-38 days) and for nonsurvivors 46 days (range, 25-76 days). 
Cultures of the pancreatic necrotic tissue revealed gram-negative bacteria in one patient, 
gram-positive bacteria in four patients, and both gram-negative and gram-positive bacteria 
in the remaining five patients. In one patient Candida albicans was isolated (Table 
1). 
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Early results 
Three patients died due to MODS, seven patients survived. No patient who died, had 
a septic focus in the abdomen at the time of death. At autopsy, the pancreas was 
largely intact in two patients, and one patient had only a few necrotic spots in the 
pancreas. 
None of the surviving patients developed a residual intra-abdominal abscess. During 
re-explorations 14 major intra-abdominal complications were encountered in five patients, 
of whom three died. 
Four patients had a bleeding from the lesser sac and one a bleeding from the pelvis, 
needing surgical reintervention and bloodtransfusions. 
Two patients developed necrosis of the transverse colon and were treated by partial 
colectomy and diverting ileostomy. 
In three patients, four enterocutaneous fistulas developed: two jejunal, one duodenal, 
and one colonic. The jejunal fistulas were treated by resection and primary anastomosis. 
The duodenal and colonic fistulas closed spontaneously. Of a total of four small bowel 
enterostomies made, three became necrotic and were corrected surgically. 
The lesser sac of the surviving patients gradually obliterated during an average period 
of 50 days (range, 24-80 days). Residual but transient pancreatico-cutaneous fistulas 
developed in four patients which closed spontaneously within one year. 
Long term results 
Abdominal wall defects 
All surviving patients had a large abdominal wall defect. In four patients, the defects 
were closed because of discomfort or cosmetic reasons, on a average of 2.5 years 
(range, 1-4 years) after initial surgery, with the use of a Goretex® patch in three, and 
a Marlex® patch in one patient. There were no complications associated with these 
repairs. Three patients declined surgical correction. 
Pancreatic exocrine function 
In six patients, clinically without steatorrhoea, the daily fat excretion was normal (median 
3.3, range 0.65-6.3 g/day). One patient (no. 3) had an excretion of more than 10 g/day 
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and needed medication to correct steatorrhoea. 
Pancreatic endocrine function 
One patient (no. 8) had developed permanent insulin dependent diabetes mellitus. 
The results of the IVGTT of the other patients and the healthy volunteers are presented 
in Figure 1, 2, 3, and 4. In the basal state blood glucose and plasma insulin levels 
were similar in both groups, whereas plasma glucagon levels and glucagon/insulin 
ratios of the patients were significantly higher (p<0.05) compared with healthy controls. 
After glucose loading, glucose tolerance as measured by the К value21 was impaired 
in all patients and insulin and glucagon levels were significantly higher (p<0 05) than 
in controls. 
glucose (mmol/l) 
1
 • • ' I I I l_ 
-15 0 5 10 20 30 40 50 60 
time (minutes) 
Figure 1 Blood glucose level during intravenous glucose tolerance test (IVGTT) of patients (O) and 
healthy controls ( · ) Median values and SEM are given At 40, 50 and 60 minutes after bolus injection 
differences are significant (p<0 05) K-values of patients were 0 8, 0 8, 0 9, 0 9, 0 9, and 1 1 K-values 
of controls were 13, 1 4, 2 3, 2 6, 2 7, and 2 9 (K-values > 1 1 are normal) 
94 
12 
g 
6 
3 
Chapter 7 
insulin (mE/l) 
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time (minutes) 
60 
Figure 2. Insulin level during IVGTT of patients (O) and healthy controls ( · ) Median values and SEM are given. 
At 5, 10, 30, 40 and 60 minutes after bolus injection differences are significant (p<0 05). 
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Figure 3. Glucagon level during IVGTT of patients (O) and healthy controls ( · ) . Median values and SEM are 
given. From 0 to 60 minutes after bolus injection differences are significant (p<0.05). 
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glucagon/insulin ratio (ng/mE) 
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Figure 4 Glucagon/insulin ratio during IVGTT of patients (O)and healthy controls ( · ) Median values 
and SEM are given Baseline ratios and ratios at 5 minutes after bolus injection differ significantly (p<0 05) 
¿DISCUSSION 
The present study demonstrates that management of infected pancreatic necrosis 
by limited necrosectomy and planned re-explorations is effective in controlling the local 
problem of necrosis and infection. However, this technique is associated with a high 
complication rate. 
Repeated limited necrosectomy and packing of the lesser sac are advised as the best 
treatment modality for extensive infected pancreatic necrosis minimizing the incidence 
of recurrent intra-abdominal sepsis and improving patient survival1013. The favourable 
results are explained by the fact that this method directly addresses the problem of 
continuing inflammation and progress of retroperitoneal necrosis, and provides optimal 
drainage. Using other drainage techniques e.g. sump drainage and continuous closed 
lavage, reoperation rate is high due to recurrent intra-abdominal sepsis3. These latter 
techniques seem particularly successful when necrosis is less extensive and confined 
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to the lesser sac. 
A significant number of serious local complications as intra-abdominal haemorrhage, 
intestinal necrosis and fistulas, was found in our series. Despite limited necrosectomy, 
haemorrhage is a significant problem, associated with increased morbidity and 
mortality21011. In our series, haemorrhage occurred particularly in the initial phase of 
the treatment due to clotting disturbances, involvement of the splenic and middle colic 
vessels in the necrotic process, and gauze packing. The latter factors are also responsible 
for the occurrence of colonic necrosis and gastrointestinal fistulas21011. The use of 
non-adherent gauzes, transverse incisions, and avoidance of a prolonged "open 
abdomen" might be measures minimizing the occurrence of fistulas101122. These local 
complications are not exclusively linked with this techniques, since the same are reported 
in association with postoperative closed continuous lavage23. The high incidence of 
necrosis of an enterostomy is mainly due to the difficulty mobilizing the bowels because 
of oedema of the bowel wall and mesentery. Moreover, the risk of necrosis of enterostomy 
is enhanced by septic shock and the use of vasopressors. This complication might 
be avoided using loop-end enterostomies or performing primary anastomoses, whenever 
possible. 
Mortality in our group of patients was associated with a high number of re-explorations, 
a high number of complications, and a long duration of ICU stay. It was of interest 
that all three deaths had pre-existent morbid obesity, another factor that has been 
associated with increased mortality24. 
Data on pancreatic function after recovery from acute necrotizing pancreatitis are scarce. 
The majority of available data refers to function after resectional therapy, which is 
accompanied by a high incidence of diabetes712. Büchler et al. demonstrated long 
term exocrine and endocrine functional impairment in about two-third of their patients, 
treated with necrosectomy, followed by continuous postoperative lavage of the lesser 
sac25. 
Extensive pancreatic necrosis inevitably will lead to pancreatic exocrine and endocrine 
insufficiency. However, both in our series as in others the incidence of steatorrhoea 
and diabetes is low10'11. These results might not only be explained by a large overcapacity 
of pancreatic tissue, but by the fact that only part of the patients with necrotizing 
pancreatitis has significant parenchymal necrosis as shown histologically in resected 
pancreatic specimens, at autopsy in our patients, and as demonstrated by normal 
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endoscopic retrograde pancreatograms after recovery from necrotizing pancreatitis2627. 
Although most of our patients had no diabetes, they had an impaired glucose tolerance. 
Surprisingly, this was not caused by lowered serum insulin levels. On the contrary, 
insulin levels were significantly higher than in healthy controls. 
The impaired glucose tolerance might be caused by peripheral insulin resistance with 
consequently increased insulin release by the ß-cells of the pancreas. However, this 
does not explain the elevated glucagon levels in the basal state and after glucose 
challenge. 
Impaired glucose tolerance might be secondary to increased glucagon levels. Particularly 
in the first minutes after glucose challenge, the higher glucagon/insulin ratio disturbs 
hepatic glucose metabolism, which may result in hepatic glucose production instead 
of cessation of hepatic glucose production28. 
We do not have an explanation for the elevated glucagon concentrations. Further studies 
will be conducted to elucidate the mechanisms involved in the disturbance of glucose 
tolerance and the elevation of insulin and glucagon levels in patients after treatment 
for infected pancreatic necrosis. 
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Chapter 8 
A INTRODUCTION 
In bacterial peritonitis fibrin is formed in the abdominal cavity, as is established 
macroscopically at surgery. Activation of the intra-abdominal coagulation system induces 
the formation of fibrin in the abdominal cavity. Intra-abdominal fibrin plays a key role 
in the local host response to inflammation, and prevents early bacteraemia and sepsis, 
by entrapment of bacteria1. Fibrin has only a temporary role and must be resolved 
in order to resume normal tissue function. For the resolution of intra-abdominal fibrin, 
stimulation of the intra-abdominal fibrinolytic system is required. However, this fibrinolytic 
system seems to be inhibited during bacterial peritonitis, as has been demonstrated 
in several experimental studies2"*. As a consequence, intra-abdominal fibrin deposits 
may persist, and these are a nidus of intra-abdominal abscesses1,5. In patients with 
bacterial peritonitis, intra-abdominal abscesses are associated with a marked morbidity 
and mortality6,7. 
There is no detailed knowledge from clinical studies about fibrin formation and fibrinolysis 
in peritonitis. Therefore, we conducted a controlled clinical study to determine the effect 
of bacterial peritonitis on coagulation and fibrinolysis in peritoneal fluid and plasma. 
A PATIENTS AND METHODS 
Study design 
Twenty-five patients, who underwent emergency laparotomy for peritonitis were studied. 
Peritonitis was due to perforated appendicitis in 10, duodenal perforation in five, per-
forated diverticulitis in five, small bowel perforation in two, toxic megacolon with 
perforation in two, and infected ascites due to pancreatic necrosis in one patient. 
Abdominal cultures revealed bacterial growth in all patients. There were 16 males 
and nine females. Their mean age was 48 years, ranging from 11 to 90 years. 
Seven patients, who underwent elective cholecystectomy for gallstone disease served 
as controls. Bacterial cultures of the peritoneal fluid were negative in all control patients. 
There were three males and four females. Their mean age was 50 years, ranging 
from 12 to 75 years. 
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After incision and meticulous haemostasis, 10 ml of peritoneal fluid were aspirated 
from the abdominal cavity in all patients with peritonitis In cholecystectomy patients, 
the amount of fluid aspirated varied between 0 5 and 2 ml, and was diluted with normal 
saline until a total amount of 10 ml 
Venous blood (10 ml) was drawn simultaneously with peritoneal fluid aspiration Peritoneal 
fluid and blood were collected in a citrate-tube (1 10) and a Stabilyte® tube (1 10), 
respectively, and placed in melting ice8 Within 30 minutes the samples were centnfuged 
at 4°C, and the supernatants were stored at -80°C, until assays were performed 
Activation of coagulation was assessed by measuring the thrombm-antitrombine III 
(TAT) complex, as thrombin (generation) is the final step in the coagulation cascade 
before fibrin formation 
To analyze fibrinolysis, tissue-type plasminogen activator (tPA), urokinase-type 
plasminogen activator (uPA), plasminogen activator inhibitor (PAI), plasmm-a2antplasmin 
(PAP) complex, and fibrin degradation products (FbDP) were assessed 
This study was approved by the hospital ethical committee and informed consent was 
obtained from all patients and/or their parents 
Assays 
TAT complex was measured by ELISA (Enzygnost TAT, Behnngwerke AG, Marburg, 
Germany) 
tPA antigen was measured by ELISA (Asserachrom tPA, Boehnnger, Mannheim, 
Germany) The assay measures both free and complexed (with PAM) human tPA 
and is calibrated against the International Standard for tPA 
tPA activity was measured by Coaset-tPA assay (Kabi Diagnostica AB, Mölndal, Sweden) 
as described by Nilsson et a l 9 
PAI-1 antigen was measured by ELISA (Biopool AB, Umea, Sweden) The assay 
measures free, latent as well as complexed (with tPA or uPA) human PAI-1 
PAI activity was measured by Benchrom-PAI assay (Behnngwerke AG, Marburg, 
Germany) as described by Stief et al 10 
uPA antigen in plasma and in peritoneal fluid was measured by ELISA according to 
Bmnema etal " Concentrations were expressed in percentage of the uPA concentration 
of normal pooled plasma of healthy volunteers 
PAP complex was measured by ELISA (EIA APP micro, Behnngwerke AG, Marburg, 
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Germany). 
FbDP were measured by ELISA (Fibrinostika FbDP, Organon Technika, Turnhout, 
Belgium). 
Statistics 
Presented data are expressed as median values and 95% confidence intervals. The 
Mann Whitney-U test was used for statistical analysis of differences between groups. 
Correlations between plasma and peritoneal fluid values were analyzed by Spearman's 
rank test. A p-value less than 0.05 was considered significant. 
ARESULTS 
Extensive fibrin deposition was found at laparotomy in all patients with bacterial peritonitis, 
but in none of the control patients. Activated coagulation in the abdominal cavity of 
patients with peritonitis was demonstrated by significantly higher TAT complex 
concentrations, as compared with controls (Table 1). 
Stimulation of the fibrinolytic system in the peritoneal fluid of patients with peritonitis 
was demonstrated by significantly elevated concentrations of tPA, uPA, PAP complex 
and FbDP, as compared with those concentrations in the peritoneal fluid of controls 
(Table 1). Median peritoneal fluid concentrations of tPA and uPA in patients with 
peritonitis were about 65 fold and 10 fold, respectively, higher than those in controls. 
PAI-1 antigen showed a more than 400 fold increase. Hence, concentrations of PAP 
complex and FbDP in the peritoneal fluid of patients with peritonitis were significantly 
elevated, in comparison with those in controls. 
By contrast, plasma concentrations of TAT and PAP complexes, and tPA and PAI-1 
antigen and activity, were comparable in patients with and without peritonitis. Only 
plasma concentrations of uPA antigen and FbDP in patients with peritonitis were higher 
than those in control patients (Table 2). 
Neither in patients with peritonitis nor in control patients, the level of any coagulation 
or fibrinolytic factor, measured in the plasma, correlated with that, measured in the 
peritoneal fluid. 
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Table 1 Parameters of coagulation and fibrinolysis in the pentoneal fluid of patients with peritonitis 
(n=25) and control patients (n=7) Results in control patients were corrected for dilution at sampling 
Median values (95% confidence intervals) are given 
peritoneal fluid peritonitis control p-value 
tPA antigen (ng/ml) 66 1 (37 5-180) 1 1 (0 5-1 8) <0 05 
tPA activity (lU/ml) 6 5 (3 7-11 9) <0 25 (<0 25-0 3) <0 05 
PAI-1 antigen (ng/ml) 395 (147-588) 0 5 (<0 5-1 3) <0 05 
PAI activity (AU/ml) 14 3 (7 4-22 2) <0 3 (<0 3-<0 3) <0 05 
uPA antigen (%) 740 (168-2000) 78 (14-168) <0 05 
TAT (ng/ml) 5500 (2976-9094) 89 (30-198) <0 05 
PAP (ng/ml) 10952 (4834-15469) 57 (17-123) <0 05 
FbDP (ng/ml) 40360 (6475-200000) 126 (31-463) <0 05 
¿DISCUSSION 
This study demonstrates, that in the abdominal cavity of patients with bacterial peritonitis 
both the coagulation system and the fibrinolytic system are stimulated The resultant 
fibrin deposition probably reflects a relative deficit of fibrinolytic activity, due to strongly 
enhanced inhibition of plasminogen activators 
The pronounced, elevated concentrations of TAT complex in the peritoneal fluid of 
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Table 2 Parameters of coagulation and fibrinolysis in the plasma of patients with pentomtis (n=25) 
and control patients (n=7) Median values (95% confidence intervals) are given 
plasma peritonitis control p-value 
tPA antigen (ng/ml) 7 9 ( 4 9-12 6) 6 4 ( 3 4-10 3) ns 
tPA activity (lU/ml) 2 3 (1 7-3 3) 1 3 (0 9-2 4) ns 
PAI-1 antigen (ng/ml) 15 (10 2-22 3) 13 8 (5 9-39 9) ns 
PAI activity (AU/ml) 1 7 (0 9-2 9) 1 4 (0 8-2 3) ns 
uPA antigen (%) 204 (138-272) 120 (96-172) <0 05 
TAT (ng/ml) 5 2 ( 3 3-16 5) 2 6 ( 1 4 - 5 5) ns 
PAP (ng/ml) 709 (450-917) 381 (290-567) ns 
FbDP (ng/ml) 1201 (559-2867) 350 (193-594) <0 05 
all patients with peritonitis demonstrate intra-abdominal stimulation of coagulation 
The coagulation cascade may be triggered by expression of tissue factor (procoagulant 
activity) on injured mesothehal and endothelial cells in the peritoneum12 " Procoagulant 
activity may also originate from peritoneal macrophages, which predominate in the 
abdominal cavity early in the course of peritonitis, and express tissue factor upon 
stimulation with, for example, endotoxin and tumor necrosis factor1415 The relative 
contribution of separate cell types to intra-abdominal coagulation has not been clarified 
yet It seems that the activation of coagulation was confined to the abdominal cavity, 
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as plasma TAT concentrations in most patients with peritonitis were not elevated. In 
a few patients with sepsis, high plasma levels of TAT were found, which is in concordance 
with earlier reports on the relation of sepsis and systemic hypercoagulability1β17. 
Based on studies of fibrinolytic activity of normal and inflamed peritoneum, it is commonly 
assumed that fibrinolytic activators are reduced in peritonitis2,18·19. Our data, on the 
contrary, show an increase of fibrinolytic activators. This finding is in agreement with 
that of Dörr et al., who reported increased fibrinolytic activity and fibrin degradation 
in the peritoneal fluid of women with pelvic inflammatory disease20. Increased tPA 
antigen levels in the peritoneal fluid, associated with normal plasma levels of tPA antigen 
in the patients with bacterial peritonitis, suggest local production of tPA. In particular, 
mesothelial cells and submesothelial endothelium might be responsible for the production 
of tPA21,22. The increased tPA concentrations, which we found, might be explained 
by a prompt release from a preformed storage pool within these cells. Several 
'stressfactors' and inflammatory mediators, stimulated upon bacterial infection, may 
induce such a release of tPA in vivo23. However, these findings are not supported 
by in vitro experiments, in which inflammatory stimuli, like tumor necrosis factor and 
interleukin-1, inhibited tPA release by cultured mesothelial and endothelial cells22 24. 
As an alternative explanation, increased levels of tPA might be due to leakage from 
mesothelial cells, which are damaged during peritoneal infection. 
PAM forms a "one to one" inactive complex with both tPA and uPA. Since the increase 
of PAI-1 in the peritoneal fluid of patients with peritonitis was much higher than that 
of tPA and uPA, complete inhibition of fibrinolytic activity in the abdominal cavity might 
be expected. However, plasmin activity was still present as shown by elevated levels 
of PAP complex and FbDP. Since plasminogen activation, mediated by tPA, is 
significantly enhanced in the presence of fibrin, tPA may display fibrinolytic effects 
even in the presence of a high PAI level2526. 
Furthermore, display of fibrinolytic activity can be explained by increased concentrations 
of uPA, which were demonstrated in the peritoneal fluid of our patients with peritonitis. 
The rise of uPA in the peritoneal fluid is probably not linked to mesothelium, but to 
endothelium, since uPA has not been demonstrated in mesothelial, but in endothelial 
cells of biopsies of inflamed appendices and in in vitro cultures, upon stimulation with 
inflammatory cytokines27,28. The more pronounced increase of uPA in peritoneal fluid 
compared with that in plasma, might be explained from the direction of secretion of 
uPA by endothelial cells, which is mainly abluminal28. Whether other uPA producing 
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or receptor bearing cells, like fibroblasts or macrophages, contributed to the fibrinolytic 
activity in the peritoneal cavity, remains to be clarified. 
It is remarkable that plasma levels were not elevated in patients with peritonitis, except 
for a, relatively small, increase of uPA and FbDP. The findings of predominantly, normal 
plasma levels, as well as the absence of correlations between plasma and peritoneal 
fluid levels, suggest that the abdominal cavity with its surrounding peritoneum is a 
separate compartment. The coagulation and fibrinolytic responses to bacterial peritonitis 
in this compartment, depend on many factors, of which the individual contribution is 
difficult to assess. Intra-abdominal fibrinolysis occurs, as shown by increased FbDP 
levels. It seems, however, that the increase of fibrinolytic activity is limited by high 
PAI levels, and does not meet the overwhelming demand to overcome fibrin production. 
When the infectious stimulus is eliminated, fibrin formation probably stops. At that 
time residual fibrin has to be removed by means of the fibrinolytic system. For this, 
it is required that tPA and/or uPA levels in the peritoneal fluid remain elevated and 
PAI levels have decreased. Further studies will be conducted to assess the coagulation 
and fibrinolytic responses to elimination of the infectious focus. 
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Chapter 9 
A INTRODUCTION 
Generalized peritonitis is a life-threatening condition that is poorly controlled by 
local defense mechanisms of the peritoneal cavity1"4. The outcome is usually fatal 
without surgical intervention if these protective systems fail. Removal of the 
source of the peritonitis, drainage of septic collections and extraction of fibrin 
deposits are essential to prevent residual abscesses. Fibrin deposits have a key 
role in abscess formation because bacteria entrapped in fibrin cannot be reached 
by phagocytes and antibiotics, and thus act as a nidus for infection35"7. 
Radical surgical debridement to achieve complete removal of fibrin was 
advocated by Hudspeth8 but its benefits, namely reduction in the incidence of 
mortality and residual abscess, were not confirmed in a prospective randomized 
trial by Polk and Fry9. Scheduled relaparotomy has decreased the frequency of 
residual abscess, but this procedure is associated with a high risk of 
complications such as bleeding, bowel perforation and abdominal wall defects1012. 
New fibrin deposits form immediately after each operation and it might be 
advantageous if they could be removed in a less traumatic way and subsequently 
prevented. 
Deposition of peritoneal fibrin is a uniform host response to local inflammation 
and may be the result of increased fibrin formation and decreased fibrinolysis. 
Peritoneal fibrinolytic activity is reduced if there is direct injury to the peritoneum, 
ischaemia and bacterial peritonitis; mesothelial cell damage, leading to diminished 
release of tissue plasminogen activator (tPA), may be the main reason for 
decreased fibrinolysis13"15. Fibrinolytic activity might also be reduced by an 
increase in levels of plasminogen activator inhibitor (PAI), which has recently 
been demonstrated in inflamed peritoneum16. The activities of tPA and PAI in 
peritoneal fluid and the extent of peritoneal tissue damage were studied in rats 
with faecal peritonitis to determine their effects in fibrinolysis. 
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A MATERIALS AND METHODS 
Study design 
Male Wistar rats weighing 250-280 gram were injected intraperitoneal^ with either 
2 ml sterile normal saline (group 1, n=10) or 2 ml faecal suspension containing 
104 colony forming units per ml of both Escherichia coli (E. coli) and Bacteroides 
fragilis (B. fragilis) (group 2, n=10). The rats were anaesthetized with a halothane-
nitrous oxide-oxygen mixture 1 h after injection and via a midline laparotomy 0.4 
ml peritoneal fluid was taken, snap frozen at -78°C in a polypropylene microfuge 
tube and stored at -80°C until assays of tPA and PAI activity were performed. A 
biopsy of the parietal peritoneum was taken for light microscopic examination. 
The abdominal cavity was debrided and rinsed thoroughly with saline solution. A 
relaparotomy was performed to take a peritoneal fluid sample and biopsy 3, 6, 24, 
96 and 192 h after injection. Rats had free access to water and standard 
laboratory chow. 
Bacterial faecal suspension 
Fresh faeces of Wistar rats were collected, sterilized by steam (120°C, 20 min) 
and stored at 4°C before use. 
E. coli strain ATCC 25922 was used for the experiment. Growth conditions and 
methods of preparation have been described previously17, ß. fragilis from a 
clinical isolate stored at -70°C was prepared in the same way as E. coli, only 
Bacteroides bile esculin agar and Schaedler broth (Oxoid, Basingstoke, UK) were 
used. 
Activities of tissue plasminogen activator and plasminogen activator 
inhibitor 
Activities of tPA and PAI in the peritoneal fluid were measured by Coaset tPA 
assay (Kabi Diagnostica, Mölndal, Sweden) and Berichrom-PAI assay (Behring-
werke, Marburg, Germany) respectively1819. 
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Histological examination 
Sections of peritoneal biopsy specimens were stained with haematoxylin and 
eosin for light microscopical examination. On the basis of inflammatory infiltrate 
and the morphology of the mesothelial cells, peritoneal damage was scored 
semiquantitatively on a scale of 0-4 by one observer: 0, absent; 1, trace; 2, mild; 
3, moderate; and 4, severe. 
Statistical analysis 
Results within a group were compared using analysis of variance (ANOVA) with 
the Friedmann test for non-parametric values. Data between the groups were 
analyzed using the Wilcoxon signed rank test. All tests were two-tailed; p<0.05 
was considered significant. 
ARESULTS 
All rats survived the experimental period. The mean weight loss was 5 (range 
2-7) per cent and did not differ significantly among animals of either group. All 
rats that received a faecal suspension (group 2) had intra-abdominal fibrinous 
exudates after induction of peritonitis and intra-abdominal abscesses by day 8. 
These findings were not observed in animals of group 1. 
Activity of tissue plasminogen activator 
Median tPA activity in animals of group 1 was less than 1 unit/ml during the 
study. Activity of tPA in animals of group 2 remained less than 1.5 units/ml during 
the first 6 h of the experiment, reached a maximum 24 h after injection and 
subsequently decreased. Although activity in both groups was low, it tended to be 
higher in the rats of group 2 than in those of group 1. A significant difference was 
found at 24 h after injection (p<0.05) (Fig. 1). 
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Figure 1 Activity of tissue plasminogen activator (tPA) in the peritoneal fluid of control 
rats (group 1,·) and those given a faecal suspension (group 2,0) Bars are median 
values * p<0 05 (group 2 versus group 1) 
Activity of plasminogen activator inhibitor 
Median PAI activity in animals of group 1 was less than 1 unit/ml at all 
determination points Activity of PAI in rats that received a faecal suspension 
(group 2) was increased within 3 h, reached a maximum between 6 and 24 h 
(p<0 05), and gradually declined during the following days Activity of PAI in rats 
of group 2 was significantly higher than in those of group 1 (Fig 2) (p<0 001) 
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Figure 2 Activity of plasminogen activator inhibitor (PAI) in the peritoneal fluid of 
control rats (group 1,·) and those given a faecal suspension (group 2,0) Bars are 
median values * p< 0 001 (group 2 versus group 1) 
Histological examination 
No signs of peritoneal damage were identified in the biopsy specimens at 1 and 
3 h after injection. There was no difference in the degree of peritoneal damage as 
assessed by median (range) score between the animals of both groups at 6 and 
24 h after injection (group 2, 0.5(0-2) and 1(0-2) respectively; group 1, 1(0-2) at 
both times). Median (range) peritoneal damage scores at 96 and 192 h after 
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injection tended to be more severe in rats of group 2 (2(1-3) and 1(0-2) 
respectively) compared with those of animals in group 1 (0.5(0-2) and 0(0-2)). 
Activities of tPA and PAI in rats of group 2 differed significantly from those of 
animals in group 1 after stratification for histological score (p<0.001). Thus, tPA 
and PAI activity in the peritoneal fluid do not correlate with the severity of damage 
to the peritoneum. 
¿DISCUSSION 
The present study demonstrates that the main cause of change in abdominal 
fibrinolysis in rats with generalized peritonitis is a marked increase in the activity 
of PAI and that the enhanced activity of tPA is minor by comparison. Operative 
trauma alone did not significantly augment tPA or PAI activity. 
Fibrinolysis in the abdominal cavity is dependent on the local activity of plasmin, 
which is determined by the balance between its generation from plasminogen and 
its inactivation by o2-antiplasmin. The conversion of plasminogen into plasmin is 
stimulated by tPA, an enzyme that originates from various cells including those of 
mesothelial and endothelial type20"22. The activity of tPA is inhibited by PAI, which 
is also released by many cells throughout the body, including mesothelial cells22. 
In contrast to others23"26, who measured fibrinolysis in the mesothelium, such 
activity was assessed in peritoneal fluid on the basis of the assumption that fibrin 
formation depends on the composition of this medium. It seems likely that, 
regarding intra-abdominal abscess formation, fibrinolytic activity of the abdominal 
exudate is a more appropriate parameter for overall fibrinolysis in the abdominal 
cavity than that of the mesothelium. Moreover, mesothelium cannot be isolated 
without being contaminated by the underlying fibrocollagenous tissue containing 
blood vessels, making meaningful measurements of fibrinolytic activity impossible. 
The activity of tPA is dependent on the amounts of tPA and PAI antigen. Under 
normal circumstances tPA is released by mesothelial cells into the abdominal 
cavity22-23·26. The observed decline in fibrinolytic activity in inflamed peritoneum 
has been attributed to decreased release of tPA by the damaged mesothelium1525" 
28
. In contrast, decreased activity of tPA was not found in the peritoneal fluid of 
rats with generalized peritonitis. The increased activity of this enzyme that was 
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found even suggests enhanced release of tPA, although this supposition could 
not be confirmed because levels of tPA antigen could not be determined. 
Augmentation of tPA antigen levels seems likely in the rats with peritonitis 
because activity of tPA in these animals remained higher than in controls despite 
substantially increased PAI activity. These experimental data are concordant with 
clinical results in patients with peritonitis, in whom increased levels of tPA antigen 
in the peritoneal fluid were demonstrated29. 
The discrepancy between the present results and those of others who assessed 
fibrinolytic activity in peritoneal biopsy specimens may be explained by the prompt 
release of tPA from mesothelial cells into the peritoneal cavity after inflammation. 
This suggestion seems unlikely as Van Hinsberg et al.22 reported decreased 
synthesis and release of tPA by mesothelial cells when inflammatory stimuli such 
as lipopolysaccharide and tumour necrosis factor (TNF) were added to 
mesothelial cell cultures. Therefore, tPA in the abdominal cavity may originate not 
only from the mesothelium but also from other tissues, such as the endothelium. 
This is corroborated by the findings of Suffredini et al.30 and Paramo and 
colleagues31, who found increased levels of tPA in the plasma of humans with 
endotoxaemia, sepsis and localized infection. 
Inhibition of tPA by PAI seems to be the most important cause of decreased 
fibrinolysis in abdominal fluid. Vipond et al.16 and Whawell and co-workers32 
reported reduced fibrinolytic activity in punch biopsies of inflamed peritoneum that 
contained high concentrations of PAI. The inhibitor in these biopsies may have 
been released by mesothelial cells challenged by lipopolysaccharide and/or TNF, 
as found in an in vitro study22. It may also have originated from connective tissue 
containing blood and blood vessels. This is supported by high plasma levels of 
PAI during peritonitis and sepsis31·33. These two sources became apparent in a 
recent study34 in which production of PAI-1 was localized to mesothelium and 
serosal blood vessel endothelium in inflamed human appendix. 
The activity of PAI was increased during the whole study period in rats with 
peritonitis, which was probably the result of ongoing infection as all animals had 
residual abscesses after 8 days. This finding suggests that fibrinolytic activity is 
impaired as long as infection is present. 
The activities of tPA and PAI did not correlate with the histological findings. A 
similar degree of peritoneal damage during the first 24 h in animals of each group 
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was striking, whereas tPA and PAI activities in the peritoneal fluid showed 
significant differences. These observations support the likelihood of an 
extramesothelial source of tPA and PAI but do not exclude the mesothelium as 
responsible for production of peritoneal tPA or PAI. It has been demonstrated that 
mesothehal cells may release tPA and PAI without evidence of histological 
change22. 
The activities of tPA and PAI in the peritoneal fluid of rats with faecal peritonitis 
were increased; these changes were not the result of operative trauma. Markedly 
enhanced activity of PAI is probably the main cause of reduced fibrinolytic activity 
in the abdominal cavity. 
Studies are warranted to assess the efficacy and safety of exogenous stimulation 
of peritoneal fluid fibrinolytic activity to overcome intrinsic inhibition by PAI and to 
reduce deposition of fibrin and formation of intra-abdominal abscesses. 
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¿INTRODUCTION 
Peritoneal fibrinolytic activity is depressed in peritonitis, which is held responsible for 
persistence of fibrin in the abdominal cavity and subsequent adhesion and abscess 
formation1"3. 
Tissue-type plasminogen activator (tPA) is an attractive agent to increase intra-abdominal 
fibrinolytic activity in order to prevent fibrin deposition. The high molecular weight and 
high affinity of tPA for fibrin tend to confine its activity to the abdominal cavity. Binding 
to fibrin also enhances catalytic efficacy of tPA and reduces its neutralization by 
plasminogen activator inhibitor (PAI)45. 
The rat is a suitable animal to study peritonitis and intra-abdominal abscess formation6. 
Rat tPA is preferred to modulate abscess formation in a rat model of peritonitis, but 
is not readily available. Human recombinant tPA (rtPA) seems to be a good alternative, 
since it is more readily available, its properties are established by clinical studies, and 
it has thrombolytic effects in animal models of thrombo-embolic stroke7"9. 
Prior to a study on the effects of intraperitoneally administered human rtPA on abscess 
formation in rats with peritonitis, we performed in vitro experiments to assess the effect 
of human rtPA on the rat fibrinolytic system. 
ι 
¿MATERIALS AND METHODS 
Human recombinant tPA (rtPA, Actilyse®, Boehringer Ingelheim, Alkmaar, The Nether-
lands) was obtained in vials of 50 mg rtPA had a specific activity of 580,000 lU/mg 
of protein. rtPA was dissolved in 5 ml sterile water and this stock solution was further 
diluted in Ringer's lactate solution (RLS) or methyl hydroxy propyl cellulose (MHPC) 
gel to obtain concentrations as used in the experiments. 
MHPC gel was manufactured locally in vials of 2 ml sterile gel. MHPC gel was intended 
to be used as a vehicle of rtPA in the abdominal cavity, in order to achieve slow release 
of rtPA from the abdominal cavity, avoiding high systemic levels of rtPA. 
Streptokinase (Streptase®, specific activity of 100,000 IU per 133-174 mg) was obtained 
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from Behringwerke, Marburg, Germany and dissolved in sterile water to prepare a 
stock solution of 3 mg/ml (range 2.7-3.5). 
Human thrombin was provided by the Central Laboratory of the Red Cross Blood 
Transfusion Service, Amsterdam, The Netherlands and dissolved in normal saline 
to prepare stock solutions of 50 and 80 lU/ml, respectively. 
Batroxobin (Fibroclotin®) was purchased from Baxter, Hyland division, California, USA. 
Normal pooled human plasma was prepared from plasma of 64 healthy hospital staff 
members, while normal pooled rat plasma was derived from plasma of 4 rats, as 
described previously10. 
Peritoneal fluid samples were taken from the abdominal cavity of rats and patients 
with peritonitis, immediately snap frozen, and stored at -80°C until assays were 
performed. 
Four experiments were performed to determine the interaction between human rtPA 
and the rat fibrinolytic system. 
(1) Capacity of human rtPA and streptokinase to lyse rat plasma clots, in comparison 
with human plasma clots. 
(2) Effect of human rtPA on fibrinogen concentrations in rat plasma, as compared 
with human plasma. 
(3) Effect of human rtPA on fibrin degradation in rat serum, in comparison with human 
serum, as measured by fibrin degradation products (FbDP). 
(4) Inhibitory effect of rat PAI versus human PAI on human rtPA. 
(1) Clot lysis capacity of human rtPA 
Clot lysis capacity was measured in plasma in two ways. Firstly, by a method described 
previously which is based on the streptokinase resistance test of Moran et al.1 0 1 1. 20 
μ\ of a series of plasminogen activator dilutions (rtPA or streptokinase) in 0.9% NaCI 
was added to 160 μ\ test plasma and the mixture was vortexed immediately. Then 
20 μ\ of a thrombin solution (50 lU/ml) was added and the mixture was vortexed again. 
Clot formation occurred within 30 sec and lysis was established after exactly 10 minutes. 
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The plasma concentrations of rtPA or streptokinase that resulted in complete lysis 
of the clot within 10 minutes were recorded and expressed in //g/ml. 
In the second method, a clot formed in the absence of plasminogen activator was 
overlaid by a solution of rtPA in either MHPC or RLS and the time required to achieve 
complete lysis of the clot was recorded. 
(2) Effect of human rtPA on rat fibrinogen 
Different concentrations (0 to 100 ng/ml) of rtPA were added to rat and human pooled 
citrated plasma, and after incubation for 15 minutes at 37°C a sample was taken to 
assess fibrinogen. Fibrinogen was measured by Clauss' method with human thrombin 
(80 lU/ml) as activator, using a KC10A coagulation analyzer (Amelung, Lemgo, 
Germany)12. 
(3) Effect of human rtPA on rat fibrin degradation 
Different concentrations (0 to 100 ng/ml) of rtPA were added to rat and human pooled 
citrated plasma and incubated for 15 minutes at 37°C. Thereafter, plasma (200 μ\) 
was recalcified (5.5 μ\ of 1 mol/L CaCI2) and incubated with Batroxobin (15 μ\ stock 
solution) and thrombin (5 μ\ of 80 lU/ml) at 37°C for 15 minutes. After centrifugation 
at 14,000 g for 10 minutes the resultant sera were used to measure FbDP by Dade's 
latex immunoassay (Baxter, Miami, USA)13. 
(4) Inhibitory effect of rat PAI on human rtPA 
Human rtPA was added to peritoneal fluid samples of two groups of rats, having a 
high (>15 AU/ml) and a low (<1 AU/ml) level of PAI, respectively. After incubation 
for five minutes at 37°C, rtPA activity was measured (added to a final concentration 
of 10 lU/ml) using Coaset-tPA assay (Kabi Diagnostica, Mölndal, Sweden). Two groups 
of patients, having a high and low level of PAI in their peritoneal fluid, respectively, 
served as controls. 
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ARESULTS 
Clot lysis capacity of human rtPA 
Human rtPAwas able to lyse rat plasma clots within 10 minutes at a minimum concentra­
tion of 0.75pg/ml, compared to 0.5/jg/ml for human plasma clots (Table 1). Streptokinase 
did not lyse rat plasma clots at all up to concentrations of 300 μglm\, while 50-150 
//g/ml were sufficient to lyse the different human plasma clots. Clots made of a mixture 
of rat and human plasma lysed at a minimum concentration of 75 ¿ig/ml, which excludes 
the possibility that streptokinase was neutralized by anti-streptokinase antibodies in 
rat plasma. 
Table 1 Clot lysis by human recombinant tissue-type plasminogen activator (rtPA) and streptokinase 
(SK). 
Three rat (RP) and two human plasma (HP) samples and one 1 1 mixture (RHP) sample were incubated 
with various (final) concentrations of rtPA or SK before clotting was induced by addition of thrombin 
Clot formation occurred within 30 sec and complete lysis (+) was established after exactly 10 mm 
rtPA SK 
jig/ml //g/ml 
RP1 
2 
3 
HP1 
2 
RHP 
01 
-
-
-
-
-
-
0 25 
-
-
-
-
-
-
05 
-
-
-
+ 
+ 
+ 
0 75 
+ 
+ 
+ 
+ 
+ 
+ 
10 
+ 
+ 
+ 
+ 
+ 
+ 
1 5 
+ 
+ 
+ 
+ 
+ 
+ 
25 
-
-
-
-
-
-
50 
-
-
-
+ 
-
-
75 
-
-
-
+ 
-
+ 
100 
-
-
-
+ 
-
+ 
150 
-
-
-
+ 
+ 
+ 
300 
-
-
-
+ 
+ 
+ 
When plasma clots were overlaid with either rtPA/MHPC or rtPA/RLS mixtures at 0 5 
mg/ml rtPA, no differences in clot lysis time were observed between the 2 diluents: 
all clots lysed within 150-165 minutes. 
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Effect of human rtPA on rat fibrinogen 
Fibrinogen degradation was observed at ^100 ng/ml of rtPA in rat plasma, while in 
human plasma this phenomenon already occurred at 33 ng/ml (Table 2). 
Table 2 Degradation of plasma fibrinogen by rtPA 
Different concentrations of rtPA (0, 0 3,1,3 3, 10, 33, and 100 ng/ml) were added to rat and human 
normal pooled plasma, and after incubation for 15 minutes at 37°C a sample was taken to assess 
fibrinogen 
Rat plasma Human plasma 
rtPA 
(ng/ml) 
Fibnnogen 
(mg/ml) 
Fibnnogen 
(mg/ml) 
0 
03 
1 
33 
10 
33 
100 
2.7 
28 
26 
28 
27 
27 
23 
2.5 
2 5 
2 5 
2 5 
2 5 
1 5 
<1 0 
Effect of human rtPA on rat fibrin degradation 
Table 3 shows that FbDP could be demonstrated in the serum of rats in a rtPA dose-
dependent manner. The measured FbDP concentrations were in general lower than 
those for the corresponding human samples. 
Inhibitory effect of rat PAI on human rtPA 
In peritoneal fluid samples with low PAI activity levels (<1 AU/ml) the recovery of rtPA 
activity was 66% for rat peritoneal fluid and 52% for human peritoneal fluid samples. 
In peritoneal fluid samples containing high levels of PAI activity (>15 AU/ml) the recovery 
was less than 5% (<0.5 lU/ml), both for rat and human samples. 
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Table 3 Degradation of fibnn by rtPA 
Different concentrations of rtPA (0, 0 3, 1,3 3, 10, 33, and 100 ng/ml) were added to rat and human 
normal pooled plasma and incubated for 15 minutes at 37°C Thereafter, clotting of the plasma was 
induced by adding Ca2*, thrombin and batroxobin and clot lysis was allowed to continue for 10 minutes 
After centrifugaron of the mixture, FbDP were measured in the supernatant 
Rat serum Human serum 
rtPA 
(ng/ml) 
FbDP 
(//g/ml) 
FbDP 
(//g/ml) 
0 
03 
1 
33 
10 
33 
100 
• DISCUSSION 
0 
32 
256 
512 
>1024 
>1024 
>1024 
0 
>1024 
>1024 
>1024 
>1024 
>1024 
>1024 
The fibrinolytic system of the rat is quite similarto that of humans, including components, 
such as plasminogen, a2-antiplasmin, plasminogen activators, and plasminogen activator 
inhibitors4 " 15. This similarity also exists at the level of molecular function as indicated 
by cross-reactivity between rat factors and human rtPA observed in this study: (1) 
human rtPA activated rat plasminogen as deduced from clot lysis experiments and 
plasminaemic fibrinogen and fibrin degradation, and (2) human rtPA was inhibited 
by rat PAI as by human PAI. It seemed, however, that a rat clot is less susceptible 
to lysis by human rtPA in comparison with a human clot. In concordance, Korninger 
et al. found only 10% activity of human rtPA on rat plasminogen compared with human 
plasminogen14. The lower rat FbDP than human FbDP concentrations found in the 
present study might also be explained by the less efficient detection of rat FbDP in 
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A qualitative difference observed by us and others is the inability of streptokinase to 
lyse rat plasma clots, which rules out the possibility to use this agent in rat experiments16. 
It is concluded that human rtPA, dissolved in MHPC gel, is suitable to study intra­
abdominal fibrinolytic therapy in the rat. 
•REFERENCES 
1 Gervln AS, Puckett CL, Silver D Serosal hypofibnnolysis A cause of postoperative adhesions Am 
J Surg 1973,125 80-8 
2 Vlpond MN, Whawell SA, Thompson JN, Dudley HA Effect of experimental pentonitis and ischaemia 
on pentoneal fibnnolytic activity Eur J Surg 1994,160 471-7 
3 Ahrenholz DH, Simmons RL Fibnn in pentonitis I Beneficial and adverse effects of fibrin in expenmental 
Escherichia coll pentonitis Surgery 1980,88 41-7 
4 Walker ID, Davidson JF Fibnnolysis In Blood coagulation and haemostasis A practical guide Thomson 
JM, (Ed) Churchill Livingstone, London, 1985 208-63 
5 Colluci M, Paramo JA, Stasse JM, Collen D Influence of the fast acting inhibitor of plasminogen 
activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits Interference 
of tissue-denved components J Clin Invest 1986,76 136-44 
6 Goor H van, Graaf JS de, Grond J, et al Fibnnolytic activity in the abdominal cavity in rats with faecal 
pentonitis Br J Surg 1994,81 1046-9 
7 TIMI Study Group The thrombolysis in myocardial infarction (TIMI) tnal phase I findings N Engl 
J Med 1985,312 932-6 
8 Overgaand К, Serenghy Τ, Boysen G, et al Reduction of infarct volume by thrombolysis with rtPA 
in an embolic rat stroke model Scand J Clin Lab Invest 1993,53 383-93 
9 Zlvln JA, Lyden PD, Degirolami U, et al Reduction of neurologic damage after expenmental embolic 
stroke Arch Neur 1988,45 387-91 
10 Bom VJJ, Brügeman J, Schaaf W van der, et al Rapid enzyme immunoassay of anti-streptokinase 
antibodies in human plasma Clin Chim Acta 1993,218 121-9 
11 Moran DM, Standnng R, Lavender EA, Hams GS Assessment of anti-streptokinase antibody levels 
in human sera using a microradioimmunoassay procedure Thromb Haemost 1985,52 281-7 
12 ClaussA Gennnungsphysiologische Schnellmethode zur besbmmung des Fibnnogens Acta Haematol 
1957,17 237-46 
13 Pitcher PM The detection of fibnnogen degradation products (FDP) in serum and unne J Clin Pathol 
1985,11 403-5 
14 Kominger C, Collen D Studies on the specific fibnnolytic effect of human extnnsic (tissue-type) plasmin-
ogen activator in human blood and in vanous animal species in vitro Thromb Haemost 1981,46 561-5 
15 Padre· Τ, Quax PHA, Hoogen CM van den, et al Tissue-type plasminogen activator and its inhibitor 
in rat aorta effect of endotoxin Artenosder Thromb 1994,14 1459-65 
133 
Human rtPA and rat fibrinolytic system 
16 Lewis JH, Thiel OH van, Hasiba U, et al. Comparative hematology and coagulation: studies on rodenba 
(rats). Comp Biochem Physiol 1985,82A.211-5 
134 
CHAPTER 11 
PHARMACOKINETICS OF HUMAN RECOMBINANT TISSUE TYPE 
PLASMINOGEN ACTIVATOR, ADMINISTERED INTRAABDOMINALLY, 
IN A RAT PERITONITIS MODEL 
H. van Goor1 
V.J.J. Bom2 
J. van der Meer2 
W.J. Sluiter2 
S. Geerards2 
W. van der Schaaf2 
J.S. de Graaf3 
R.P. Bleichrodt3 
1
 Department of Surgery, University Hospital Groningen 
2
 Department of Internal Medicine (Division of Thrombosis, Haemostasis, 
and Rheology), University Hospital Groningen 
3
 Department of Surgery, Twenteborg Hospital Almelo 
The Netherlands 
European Surgical Research, accepted for publication 

Chapter 11 
A INTRODUCTION 
Peritonitis is associated with fibrin deposition in the abdominal cavity as part of the 
host response to inflammation1. Fibrin entraps bacteria, thereby preventing early 
bacteremia. However, bacteria entrapped in fibrin cannot be reached by phagocytes 
and antibiotics, and thus fibrin acts as a nidus for intra-abdominal abscesses23. In 
patients with peritonitis, intra-abdominal abscess formation is a major cause of morbidity 
and mortality4· 
Fibrinolytic activators in the peritoneum are considered to play a key role in the resolution 
of fibrin deposits5·6. Fibrinolytic activity is reduced in peritonitis. This reduction has 
been attributed to a decrease in plasminogen activators and an increase in plasminogen 
activator inhibitors (PAI)5"7. Therefore, intra-abdominal administration of fibrinolytic 
agents, like human recombinant tissue-type plasminogen activator (rtPA), might be 
rational in an attempt to increase intra-abdominal fibrinolytic activity, and thus to prevent 
the development of abscesses. 
There are only scarce data on the intra-abdominal use of rtPA in peritonitis8. The local 
fibrinolytic effect of rtPA may be influenced by PAI in the abdominal cavity during 
peritonitis. A potentially adverse systemic effect of rtPA, as bleeding, may be abolished 
by PAI in the plasma during peritonitis. 
In order to obtain information on the fibrinolytic activity of rtPA in peritonitis, we first 
measured endogenous tPA and PAI activity in the peritoneal fluid and plasma of rats 
with peritonitis. Subsequently, we investigated the pharmacokinetics of rtPA, administered 
intra-abdominally, in such rats. 
A MATERIALS AND METHODS 
Materials 
Human recombinant tPA (rtPA, Actilyse®) was kindly donated by Boehringer Ingelheim, 
Alkmaar, The Netherlands, in vials of 50 mg. This rtPA had a specific activity of 580,000 
lU/mg of protein. rtPA was dissolved in 5 ml sterile water and this stock solution was 
diluted in sterile methyl hydroxy propyl cellulose (MHPC) gel to obtain concentrations 
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of 0.5 and 2 mg/ml rtPA, respectively. Sterile MHPC gel was manufactured locally. 
MHPC was used with the intention to obtain slow release of rtPA. In vitro, MHPC gel 
did not interfere with rtPA activity. The rtPA/MHPC mixtures were vigorously vortexed 
before use. 
Design of the study 
This study consisted of two experiments. In experiment 1, the endogenous tPA activity 
and PAI activity were measured in the peritoneal fluid and plasma of rats with peritonitis, 
and compared with a control group of rats without peritonitis. In experiment 2, tPA 
antigen and activity in these compartments were assessed after intraperitoneal 
administration of a single dose of rtPA, in rats with and without peritonitis. 
Experiment 1 
Male Wistar rats, weighing 250-280 gram, were injected intraperitoneal^ with either 
2 ml sterile saline solution (n=8; group 1) or 2 ml sterile faecal suspension mixed with 
104 colony forming units/ml of both Escherichia coli and Bacteroides fragilis (n=13; 
group 2). After one hour, the rats were anaesthetized and a midline laparotomy was 
performed to debride and lavage the abdominal cavity. After abdominal closure, 5 
ml of normal saline were administered subcutaneously for resuscitation. This experimental 
model has previously been described in more detail9. 
At 1, 2, 4, 8, 16, 32 hours (group 1), and at 1, 2, 4, 8, 16, 32, 64, 128 and 192 hours 
(group 2) after injection, rats were anaesthetized and a peritoneal fluid sample was 
taken for assessment of tPA and PAI activity. Due to small amounts, no peritoneal 
fluid was recovered at 64,128 and 192 hours after injection in rats of group 1. In both 
groups, blood samples were taken before and at 1, 2, 4, 8, 16, 32, 64, 128 and 192 
hours after injection. 5 ml of saline were administered subcutaneously to compensate 
for fluid losses due to blood sampling. 
Experiment 2 
The same model as described above was used in 20 rats; 10 were injected with saline 
(control group) and another 10 with the faecal suspension (peritonitis group). During 
laparotomy, half of the rats in each group received 2.5 ml of MHPC gel containing 
0.5 mg/ml rtPA, the other half 2.5 ml of MHPC gel containing 2.0 mg/ml rtPA. At 1.5, 
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2,4,6,8 and 24 hours after injection, a peritoneal fluid and a blood sample were taken 
to measure tPA antigen and tPA activity. Since the peritoneal fluid recovered from 
rats in the control group was not sufficient for both measurements, only tPA antigen 
was measured in this group. 
In addition, the influence of MHPC gel on plasma tPA antigen levels was assessed. 
To investigate this, another five rats with faecal peritonitis received 0.5 mg/ml rtPA 
dissolved in Ringer's lactate solution (RLS) and their plasma tPA antigen levels were 
compared with those of rats in the peritonitis group, given 0.5 mg/ml rtPA in MHPC 
gel. 
During the experiments rats had free access to water and standard rat chow (MH-B 
1010, Hope Farms, Woerden, The Netherlands). Experiments were performed following 
guidelines of the animal experiments ethical committee. 
Samples 
Peritoneal fluid samples (0.2-0.5 ml) were snap frozen at -80°C immediately after 
percutaneous aspiration from the abdominal cavity. All samples were thawed for exactly 
5 minutes at a temperature of 4°C prior to use. 
Blood samples (0.45 ml), drawn by cardiac puncture, were collected into 0.1 volume 
of ice-cold 0.109 M citrate, pH 6.0, cooled for 5 minutes and centrifuged at 14,000 
g (Eppendorf centrifuge 5415-c) for 5 minutes to prepare platelet free plasma. The 
plasma samples were stored at -80eC. 
Assays 
tPA antigen was measured by ELISA (Asserachrom-tPA, Boehringer, Mannheim, 
Germany). The assay measures both complexed (to PAI) and uncomplexed tPA. Rat 
tPA antigen cannot be measured by this assay. 
tPA activity was measured on euglobulin fractions using the Coaset-tPA assay (Kabi 
Diagnostica, Mölndal, Sweden) described by Nilsson et al.10,11. The assay was performed 
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on euglobulin fractions which were made by acidification of plasma samples or peritoneal 
fluid samples mixed with an equal volume of tPA-poor plasma. The acidification procedure 
was rigorously standardized and was performed by adding 15 //I of 0.044 N acetic 
acid to 200 μΙ of sample on ice, followed by incubation for 30 minutes and centrifugation 
at 14,000 g for 10 minutes to obtain the precipitate. The euglobulin fractions were 
incubated in a suitable dilution (usually 1:100) with plasminogen in the presence of 
a tPA stimulator at 37°C for 3 hours. Plasminogen activation was monitored by the 
presence of S2251, a chromogenic substrate specific for plasmin, by reading the increase 
in absorbance at 405 nm. The assay measured both human and rat tPA activity and 
was calibrated with a tPA standard which is expressed in International Units (IU), asses­
sed by calibration against the International Standard for tPA (NIBSC standard). The 
assay procedure resulted in full recovery of rtPA, spiked into pooled normal human 
plasma for 15 minutes (range 94-110%). 
PAI activity was measured by Berichrom-PAI assay (Behringwerke, Marburg, Germany) 
in peritoneal fluid and plasma samples mixed with one or more volume(s) of PAI-deficient 
plasma. In this assay the sample is incubated with a fixed amount of urokinase at 
37°C during 5 minutes, after which remaining urokinase activity is measured via 
plasminogen activation and subsequent hydrolysis of a chromogenic substrate12. PAI 
activity is expressed in Arbitrary Units (AU) where 1 AU/ml sample is able to inhibit 
1 lU/ml of urokinase in 5 minutes. 
Statistical analysis 
Median values and 95% confidence intervals (CI) or ranges are given. Results were 
analyzed using the Friedmann test with Duncan's correction for multiple comparison 
within groups and using the Mann Whitney-U test for comparison between groups 
after calculation of the area under the curve (AUC). A p-value less than 0.05 was 
considered significant. 
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ARESULTS 
Experiment 1 
In rats of group 1, levels of tPA activity in the peritoneal fluid and plasma were less 
than 2 lU/ml and 6 lU/ml, respectively, at all determination points. 
In rats of group 2, tPA activity in the peritoneal fluid only slightly but significantly increased 
up to 64 hours after inoculation and subsequently declined (Figure 1). 
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Figure 1. Activity of tissue-type plasminogen activator (tPA) in the peritoneal fluid ( · ) and 
plasma (O) of rats inoculated with a faecal suspension. Median values and 95% confidence 
intervals are given. * p<0.05; 4, 16, 32 and 64 hours versus 1 hour after inoculation. 
** p<0.05; 16 hours versus before (0) and 1, 2, 4 and 8 hours after inoculation. 
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The AUC of tPA activity in the peritoneal fluid of animals of group 2 was significantly 
higher than in animals of group 1, between 1 and 32 hours after inoculation. 
Median plasma tPA activity remained about 5.5 lU/ml during the first 8 hours of the 
experiment, dropped to a minimum at 16 hours after injection of the faecal suspension 
and subsequently recovered (Figure 1). There was no significant difference in plasma 
tPA activity between both groups. 
In rats of group 1, levels of PAI activity in the peritoneal fluid and plasma remained 
less than 4 AU/ml and 2 AU/ml, respectively, during the whole experimental period. 
PAI activity in the peritoneal fluid of rats of group 2 steadily increased, reached a 
maximum at 16 hours after inoculation and subsequently decreased (Figure 2). 
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Figure 2. Activity of plasminogen activator inhibitor (PAI) in the peritoneal fluid ( · ) and 
plasma (O) of rats given a faecal suspension. Median values and 95% confidence intervals 
are given. * p<0.05; 4, 8,16, 32, 64 and 128 hours versus 1 hour after injection. ** p<0.05; 
8, 16 and 32 hours versus before (0) and 1 hour after injection. 
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The AUC of PAI activity in group 2 was significantly higher than that in group 1, between 
1 and 32 hours after inoculation. 
Plasma PAI activity in rats of group 2 showed a similar pattern as that in the peritoneal 
fluid (Figure 2). The AUC of plasma PAI activity in these rats was significantly higher 
than in rats of group 1. 
Experiment 2 
tPA antigen levels in the peritoneal fluid of rats in the peritonitis group and in the control 
group were approximately the same. These levels showed a similar pattern of continuous 
decrease in time starting with levels above 100,000 ng/ml for both doses used. The 
biological half life of rtPA dissolved in MHPC gel was approximately two hours. 
tPA activity in the peritoneal fluid of rats with peritonitis was dose-dependent and 
continuously decreased in time starting with median levels of 60,000 and above 100,000 
lU/ml at the dose of 0.5 mg/ml and 2 mg/ml rtPA, respectively. 
The measured tPA antigen levels, the tPA activity calculated from tPA antigen levels 
and the specific activity of rtPA (580,000 lU/mg), and the measured tPA activity, at 
the dose of 0.5 mg/ml rtPA, are shown in Figure 3. The measured tPA activity tended 
to be lower than the calculated tPA activity, reaching a significant difference (p<0.05) 
at 8 and 24 hours after inoculation. A similar, but less pronounced difference, was 
observed at the dose of 2.0 mg/ml rtPA (data not shown). As mentioned before, tPA 
activity was not measured in the peritoneal fluid of control rats due to insufficient amounts 
of fluid. 
Plasma tPA antigen levels showed a dose-dependent increase after administration 
of 0.5 and 2.0 mg/ml rtPA in MHPC gel followed by a decline in both rats with peritonitis 
and control rats (Table 1 ). Maximum levels of tPA antigen at both doses of rtPA tended 
to be lower and showed to occur earlier in rats with peritonitis than in control rats. 
In both groups of animals, plasma tPA activity levels remained below 6 lU/ml during 
the first 8 hours and even decreased to below 1 lU/ml at 24 hours, and these showed 
no dose-level relationship. Similar to peritoneal fluid, the measured tPA activity in the 
plasma of rats in the peritonitis group was markedly lower than the calculated tPA 
activity. Surprisingly, this relative deficit in tPA activity was also found in the plasma 
of the control group. 
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Median plasma levels of tPA antigen at 1.5, 2, 4, 6, 8 and 24 hours after injection 
in rats with peritonitis, given 0.5 mg/ml rtPA in RLS, are listed in Table 1. The AUC 
of tPA antigen in rats given rtPA in RLS was significantly higher than that in rats given 
rtPA in MHPC gel. 
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Figure 3 Median values and ranges of tPA antigen (·), calculated tPA activity (O), and 
measured tPA activity ( • ) in the peritoneal fluid, after administration (one hour after 
inoculation) of 0 5 mg/ml rtPA, dissolved in MHPC gel, in rats of the pentonitis group 
* p<0 05, calculated versus measured tPA activity at 8 and 24 hours after inoculation. 
A DISCUSSION 
This study demonstrates that the fibrinolytic activity in the abdominal fluid of rats with 
faecal peritonitis can be raised substantially up to 24 hours after a single dose of human 
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Table 1. Plasma levels of tPA antigen (AG) at the doses of 0.5 and 2 mg/ml rtPA dissolved in MHPC 
gel, and at the dose of 0.5 mg/ml rtPA dissolved in RLS administered intraperitoneally one hour after 
inoculation (a.i.), in rats with peritonitis and control rats (5 rats in each group). Median values and ranges 
are given. 
tPA Ag plasma ng/ml 
peritonitis rats 
tPA Ag plasma ng/ml 
control rats 
dose 
mg/ml 
05 
MHPC gel 
2 
MHPC gel 
05 
RLS 
05 
MHPC gel 
2 
MHPC gel 
1 5 hours 
ai. 
13 
(8-16) 
50 
(16-100) 
6 
(4-9) 
3 
(0-5) 
24 
(17-33) 
2 hours 
ai 
27 
(15-32) 
90 
(20-480) 
20 
(15-30) 
4 
(4-25) 
30 
(21-42) 
4 hours 
a ι 
32 
(27-39) 
52 
(20-106) 
56 
(42-80) 
8 
(3-30) 
190 
(62-240) 
6 hours 
a i 
25 
(20-42) 
130 
(70-520) 
315 
(273-368) 
27 
(16-36) 
470 
(170-520) 
β hours a i 
15 
(8-20) 
77 
(21-240) 
213 
(145-250) 
76 
(23-84) 
1100 
(470-2000) 
24 hours 
a ι 
3 
(0-5) 
14 
(5-20) 
10 
(5-21) 
3 
(2-5) 
50 
(20-176) 
rtPA, administered intraperitoneally, despite simultaneously high levels of inhibitor 
of fibrinolytic activity. 
Rotstein et al. demonstrated that intra-abdominal administration of 0.01 mg/ml human 
rtPA in Hanks balanced salt solution prevented abscess formation in an infected human 
fibrin clot model8. In the same model high dose rtPA (0.1 mg/ml) prevented abscess 
formation following a 6-hour delay in administration13. They did not report on intra­
peritoneal tPA activity or PAI activity. 
Previously, we have performed a pilot experiment in normal rats, given 0.1 mg/ml human 
rtPA dissolved in MHPC gel intraperitoneally. In this experiment, tPA antigen 
concentrations in the peritoneal fluid were 5000 ng/ml, 10 ng/ml and 0 ng/ml at 0.5, 
8 and 24 hours, respectively, after administration of rtPA. Corresponding plasma levels 
were zero. 
In the present study higher doses than 0.1 mg/ml rtPA were tested for three reasons. 
First, rat fibrin is less susceptible to human rtPA than human fibrin, which was used 
in the fibrin clot model of Rotstein and co-workers14. Second, higher amounts of intra­
abdominal fibrin were expected in the present model, as compared with the fibrin clot 
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model, due to the difference in seventy of peritonitis. Third, the dose of 0.1 mg/ml 
rtPA resulted in very low tPA antigen levels in the abdominal cavity, particularly at 
8 and 24 hours. These levels were not expected to be sufficient to lyse rat fibrin. 
High tPA antigen levels were obtained in the abdominal cavity in the present experiment, 
especially during the first six to eight hours after administration of rtPA. However, 
measured tPA activity levels in peritonitis were much lower than inferred from antigen 
levels and the specific activity of the rtPA agent (580,000 lU/mg pure protein). Inhibition 
by PAI might explain the differences between the calculated and measured tPA activity15. 
This is supported by the simultaneity in the most pronounced differences in calculated 
and measured tPA activity levels in the peritoneal fluid of rats with peritonitis in the 
second experiment, and the highest endogenous PAI activity levels in the peritoneal 
fluid of those in the first experiment. Moreover, the differences between the calculated 
and measured tPA activity levels tended to be smaller at the high dose (2.0 mg/ml) 
rtPA. 
Plasma levels of tPA antigen in rats with peritonitis tended to be lower than those in 
control rats. First, this might be due to the high affinity of rtPA for the intra-abdominal 
fibrin deposits of rats with peritonitis16. Second, rtPAthat is complexed to intra-abdominal 
PAI, might not enter the circulation in these rats. The use of MHPC gel has contributed 
to low plasma levels of tPA antigen in rats with peritonitis. 
The relatively low levels of tPA antigen and particularly of tPA activity in the plasma 
may be a favourable aspect of the intra-abdominal use of rtPA in peritonitis, reducing 
the risk of bleeding, a potential side effect of rtPA. However, these findings do not 
reassure that bleeding cannot occur, as these may occur locally within the peritoneal 
cavity following surgery and sepsis. In another experiment in rats with faecal peritonitis, 
we found normal plasma levels of fibrinogen at the dose of 2.0 mg/ml rtPA, and even 
increased fibrinogen levels at the dose of 0.5 mg/ml rtPA. 
Analogous to peritoneal fluid, the observed increased plasma levels of endogenous 
PAI might be responsible for the low levels of tPA activity found in plasma. However, 
forming an inactive complex with PAI does not explain the low plasma tPA activity 
in control rats, since plasma PAI activity in these rats was low. Other circulating inhibitors 
of tPA than PAI, as described in mice, might explain this discrepancy between tPA 
antigen and activity levels17. 
In comparison with 0.5 mg/ml rtPA, the dose of 2 mg/ml rtPA resulted in higher levels 
of tPA activity in the abdominal cavity but not in plasma. Based on these results, 
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2 mg/ml rtPA might be preferred for further experiments. 
Finally, we would like to take into consideration that in this study a mildly acidic citrate 
anticoagulant (pH 6 0) in stead of one of the newly recommended strongly acidic citrate 
anticoagulants (pH 4.0-4.4) was used for blood sampling to prevent ex vivo complex 
formation between PAI and tPA or urokinase-type plasminogen activator1819. Although 
in normal citrated plasma the tPA recovery was about 100% (see tPA activity assay), 
a recent study in patients with peritonitis showed that the more acidic citrate anticoagulant 
(Stabilyte® tubes) resulted in a 2.3-fold (range 1.4- to 6.0-fold) higher level of tPA acti­
vity20. Thus, plasma levels of tPA activity might have been underestimated in the present 
study. For peritoneal fluid samples we did not use an anticoagulant at all, but we snap 
froze these samples immediately after aspiration and used minimal thawing times before 
measurements. Theoretically this procedure also might have resulted in underestimation 
of tPA activity levels in the peritoneal fluid. Comparison of different sampling procedures 
in a recent study on patients with peritonitis suggests that peritoneal fluid levels are 
not affected by the anticoagulant method used, possibly because of the acidic nature 
of the peritoneal fluid in peritonitis21. 
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• INTRODUCTION 
Fibrin deposition in the abdominal cavity is an integral host reaction to intra-abdominal 
inflammatory processes. In one respect, it has beneficial effects, walling off infectious 
foci thus localizing infection and preventing early systemic spread of bacteria1"1. However, 
it has deleterious effects on the intra-abdominal defense mechanisms. Fibrin deposits 
prevent the clearance of bacteria from the abdominal cavity by occluding the stornata 
in the diaphragm. Moreover, bacteria that are caught in fibrin are not accessible to 
the immunologic defense mechanisms and to antimicrobial agents5"7. The colonized 
fibrin clots are a nidus for abscess formation, which is an important cause of morbidity 
and mortality in patients with generalized peritonitis8 9. Therefore, a thorough debridement 
of the abdominal cavity that removes all fibrin deposits, is of utmost importance in 
the operative treatment of patients with generalized peritonitis. However, surgical debride-
ment is often incomplete and has a high risk of complications, such as bleeding and 
intestinal perforation10. Moreover, new fibrin deposits will be formed immediately after 
operation. 
Fibrin deposition depends on the balance between fibrin formation and fibrinolysis. 
During peritonitis, intra-abdominal fibrin formation is enhanced, whereas fibrinolytic 
activity is reduced11"13. Therefore, exogenous stimulation of intra-abdominal fibrinolysis 
could be of benefit in preventing abscess formation. 
The present study was designed to determine first, if topically applied recombinant 
tissue plasminogen activator (rtPA), which is a potent stimulator of fibrinolysis14, is 
able to prevent intra-abdominal abscess formation in rats with generalized peritonitis, 
and second, if intra-abdominal use of rtPA is safe with respect to complications, such 
as sepsis and bleeding. 
•MATERIALS AND METHODS 
Design of the study 
The study consisted of two consecutive experiments. In experiment 1, the effects of 
rtPA on intra-abdominal abscess formation and bacteraemia were assessed. In 
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experiment 2, the effect of rtPA on early bacteraemia was studied, using a higher dose 
of bacteria in the inoculum as compared with experiment 1. 
Experiment 1 
Male Wistar rats, weighing 250 to 280 g, were injected intraperitoneal^ with 2 ml of 
a faecal suspension containing 104 colony forming units (cfu) per ml of Escherichia 
coli(E. coli) and 104cfu per ml Bactericides fmgilis (B. fragilis). One hour after inoculation, 
the rats were anaesthetized with a halothane-nitrous oxide-oxygen mixture. Through 
a midline laparotomy, the abdomen was debrided, which included a partial omentectomy, 
and was thoroughly rinsed with normal saline solution. Before closure of the abdomen, 
the rats were randomly assigned to one of three treatment groups. Group 1 (n= 20) 
received 2.5 ml Ringer's lactate solution intraperitoneally, group 2 (n= 20) received 
2.5 ml methyl hydroxy propyl cellulose (MHPC) gel, and group 3 (n= 32) received 2.5 
ml MHPC gel containing 0.5 mg per ml rtPA (kindly provided by Boehringer Ingelheim, 
Alkmaar, The Netherlands). MHPC gel was used as a vehicle. The abdomen was 
closed in two layers with running 4x0 polypropylene sutures. Postoperatively, 5 ml 
of normal saline solution were administered subcutaneously for resuscitation. Following 
operation, the rats had free access to water and standard rat chow (MH-B 1010, Hope 
Farms, Woerden, The Netherlands). At zero, six, 12 and 24 hours after laparotomy, 
blood samples were taken under general anaesthesia to assess bacteraemia. The 
rats were weighed at day zero and day 5. At day 5, the surviving rats were sacrificed 
by intracardiac pentobarbital injection. In all rats, the abdomen was reopened using 
sterile conditions and meticulously inspected for abscess formation and haematomas. 
All intra-abdominal collections containing "purulent' material were counted as abscesses. 
The abscess localization was noted and, if present, abscesses at different spots were 
excised for culture. 
Experiment 2 
The aforementioned model of intra-abdominal infection was used, but 10s cfu per ml 
E. coli was instilled instead of 10* cfu per ml E. coli. At laparotomy, the rats received 
either 2.5 ml of MHPC gel (n=8; control group) or 2.5 ml of MHPC gel containing 0.5 
ml per mg rtPA (n=11 ; rtPA group). At zero, one, three, six and 12 hours after laparotomy, 
blood samples were taken under general anaesthesia for culture. At the same time, 
5 ml of sterile saline solution were injected subcutaneously for resuscitation. 
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Bacterial faecal suspension 
E. coli strain American Type Culture Collection (ATCC) 25922 and S. fragilis from 
a clinical isolate were used in a concentration of 10" cfu per ml Schaedler broth (Oxoid, 
Hampshire, United Kingdom) in experiment 1. In experiment 2, E. coli was used in 
a concentration of 108 cfu per ml. Bacteria were cultured according to standard methods 
described previously13. 
Fresh faeces of Wistar rats were weighed and 1:2 suspended into pyrogen free water. 
After homogenization, the suspension was sterilized by steam (121 degrees С for 
20 minutes) and centrifugea at 2,000 revolutions per minute for 15 minutes. The 
supernatant was homogenized, resterilized and stored at 4 degrees С Immediately 
before intraperitoneal injection, the faecal suspension was mixed with the bacterial 
suspensions. 
Bacteria within abscesses 
The excised abscesses were minced in Brain Heart Infusion (BHI) broth (Oxoid, 
Hampshire, United Kingdom) and in Schaedler broth for aerobe and anaerobe culturing, 
respectively, and were subsequently outplated. After 24 (aerobes) and 48 (anaerobes) 
hours of incubation at 37 degrees C, any growth was identified according to standard 
procedures. 
Blood cultures 
Blood samples (0.45 ml) were taken by cardiac puncture under general anaesthesia 
and collected in sterile tubes containing 0.05 ml buffered citrate. Serial dilutions in 
BHI broth were made and plated onto both aerobic (Mac Conkey, blood agar; Oxoid, 
Hampshire, United Kingdom) and anaerobic (Bacteroides bile esculin agar, Brucella 
blood agar Becton-Dickinson, Baltimore, USA) plates. After 24 and 48 hours of incubation 
at 37 degrees C, bacteria were counted and identified. Bacterial concentration was 
expressed in "log cfu per ml whole blood. 
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Statistics 
Statistical analysis was performed using chi-square test, and Student's f test or Kruskall 
Wallis rank analysis, when appropriate. When p-values were less than 0.05, a difference 
between groups was considered significant. 
ARESULTS 
Experiment 1 
All rats lost weight during the experimental period. Average (± SD) weight loss at day 
5 was 8.0 percent (± 2.9) in group 1, 7.3 percent (± 2.2) in group 2, and 8.5 percent 
(± 1.8) in group 3. The differences between groups were not statistically significant. 
The mortality rate in group 3 (ten of 32 rats, 31 percent) was significantly higher (p<0.01) 
than in groups 1 and 2 (two of 40, 5 percent). None of the ten rats in group 3 that 
died had intra-abdominal abscesses at autopsy. All of these rats died between 12 
and 24 hours after laparotomy. Rats in group 1 and 2 died three days after laparotomy 
and had multiple intra-abdominal abscesses at autopsy. No rat died due as a result 
of intra-abdominal bleeding. 
All rats in group 1 (20 of 20 rats) and group 2 (20 of 20 rats) had intra-abdominal 
abscess, in contrast to only one-half of those in group 3 (16 of 32 rats). Of the 22 
surviving rats in group 3 that had received rtPA, six (27 percent) did not have any 
abscesses. The number of abscesses in the 16 rats in group 3 that bore abscesses 
was significantly lower when compared with group 1 or group 2 (Table 1). The localization 
of abscesses differed also between rats in group 3 and rats in groups 1 and 2. Whereas 
abscesses in 15 of 16 rats of group 3 were found in the subdiaphragmatic space and 
around the liver, 34 of 38 rats in groups 1 and 2 showed abscesses spread over the 
whole abdominal cavity. 
The bacterial species cultured from the intra-abdominal abscesses are listed in Table 
2. E. coli (ATCC 25922) was found in most of the abscesses. In contrast, B. fragilis 
was only cultured from abscesses in one rat. Three rats had sterile abscesses, two 
in group 1, and one in group 3. A Proteus mirabilis species was cultured in 32 percent 
of the rats in group 1, in 37 percent of group 2, and in 25 percent of group 3. Other 
than E. coli (ATCC 25922) and B. fragilis, all species isolated from the abscesses 
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were present in the faecal contents obtained from the caecum of these rats (data not 
shown) 
All rats had negative blood cultures at all determination points None of the rats had 
intra-abdominal haematomas 
Table 1 Effect of rtPA on abscess formation in surviving rats 
—^ 
group no of rats no of abscesses 
with abscesses per rat 
(total no ) median (range) 
1 19 (19) 
2 19(19) 
3 16 (22) 
* p<0 01, group 3 vs group 1 and 2 
Experiment 2 
In none of the blood samples, which were taken immediately before and one hour 
after laparotomy, bacterial growth was detected Three hours after laparotomy, only 
one rat in the rtPA group had a positive blood culture Six hours after laparotomy, 
eight (73 percent) of 11 rats in the rtPA group had a positive blood culture, compared 
with none (zero percent) of the eight rats in the control group The median (range) 
blood bacterial concentration in the rtPA group was 103 (zero to 105) Twelve hours 
after laparotomy, all rats in both groups had a positive blood culture The median (range) 
blood bacterial concentration in the rtPA group was 106 (104 to 108) and in the control 
group, 10s (103 to 107) In all rats with positive blood cultures, only E coli (ATCC 25922) 
was isolated from the blood None of the rats in either group survived for more than 
24 hours after laparotomy 
.^DISCUSSION 
The present study demonstrates that enhancement of the intra-abdominal fibrinolytic 
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Table 2 Bacteriology of intra-abdominal abscesses in surviving rats 
group no of rats no (%) of rats with positive cultures 
with abscesses E coli В fragilis P. mirabilis 
17 (89) 0 (0) 6 (32) 3 (16) 
19 (100) 0 (0) 7 (37) 4 (21) 
13 (81) 1 (6) 4 (25) 2 (13) 
E coli, Eschenchia coir, В fragilis, Bacteroides fragilis, Ρ mirabilis, Proteus mirabilis 
'other species are Enterococci, Staphylococci epidermide, E coli (other than ATCC 25922) and anaerobe 
gram-positive rods 
activity by intra-abdominal administration of rtPA substantially reduces the number 
of abscesses in rats with generalized peritonitis. Entrapment of bacteria in fibrin in 
the abdominal cavity is a significant cause of abscess formation in generalized peritonitis2. 
As operative treatment alone cannot prevent intra-abdominal abscess formation, enhance­
ment of intra-abdominal fibrinolysis by rtPA to optimize removal of fibrin might be a 
beneficial adjunct to operative treatment. This supposition is based on recently published 
studies of Rotstein and others, who showed that rtPA prevents abscess formation 
in rats in whom colonized fibrin clots were implanted intra-abdominally1516. Because 
their model, using human fibrin clots in rats, has limited similarity to the clinical situation, 
we used a model of generalized peritonitis, in which residual intra-abdominal abscesses 
occur in nearly 100 percent of rats. In our opinion, this approach has more clinical 
relevance. 
In the experiments, we used a dose of 0.5 mg per ml rtPA. This dose was based on 
the results of previously performed studies by our group17. This dose resulted in high 
intra-abdominal levels of tPA activity during eight hours after instillation and only slightly 
increased plasma tPA activity levels. Plasma tPA activity levels probably were low 
because of a slow release of rtPA from the abdominal cavity due to its high molecular 
weight and its high affinity for fibrin18. Furthermore, tPA might be inhibited by high 
plasma levels of plasminogen activator inhibitor. These were demonstrated by Paramo 
other* 
1 19 
2 19 
3 16 
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and co-workers in patients with bacterial infections18. Methyl hydroxy propyl cellulose 
gel was used as a vehicle to further reduce the release of rtPA from the abdominal 
cavity17. Moreover, it has been suggested that cellulose gel prevents adhesion formation. 
This effect of cellulose gel has been attributed to mechanical separation of the bowels 
and high local activity of plasminogen activator on peritoneal surfaces20,21. However, 
we were not able to demonstrate a favourable effect of MHPC gel alone on abscess 
formation, whereas gel containing rtPA reduced the abscess rate, particularly for 
abscesses localized between the bowels. 
Cultures from the abscesses revealed two interesting observations. First, B. fragilis 
was not cultured from the abscesses. The absence of B. fragilis in the abscesses might 
be explained by the fact that the abdominal concentration of this anaerobe had been 
reduced substantially after operative treatment". Secondly, the presence of P. mirabilis 
and other species in the abscesses, originating from the intestines of the rats, showed 
the occurrence of bacterial translocation. A similar observation has been reported 
previously by other authors in experimental and clinical studies23"26. 
Early bacteraemia and bleeding are potential hazards of (intra-abdominal) use of rtPA1527" 
2e
. To our surprise, bacteraemia was not observed in experiment 1. Therefore, we 
repeated the experiment with a 10,000 fold higher dose of E. coli. In that experiment, 
E. coli bacteraemia was observed earlier indeed in the rtPA treated group. Rotstein 
and associates demonstrated a correlation between rtPA, early E. coli bacteraemia, 
and increased mortality rates15. This is not corroborated by the results of our study. 
Although early bacteraemia was present more frequently in the rtPA group in experiment 
2, we did not find a relation between mortality and bacteraemia in either experiment 
1 or 2. Nevertheless, Rotstein and associates showed a marked reduction of mortality 
rates when bacteraemia was avoided by systemic use of antibiotics in their experiments15. 
In concordance with others, we did not observe an increased incidence of bleeding 
in the abdomen or elsewhere associated with the use of rtPA27·30. This is explained 
most likely by the low tPA activity in the plasma, as was previously discussed. 
Recombinant tissue plasminogen activator administered into the abdominal cavity in 
rats with generalized peritonitis reduces the number of intra-abdominal abscesses. 
However, early bacteraemia and increased mortality rates are serious drawbacks of 
the intra-abdominal use of rtPA in this rat model. 
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Chapter 13 
¿INTRODUCTION 
Intra-abdominal abscesses are an important cause of morbidity and mortality in patients 
with generalized peritonitis1. Formation of intra-abdominal abscesses is mediated by 
fibrin clots, which are colonized by bacteria2. Several experimental studies have been 
attempted to prevent the formation of intra-abdominal abscesses by inhibition of fibrin 
formation with heparin or by activation of fibrinolysis with plasminogen activators3,4. 
In a previous experiment, we demonstrated a reduction of intra-abdominal abscesses 
with the use of a viscous gel that contained recombinant tissue plasminogen activator 
(rtPA) in rats with generalized peritonitis5. However, rats treated with rtPA had an 
increased mortality rate, and early Escherichia coli (E. coli) bacteraemia was observed 
more frequently, probably as a result of early degradation of fibrin. In the present study, 
it was determined whether or not mortality and bacteraemia could be prevented by 
the administration of gentamicin in rats with generalized peritonitis treated with rtPA 
intraperitoneal^. 
A MATERIALS AND METHODS 
Design of the study 
Experiment 1 
Male Wistar rats, weighing between 255 and 290 g were used. Generalized peritonitis 
was induced by intraperitoneal injection of 2 ml faecal suspension containing 1 tf colony 
forming units (cfu)/ml E. coli and 10* cfu/ml Bacteroides fragilis (β. fragilis). After one 
hour, a midline laparotomy was performed under general anaesthesia (halothane-nitrous 
oxide-oxygen mixture). The abdomen was debrided (including partial omentectomy) 
and rinsed with normal saline solution. Before closure of the abdomen, the rats received 
either2.5 ml methyl hydroxy propyl cellulose (MHPC) gel (Clinical Pharmacy, Groningen, 
The Netherlands) (n=14) or 2.5 ml MHPC gel containing 0.5 mg/ml human rtPA 
(Boehringer Ingelheim, Alkmaar, The Netherlands) (n=20) intraperitoneally. MHPC 
gel was used as a vehicle. After operation, 5 ml of normal saline solution were 
administered subcutaneously for resuscitation. At three hours after induction of peritonitis, 
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one-half of the rats in each group received gentamicin sulphate, 6 mg/kg body weight, 
intramuscularly (IM) in a single dose. Thus, four experimental groups were formed: 
MHPC gel alone (M), MHPC gel plus rtPA (M-tPA), MHPC gel plus gentamicin (M-G), 
and MHPC gel plus rtPA plus gentamicin (M-tPA-G). At one, three, six, 12 and 24 
hours after inoculation, blood samples (0.45 ml) were taken by cardiac puncture while 
rats were under general anaesthesia to assess bacteraemia. Lost blood volume was 
compensated by subcutaneous administration of 5 ml of normal saline solution. Five 
days after inoculation, the surviving rats were sacrificed by intracardiac pentobarbital 
(Nembutal®, Abbott Laboratories, North Chicago, USA) injection and inspected for 
intra-abdominal abscess formation. 
Experiment 2 
In a similar experiment, published previously5, we inoculated 104 instead of 10e cfu/ml 
E. coli. It was found that mortality rates in rats treated with rtPA were significantly higher 
but bacteraemia was not observed. In the present study, this experiment was repeated 
including a group of rats receiving gentamicin IM. 
The same model of intra-abdominal infection and treatment was used as already 
described. Faecal suspension contained 104 cfu/ml E coli and 104 cfu/ml B. fragilis. 
At laparotomy, the rats received either 2.5 ml of MHPC gel (n=16) or 2.5 ml of MHPC 
gel containing 0.5 mg/ml rtPA (n=24). Half of the rats in each group received gentamicin 
sulphate (6 mg/kg body weight IM, three hours after inoculation). Thus, analogous 
experimental groups to those in experiment 1 were obtained. Blood cultures were taken 
at three, six, 12 and 24 hours after inoculation. Five days after inoculation, the abdomens 
of surviving rats were reopened under sterile conditions and abscesses were counted. 
If present, abscesses on different spots were excised for culture. During the experiments, 
the rats had free access to water and standard rat chow (MH-B 1010, Hope Farms, 
Woerden, The Netherlands). 
Bacterial faecal suspension 
E coli strain American Type Culture Collection (ATCC) 25922 and B. fragilis from 
a clinical isolate were used. Bacteria were cultured according to standard methods. 
The mean inhibitory concentration of gentamicin for this E. coli strain was 0.5 mg/l 
as measured by the Ε-test (AB Biodisk, Solna, Sweden). 
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Fresh faeces of Wistar rats were prepared as described previously*. Prior to intraperito-
neal injection, the sterile faecal suspension was vigorously mixed with the bacterial 
suspensions. 
Cultures of abscesses 
The excised abscesses were cultured semiquantitatively using standard aerobic and 
anaerobic bacteriologie techniques. 
Blood cultures 
Blood (0.45 ml) was collected in sterile tubes containing 0.05 ml buffered citrate. Serial 
dilutions in Brain Heart Infusion broth were made and plated onto both aerobic 
(MacConkey, blood agar; OxokJ, Hampshire, United Kingdom) and anaerobic (Bacteroides 
bile escutine agar, Brucella blood agar; Becton-Dickinson, Baltimore, USA) plates. 
After 24 and 48 hours of incubation at 37°C bacteria were counted and identified. Bacte-
rial concentration was expressed in 10log cfu/ml whole blood. 
Statistics 
Statistical analysis was performed using chi-square test, Yates and Cochran or Kruskall 
Wallis rank analysis, when appropriate. When the p-value was less than 0.05, a difference 
between groups was considered significant. 
•RESULTS 
Experiment 1 
At one hour after inoculation none of the rats had bacteraemia. At 12 hours after 
inoculation, all rats in group M and M-tPA had bacteraemia, and all died within 24 
hours. Bacteraemia occurred earlier in rats in group M-tPA in comparison with those 
in group M, as reflected by a significantly (p<0.05) higher number of rats with bacteraemia 
at six hours after inoculation (Figure 1). Gentamicin significantly reduced the number 
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of rats with bacteraemia: in the M-tPA-G group at six and 12 hours and in the M-G 
group at 12 hours after inoculation. Also, mortality was significantly (p<0.05) reduced 
by gentamicin in these groups of rats (Figure 2). 
p<0.05 p<0.05 
, I 
p<0,02 p<0,01 
rats with bacteremia ή ή ή 
100% -ι 
80% 
60% 
4 0 % -
2 0 % -
0% 
hours 
M M-G M-tPA M-tPA-G 
Figure 1. Percentage of rats with bacteraemia at three, six and 12 hours after inoculation 
of 2 ml sterile faeces contaminated with 10e cfu per ml E coli and 10" cfu per ml B. fragilis. 
At six hours there was a significant effect of gentamicin in the M-tPA-G group and at 12 
hours in both groups. At six hours significantly (p<0.05) more rats in group M-tPA than 
in group M had bacteraemia. 
At 12 hours after inoculation, blood cultures revealed a median bacterial concentration 
of 105, ranging from 102 to 107, in rats in group M and M-tPA. The bacterial concentration 
was significantly (p<0.05) reduced in rats treated with gentamicin to a median concen-
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tration of zero (range, zero to 107). However, the bacterial concentration in the one 
rat in group M-G and the three rats in group M-tPA-G that had bacteraemia did not 
differ significantly from those in group M and M-tPA: 104 (102-105) compared with 10s 
(102-107). Only E. coli (ATCC 25922) was isolated from the blood. At 24 hours after 
inoculation, all blood cultures available from surviving rats revealed no growth. Three 
of the six surviving rats in group M-tPA-G were free of intra-abdominal abscesses 
at day 5, whereas all five surviving rats in group M-G had multiple intra-abdominal 
abscesses. 
p<0.05 
I 
100%i 
80% 
60% 
40% 
20% 
0% 
mortality 
p<0.05 
I 
1 i 
M M-G M-tPA M-tPA-G 
Figure 2. Mortality rates in rats after inoculation of sterile faeces contaminated with 10e 
E. coli and 104 В. fragilis. Mortality is significantly (p<0.05) reduced by gentamicin. 
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Experiment 2 
When inoculated with 104 £. coli, five out of 12 rats (42%) in group M-tPAdied compared 
to zero out of eight rats (0%) in group M. Rats died between 12 and 24 hours after 
inoculation and none of them had abscesses at autopsy. Positive blood cultures were 
not found in any rat during this experiment. Surpnsingly, gentamicin prevented mortality: 
0/12 in group M-tPA-G compared with 5/12 in group M-tPA; p<0.05. None of the eight 
rats in group M-G died. 
Five days after inoculation, intra-abdominal abscesses were found in all rats in group 
M and M-G, in six of seven surviving rats in group M-tPA, and in 11 of 12 rats in group 
M-tPA-G. In four rats (two in group M-G, two in group M-tPA-G) no bacteria were isolated 
from the excised abscesses. In rats with positive cultures of intra-abdominal abscesses 
and treated with rtPA, the median number of abscesses was significantly lower (p<0.01) 
than in those not treated with rtPA: 3 (range, 1-4) in group M-tPA and 4 (range, 1-8) 
in group M-tPA-G compared with 11 (range, 8-15) in group M and 10 (range, 7-13) 
in group M-G. Gentamicin did not influence the number of abscesses. 
E. coli ATCC 25922 was cultured from abscesses in most cases (Table 1). In contrast, 
B. fragilis was not found. Other species seemed to be more frequently isolated from 
abscesses in rats treated with gentamicin compared with those not treated with 
gentamicin. 
Table 1. Bacteriology of intra-abdominal abscesses in surviving rats with positive cultures 
group 
M 
M-G 
M-tPA 
M-tPA-G 
number of rats 
with positive cultures 
θ 
6 
6 
9 
number of rats 
with E coli ATCC 25922 
(%) 
7(88) 
4(67) 
6 (100) 
7(7B) 
number of rats 
with other species* 
(%) 
4(50) 
6 (100) 
1(17) 
6(67) 
'other species are Enterococci, Staphylococci, Proteus, and Candida, which were not sensitive to 
gentamicin 
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A DISCUSSION 
The present study demonstrates that antibiotic treatment markedly reduces early 
bacteraemia and reduces the mortality rate in rats with generalized peritonitis that 
are treated with rtPA to prevent the formation of residual abscesses. 
Fibrin entraps bacteria, thus preventing early bacteraemia and mortality in generalized 
peritonitis26. However, these colonized fibrin clots are the nidus for intra-abdominal 
abscesses. It is expected that intra-abdominal application of rtPA to prevent these 
abscesses will cause early bacteraemia. In concordance with previous findings, early 
bacteraemia occurred in association with the use of rtPA45. 
A single dose of 6 mg/kg gentamicin sulphate, administered intramuscularly three hours 
after onset of peritonitis, reduced bacteraemia and mortality rates in experiment 1, 
and the mortality rates in experiment 2. rtPA appeared to be the main factor reducing 
abscess formation in contrast to gentamicin. Several authors have reported the inability 
of antibiotics to reduce abscess formation6"8. Hau and associates have demonstrated, 
using a fibrin clot model, that gentamicin like several other antibiotics does not influence 
abscess formation mainly because inhibitory levels within the fibrin clot are not reached7. 
However, in the same model a reduction of colony count per abscess by gentamicin 
sulphate has been reported8. We did not quantitate bacteria in abscesses. Qualitatively, 
the use of gentamicin seemed to have altered the bacterial flora of the abscesses. 
The absence of B. 'fragilis in the abscesses was remarkable. This might be due to 
the peritonitis model used, as was pointed out previously5. 
From this and previous studies459 it emerges that intra-abdominal administration of 
rtPA may be a valuable adjunct to the standard treatment of patients with generalized 
peritonitis in order to prevent intra-abdominal abscess formation. Antibiotics directed 
against the causal bacteria are an essential part of this treatment. With the use of 
appropriate antibiotics, the risk of bacteraemia associated with the use of rtPA in the 
clinical situation is expected to be minor. Bleeding, another potential risk of the use 
of rtPA clinically, has so far not been observed in experiments wherein rtPA has been 
administered into the abdominal cavity5,10. 
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д INTRODUCTION 
Generalized peritonitis, caused by a perforated viscus or anastomotic leakage, is a 
life-threatening illness. With surgical intervention, antibiotic therapy and supportive 
techniques for the care of patients with serious intra-abdominal infection, mortality 
has decreased from 90% early this century to 25% in more recent years1. Despite 
these advances, mortality from several forms of intra-abdominal infection remains high. 
For example, patients with large bowel perforation, anastomotic leakage and pancreatic 
necrosis have mortality rates, varying from 20% to 60%2. Many of these patients suffer 
from persistent or recurrent intra-abdominal infection and eventually die due to multiple 
organ dysfunction syndrome3. 
In the past twenty years, new operative techniques, such as "radical debridement", 
continuous postoperative peritoneal lavage and "planned relaparotomy" have been 
introduced to treat patients with severe intra-abdominal infection4"9. These techniques 
have a common aim: to eliminate infection potentiating material, such as bacteria, 
necrosis and fibrin from the abdominal cavity as radical and as soon as possible, in 
order to prevent residual or recurrent infection. 
In this thesis, the results of "planned relaparotomy" to treat patients with generalized 
peritonitis due to perforation of the colon or anastomotic leakage (Chapter 6) and patients 
with infected pancreatic necrosis (Chapter 7), have been described. 
The goal of this aggressive treatment was achieved. In the majority of patients intra­
abdominal infection was controlled effectively and only 3% of the patients developed 
an intra-abdominal abscess. A major drawback of "planned relaparotomy" was the 
high frequency of intra-abdominal complications. The nature of these complications, 
such as bleeding and bowel perforation, strongly suggests repeated mechanical removal 
of fibrin and necrosis to be a causal factor. 
The adverse effect of repeated mechanical removal of fibrin and debris from the abdominal 
cavity has stimulated our search for an alternative to remove fibrin from the abdominal 
cavity, in order to prevent residual intra-abdominal abscess formation. Enzymatic removal 
of fibrin, by increasing the fibrinolytic activity in the abdominal cavity, seemed us to 
be a good alternative. 
In this thesis the following objectives were addressed: 
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1. What is the influence of intra-abdominal infection on the coagulation cascade 
and the fibrinolytic system in the abdominal cavity (Chapter 8 and 9)? 
2. What is the effect of enhancement of fibrinolytic activity on intra-abdominal abscess 
formation after peritonitis (Chapter 10, 11, 12 and 13)? 
1. The influence of intra-abdominal infection on fibrin formation and fibrinolysis 
in the abdominal cavity 
Intra-abdominal inflammatory processes result in the exudation of protein-rich fluid 
in the abdominal cavity. In this fluid fibrin is formed through activation of the coagulation 
cascade. These fibrin deposits are degraded by the fibrinolytic system in the peritoneal 
cavity. When this system fails, fibrinous adhesions are invaded by fibroblasts, and 
are transformed into permanent fibrous tissue within five days after the insult. 
In the peritoneal fluid of our patients with peritonitis the coagulation cascade was found 
to be activated. It is assumed that the coagulation cascade is activated via the extrinsic 
pathway, which is initiated by tissue factor (TF)7. This assumption is based on the 
fact that TF is expressed in vitro on the surfaces of cells, involved in peritoneal inflammation, 
upon stimulation with inflammatory mediators8. Furthermore, recent studies in healthy 
volunteers and non-human primates revealed that the activation of coagulation in plasma 
by administration of endotoxin or tumor necrosis factor (TNF) is completely TF pathway 
dependent9,10. However, the intrinsic pathway may also been involved in intra-abdominal 
fibrin formation, since activators of this pathway, such as prekallikrein, have been 
demonstrated in the peritoneal fluid of patients with peritonitis11. 
We also have demonstrated activation of the fibrinolytic system in combination with 
high concentrations of plasminogen activator inhibitor (PAI) in the peritoneal fluid of 
both rats and humans with peritonitis. 
It seems that the balance between coagulation and fibrinolysis in the abdominal cavity 
is disturbed following intra-abdominal infection. This disturbance is probably responsible 
for persistence of intra-abdominal fibrin and subsequent adhesion and abscess formation. 
However, the degree of disturbance in the balance between coagulation and fibrinolysis 
may vary in time during intra-abdominal infection and it may be possible that the balance 
is rapidly restored after elimination of the infectious focus. Thus, it is important to know 
the sequential changes of coagulation and fibrinolysis in the abdominal cavity during 
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infection and after removal of the infectious source. 
To our knowledge, there are no longitudinal studies of the coagulation response in 
the peritoneal fluid to bacterial peritonitis. However, it is obvious that fibrin will be formed 
in the abdominal cavity as long as the infectious focus remains in situ. 
Stimulation of the coagulation process may continue for some time after elimination 
of the source of infection, since the inflammatory response will diminish only slowly. 
More is known about sequential changes in the fibrinolytic response to bacterial peritonitis. 
Recently, Vipond et al. measured the time course of alteration in plasminogen activating 
activity (PAA, resultant of activation and inhibition of fibrinolysis) in biopsies of the 
peritoneum in an animal model of mild bacterial peritonitis12. They demonstrated a 
pronounced reduction of PAA in the first 12 hours after inoculation followed by a rise 
of PAA and return to baseline levels at one week. The initial drop of PAA was attributed 
to increased concentrations of PAI, whereas the rise of PAA thereafter was related 
to increased concentrations of tissue-type plasminogen activator (tPA). 
Most studies have shown that the increased PAI activity is mainly responsible for the 
initial depression of fibrinolytic activity during peritonitis12'14. We have demonstrated 
not only an initial increase in PAI activity in the peritoneal fluid of rats with peritonitis, 
but persistently elevated levels of PAI activity for 5 to 8 days after the initial insult1 
5
. This persistent elevation of PAI might be attributed to the presence of residual intra-
abdominal infection in our experimental model. Others found a reduction of peritoneal 
fibrinolytic activity, which was due to increased release of plasminogen activator inhibitors, 
for more than 4 days after abrasion of a great part of the parietal peritoneum16. 
The regeneration of fibrinolytic activity in the peritoneum coincides with the timing of 
healing of the peritoneum. Histological studies of peritoneum after mild ischaemic or 
mechanic injury show complete healing within 7 days17"19. The timing of healing of 
the peritoneum might depend on the severity of the initial injury16. In our experiment 
of rats with faecal peritonitis the peritoneum still was not healed 8 days after bacterial 
injury15. This delay in peritoneal healing may not only be explained by the severity 
of peritoneal injury but by the repeated laparotomies and the presence of residual 
intra-abdominal abscesses in these rats. 
The effect of removal of the infectious focus on fibrinolytic activity has not been investigated 
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sofar. There is scarce information on the effect of surgery itself on the fibrinolytic activity. 
Recently, a biphasic fibrinolytic response of human peritoneal fluid to elective abdominal 
surgery was found by Scott-Coombes et al.: an early reduction of PAA secondary 
to a reduction in tPA levels in the first 24 hours after surgery and subsequent loss 
of PAA due to an increase in PAM and PAI-2 concentrations in the following 24 hours20. 
The influence of surgery on fibrinolytic activity of rabbit peritoneal macrophages has 
been described by Orita et af1. They have demonstrated a reduction in PAA of macrophages 
recovered from the peritoneal fluid on the first and second postoperative day, followed 
by an increase in PAA reaching peak values on the 14th postoperative day. They have 
not determined if a rise in tPA or urokinase-type plasminogen activator (uPA) or a 
decline in PAI-2 was responsible for the rise in PAA after the second postoperative 
day. 
Based on the above mentioned it is hypothesized that patients with severe intra-abdominal 
infection suffer from a prolonged activation of the coagulation cascade in the abdominal 
cavity, a prolonged depression of fibrinolytic activity because of persistently elevated 
PAI levels, and a delay in peritoneal healing because of severe peritoneal damage. 
Repeated laparotomies in these patients might contribute to continuous activation of 
coagulation and might jeopardize peritoneal healing and regeneration of fibrinolytic 
activity. 
The sequential changes in coagulation and fibrinolysis in the abdominal cavity during 
intra-abdominal infection and after surgical elimination of the infectious focus need 
to be further elucidated. Moreover, the contribution of various cells such as mesothelial 
cells, endothelial cells and peritoneal macrophages to the coagulation and fibrinolytic 
processes is largely unknown. Future studies should address these topics in order 
to fully understand why in some circumstances fibrin deposits persist in the abdominal 
cavity and cause intra-abdominal abscesses. 
2. The effect of enhancement of fibrinolytic activity on intra-abdominal abscess 
formation 
Fibrin deposition in the abdominal cavity may be prevented by inhibition of the intraperitoneal 
coagulation cascade and/or enhancement of the intraperitoneal fibrinolytic activity. 
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Inhibition of the coagulation cascade 
Heparin has shown to be successful in several experimental studies, reducing intra-abdominal 
abscess formation and preventing mortality from peritonitis22"25. Major drawbacks of 
heparin, however, are the unpredictable anticoagulant effect and the risk of bleeding. 
More selective antithrombotic agents, such as low molecular weight heparins, hirudin, 
specific factor Xa inhibitor and anti-TF have recently been studied in experimental 
models of arterial and venous thrombosis and in experimental endotoxaemia26"29. These 
agents may not only be useful in attenuating intra-abdominal fibrin formation, but also 
to unravel the pathways involved in intra-abdominal coagulation. 
Enhancement of the fibrinolytic activity 
We have used human recombinant tPA (rtPA) to enhance the intra-abdominal fibrinolytic 
activity, in order to prevent intra-abdominal abscess formation in experimental peritonitis30. 
It was hypothesized that rtPA would have a pronounced local effect because of its 
high affinity for fibrin, and a minimal systemic fibrinolytic effect, because of high circulating 
PAI levels in peritonitis. Our study on the pharmacokinetics of rtPA and those on prevention 
of experimental intra-abdominal abscesses seem to support this hypothesis. 
Administration of rtPA early in the course of peritonitis successfully reduced intra-abdominal 
abscess rate. In this period endogenous PAI activity still was relatively low, which may 
have contributed to this success. Later in the course of peritonitis, treatment with rtPA 
probably is less-effective due to inhibition by PAI and to resistance of fibrin deposits 
to lysis by cellular invasion and collagen production. This may have implications for 
the use of rtPA in the clinical situation, as in patients the infectious process may be 
present for some time before institution of therapy. 
In patients with generalized bacterial peritonitis rtPA may increase the risk of bacteraemia. 
This risk probably is low, since most patients with generalized peritonitis are treated 
systemicalty with (broad-spectrum) antibiotics for several days. Local efficacy of antibiotics 
is expected even to be increased, as bacteria are no longer protected by fibrin in the 
abdominal cavity. 
Another risk of the use of rtPA in patients with peritonitis is bleeding. In our animal 
experiments this complication was not observed, most likely due to high concentrations 
of PAI in the plasma during peritonitis. In patients with peritonitis we did not find elevated 
plasma PAI concentrations. This might be explained by the local character of the infectious 
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process in the majority of our patients. Paramo et al. demonstrated strongly elevated 
plasma levels of PAI in patients with generalized infectious processes31. 
Fibrinolytic activity in the abdominal cavity may also be influenced by inhibition of PAI 
with, for example, PAM neutralizing monoclonal antibody. Recently, it has been 
demonstrated that PAI-1 monoclonal antibody promotes endogenous thrombolysis 
in experimental models of venous and arterial thrombosis32. The use of antagonists 
towards plasminogen activator inhibitors may not only be of therapeutic interest but 
to study the non-inhibited endogenous tPA and uPA activity in the abdominal cavity 
during peritoneal healing. 
Inhibition of inflammatory cytokines is a less specific approach to influence fibrinolytic 
activity in order to prevent intra-abdominal abscess formation. Anti-TNF antibodies 
have shown to abolish plasma PAI-1 activity in experimental endotoxaemia33. However, 
tPA activity was also completely blocked. Similar results were obtained with the use 
of pentoxifylline33. In a study of Chalkiadakis et al., pentoxifylline reduced the development 
of abscesses in the abdominal cavity of rats with peritonitis, which effect was attributed 
to increased fibrinolytic activity34. 
Modulation of coagulation and/or fibrinolysis in the abdominal cavity by the intra-abdominal 
administration of drugs may be a useful adjunct to surgery in patients with generalized 
peritonitis and a high risk of developing a residual intra-abdominal infection. In combination 
with appropriate antibiotics infection may be cleared very rapidly, preventing the deleterious 
local and systemic effects of persistent intra-abdominal infection. 
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Patients with severe intra-abdominal infection, caused for example by perforation of 
the colon, leakage of intestinal anastomoses or pancreatic necrosis, have a poor 
prognosis. Conventional operative therapy in this condition frequently results in persistent 
or recurrent intra-abdominal infection. 
Persistence of fibrin deposits in the abdominal cavity is associated with development 
of residual intra-abdominal infection. Removal of fibrin may beneficially influence residual 
infection rate and patient outcome. New operative methods, characterized by meticulous 
removal of all infection potentiating material, such as fibrin, from the abdominal cavity 
have reduced the incidence of persistent or recurrent infection. However, morbidity 
associated with these methods is high and improved survival is not evident. 
In this thesis we focused on fibrin formation and fibrin degradation in the abdominal 
cavity during peritonitis and the effect of enzymatical removal of fibrin on residual intra-
abdominal infection, in a search for adjuvant treatment to surgery in patients with severe 
intra-abdominal infection. 
Chapter 2 describes the anatomy and (patho)physiology of the abdominal cavity. Local 
host defenses are described, including the formation of fibrin in the abdominal cavity. 
The dualistic character of fibrin is outlined: on the one hand sequestration of bacteria, 
preventing bacteraemia, on the other hand impairment of other local defenses, which 
may lead to residual intra-abdominal infection. 
In Chapter 3 the definitions and aetiology of intra-abdominal infections are outlined. 
Most frequently used are the terms: primary, secondary and tertiary peritonitis. Secondary 
peritonitis, which is caused by perforation or transmural necrosis of the gastrointestinal 
tract is most important for surgeons. In this condition a polymicrobial flora of gut derived 
bacteria will be isolated from the abdominal cavity in most cases. 
Chapter 4 focuses on the surgical treatment of intra-abdominal infection. Elimination 
of the source of infection and debridement and lavage of the abdominal cavity are 
the cornerstones of operative treatment. Various surgical options of treatment after 
the initial operation in patients with severe intra-abdominal infection are discussed. 
The optimal surgical strategy is still under debate. 
In Chapter 5 the coagulation cascade, the fibrinolytic system, intra-abdominal coagulation 
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and fibrinolytic processes in peritonitis and the possibilities to modulate intra-abdominal 
fibrin deposition are outlined. During infection, intra-abdominal coagulation is enhanced 
and fibrinolytic activity in the peritoneum is depressed. This latter is held responsible 
for persistence of fibrin deposits in the abdominal cavity. 
There are scarce data on successful modulation of intra-abdominal coagulation and 
fibrinolysis in experimental peritonitis; clinical data are lacking. 
In Chapter 6 an analysis of the intra-abdominal complications of "planned relaparotomy" 
in 24 patients with severe generalized peritonitis is reported and an attempt has been 
made to define when to stop relaparotomies. Intra-abdominal complications occurred 
in 71 % of the patients, more frequently in nonsurvivors than in survivors, and correlated 
strongly with the number of planned relaparotomies. 
Control of intra-abdominal infection (less than 103 colony forming units (cfu) per ml 
microorganisms) was achieved after three relaparotomies in the majority of patients. 
Organ dysfunction, as measured by the MOF score, remained unchanged in the first 
week of "planned relaparotomy". 
It is concluded that "planned relaparotomy" introduces pronounced morbidity and does 
not reverse organ dysfunction at the short run. The - less than 103 cfu/ml - criteria 
may be useful for the decision to cease relaparotomies. 
In Chapter 7 we report on early and long term results of necrosectomy, planned re-
explorations and "open" drainage in the management of 10 patients with infected 
pancreatic necrosis. Three patients died because of multiple organ failure. In half of 
the patients complications such as intra-abdominal haemorrhage, necrosis of the 
transverse colon and enterocutaneous fistula were encountered. None of the patients 
developed a residual intra-abdominal abscess. 
One patient developed steatorrhoea, another developed insulin dependent diabetes 
mellitus during follow-up. All non-diabetic patients had an impaired glucose tolerance 
and significantly elevated glucagon and insulin serum levels compared to matched 
healthy volunteers. 
It is concluded that this treatment method prevents residual intra-abdominal abscesses 
in patients with infected pancreatic necrosis but is associated with pronounced morbidity. 
Long term glucose metabolism is disturbed, as demonstrated by impaired glucose 
tolerance and elevated serum insulin and glucagon levels. 
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Chapter 8 describes the coagulation and fibrinolytic responses of the peritoneal fluid 
and plasma to bacterial peritonitis in humans. In 25 patients with bacterial peritonitis 
and seven control patients, thrombin-antithrombine III (TAT) complex (measure of 
activation of coagulation), tissue-type plasminogen activator (tPA), urokinase-type 
plasminogen activator (uPA), plasminogen activator inhibitor (PAI), plasmin-or2-antiplasmin 
(PAP) complex (measure of stimulation of fibrinolysis) and fibrin degradation products 
(FbDP) were measured in the peritoneal fluid and plasma. 
TAT complex was significantly higher in the peritoneal fluid of patients with peritonitis 
than in control patients. Peritoneal fluid concentrations of tPA and uPA in peritonitis 
were increased by a factor 65 and 10, respectively; concentrations of PAI (inhibitor 
of tPA and uPA) by a factor 400. Despite high intra-abdominal PAI concentrations, 
intra-abdominal fibrinolysis was stimulated in peritonitis patients in comparison with 
controls, as reflected by significantly higher PAP complex and FbDP. Plasma 
concentrations of uPA and FbDP were significantly higher in peritonitis patients, as 
compared with controls. No correlations were found between plasma and peritoneal 
fluid levels. 
It is concluded that in bacterial peritonitis, both intra-abdominal coagulation and fibrinolysis 
are stimulated. However, due to inhibition of plasminogen activators, fibrinolytic activity 
may not meet its demand. 
In Chapter 9 the activities of tPA and PAI were measured in the peritoneal fluid of 
rats with faecal peritonitis (intra-abdominal injection of sterilized faeces contaminated 
with 104 cfu/ml Escherichia coli (E coli) and Bacteroides fragilis (B. fragilis) to determine 
the cause of persistence of intra-abdominal fibrin with subsequent adhesion and abscess 
formation. These activities were correlated with the extent of peritoneal damage. 
Activity of tPA was low during the study period of 8 days. In rats with peritonitis, tPA 
activity was higher than in controls. The activity of PAI in rats with peritonitis was 
significantly increased compared with controls during the whole study period. Histological 
signs of damage to the peritoneum were similar in rats with peritonitis and controls. 
There was no correlation between the extent of peritoneal damage and tPA or PAI 
activity. 
The increased activity of PAI in the peritoneal fluid of rats with faecal peritonitis may 
be the main cause of reduced fibrinolysis in the abdominal cavity. Activities of tPA 
and PAI may originate not only from the mesothelium but from other sources. 
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Chapter 10 provides data on the in vitro interaction between human recombinant tPA 
(rtPA) and the rat fibrinolytic system. There were several cross-reactivities between 
human rtPA and rat factors, as deduced from lysis of rat clots by human rtPA, 
plasminaemic fibrinogen and fibrin degradation in rat plasma by human rtPA, and 
inhibition of human rtPA by rat PAI. However, rat plasma clots seemed to be more 
resistant to lysis by human rtPA in comparison with human plasma clots. Moreover, 
the assay to detect fibrin degradation products was less sensitive to rat FbDP than 
human FbDP. Streptokinase was unable to lyse rat plasma clots. 
The interaction between human rtPA and components of the rat fibrinolytic system 
makes the rat a useful animal for studies on modulation of fibrinolytic activity by human 
rtPA in peritonitis. 
Chapter 11 describes the pharmacokinetics of human rtPA, when administered 
intraperitoneally in rats with faecal peritonitis. In the first experiment the endogenous 
tPA and PAI activity in the peritoneal fluid and plasma were measured in rats with 
faecal peritonitis. In the second experiment tPA antigen and tPA activity were measured 
in both compartments after intra-abdominal administration of a single dose of either 
0.5 mg/ml or 2.0 mg/ml human rtPA to rats with peritonitis. 
Endogenous tPA activity in the peritoneal fluid was only slightly elevated, whereas 
endogenous PAI activity showed a strong increase with a peak at 16 hours. In plasma 
only PAI activity was increased. 
Both doses of human rtPA substantially enhanced fibrinolytic activity of the peritoneal 
fluid up to 24 hours. However, tPA activity measured in the peritoneal fluid of rats with 
peritonitis was lower than that calculated from the measured tPA antigen levels. Plasma 
tPA activity was low at both doses. Use of a gel in comparison with Ringer's lactate 
solution, as a solvent of rtPA, lowered the plasma concentration of tPA antigen. 
A single dose of 0.5 mg/ml or 2.0 mg/ml human rtPA will raise fibrinolytic activity in 
the abdominal cavity up to 24 hours. High concentrations of endogenous PAI in the 
peritoneal fluid may adversely effect intra-abdominal use of human rtPA in peritonitis. 
The risk of bleeding, associated with the (intra-abdominal) use of rtPA in peritonitis, 
is probably low. 
In Chapter 12 the effect of increasing the intra-abdominal fibrinolytic activity on abscess 
formation by intra-abdominal administration of human rtPA in rats with faecal peritonitis 
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is reported (the peritonitis model has been described in Chapter 9). 
Rats, treated with rtPA dissolved in methyl hydroxy propyl cellulose (MHPC) gel (0.5 
mg per ml), which was used as a vehicle, had significantly less intra-abdominal abscesses 
than rats in the control groups, given either Ringer's lactate solution or MHPC gel 
alone. Other than E. coli, cultures of abscesses revealed species originating from the 
intestine, demonstrating bacterial translocation. The mortality rate was significantly 
higher in rats treated with rtPA as compared with controls, which was surprising 
considering the absence of bacteraemia. By challenging the rats with a higher dose 
of E. coli in the inoculum (10s cfu/ml), early bacteraemia was observed in the rats 
treated with rtPA, not related to increased mortality rates. Intra-abdominal use of rtPA 
was not associated with an increased incidence of bleeding events. 
Recombinant tissue-type plasminogen activator prevents abscess formation in rats 
with faecal peritonitis. However, early bacteraemia and increased mortality rates are 
serious drawbacks of the intra-abdominal use of rtPA in this rat model. 
In Chapter 13 the effect of gentamicin on mortality and bacteraemia, which are induced 
by intraperitoneal administration of rtPA in rats with faecal peritonitis, as described 
in the previous chapter, is studied. 
Gentamicin significantly reduced the number of rats with bacteraemia, the bacterial 
concentration in the blood, and mortality at the high dose E.coli in the inoculum 
(108 cfu/ml). Although none of the rats at the low dose E. coli in the inoculum (104 cfu/ml) 
developed bacteraemia, gentamicin prevented mortality associated with the use of 
rtPA. The number of abscesses in animals treated with rtPA was significantly lower 
than in those not treated with rtPA. Gentamicin did not influence the number of 
abscesses. 
It is concluded that gentamicin reduces bacteraemia and mortality in rats with faecal 
peritonitis treated with rtPA, that is administered intraperitoneally to prevent intra-
abdominal abscess formation. 
Chapter 14 contains the general discussion. Both the coagulation cascade and the 
fibrinolytic system in the abdominal cavity are stimulated, as a response to intra-
abdominal infection. However, due to a concomitant increase of inhibitors of the fibrinolytic 
system, fibrinolytic activity may not meet its demand. As a result fibrin may persist 
in the abdominal cavity, become organized and may promote residual intra-abdominal 
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infection. Increasing the fibrinolytic activity in the abdominal cavity by means of rtPA 
in combination with antibiotic treatment, is effective and safe in the prevention of residual 
intra-abdominal infection in rats with faecal peritonitis. 
Further longitudinal studies are needed to elucidate the changes in coagulation and 
fibrinolysis in the abdominal cavity during peritonitis and after elimination of the infectious 
focus, in order to understand why in some circumstances fibrin persists and promotes 
residual intra-abdominal infection, and fibrinolytic therapy may be indicated. 
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De prognose van patiënten met een ernstige intra-abdominale infectie, veroorzaakt 
door bijvoorbeeld een colonperforatie, lekkage van een intestinale anastomose of 
pancreas necrose is slecht. De behandeling van deze patiënten is niet altijd succesvol 
met als gevolg aanwezig blijven of het opnieuw optreden van intra-abdominale infectie. 
Er is een verband tussen het aanwezig blijven van fibrinedeposities in de buikholte 
en de ontwikkeling van restinfectie. Verwijdering van fibrine zou het percentage 
restinfectie en daarmee de prognose van de patiënt gunstig kunnen beïnvloeden. 
Nieuwe operatieve methoden, die worden gekenmerkt door het zorgvuldig uit de buikholte 
verwijderen van al het infectie onderhoudende materiaal -zoals fibrine-, hebben de 
frequentie van optreden van restinfectie gereduceerd. De morbiditeit van deze methoden 
is echter hoog en een gunstig effect op de overleving is niet duidelijk aangetoond. 
De fibrinevorming en -afbraak in de buikholte tijdens peritonitis en het effect van, op 
enzymatische wijze, verwijderen van fibrine op het optreden van restinfectie in de buik, 
als aanvullende behandeling op de operatie bij patiënten met een ernstige intra-
abdominale infectie staat centraal in dit proefschrift. 
Hoofdstuk 2 bevat de beschrijving van de anatomie en de (patho)fysiologie van de 
buikholte. De locale afweermechanismen worden beschreven, waaronder de 
fibrinevorming in de buikholte. De tweeledige werking van fibrine wordt uiteengezet: 
enerzijds het sequestreren van bacteriën in de buikholte, waardoor bacterie mie wordt 
voorkomen, anderzijds het remmen van andere locale afweer mechanismen, hetgeen 
kan leiden tot restinfectie in de buik. 
In Hoofdstuk 3 worden de definities en etiologie van intra-abdominale infecties 
uiteengezet. De termen primaire, secundaire en tertiaire peritonitis worden het meest 
frequent gebruikt. Secundaire peritonitis, die wordt veroorzaakt door een perforatie 
of transmurale necrose van de tractus digestivus, is voor chirurgen de belangrijkste 
vorm van peritonitis. Meestal wordt bij deze vorm een polymicrobiële darmflora uit 
de buikholte geïsoleerd. 
In Hoofdstuk 4 staat de chirurgische behandelwijze van intra-abdominale infecties 
centraal. De hoekstenen van de operatieve behandeling zijn het opruimen van de 
infectiebron, het verwijderen van debris en het spoelen van de buikholte. De diverse 
chirurgische behandelingsmogelijkheden na de eerste operatie bij patiënten met een 
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ernstige intra-abdominale infectie worden besproken. De optimale behandelingsstrategie 
staat nog ter discussie. 
In Hoofdstuk 5 worden achtereenvolgens uiteengezet: de stollingscascade, het 
fibrinolytische systeem, de stollings- en fibrinolytische processen in de buik tijdens 
peritonitis en de mogelijkheden om fibrine-afzetting in de buik te beïnvloeden. Tijdens 
infectie wordt de stolling in de buik geactiveerd en de fibrinolytische activiteit van het 
peritoneum onderdrukt. Dit laatste wordt verantwoordelijk geacht voor het aanwezig 
blijven van fibrinedeposities in de vrije buikholte. 
Er zijn weinig gegevens over succesvolle beïnvloeding van de stolling en fibrinolyse 
in de buik tijdens experimentele peritonitis; klinische gegevens ontbreken volledig. 
In Hoofdstuk 6 worden de intra-abdominale complicaties geanalyseerd die optraden 
bij 24 patiënten met ernstige gegeneraliseerde peritonitis en die zijn behandeld volgens 
de methode van de "geplande relaparotomie". Tevens wordt getracht te definiëren 
wanneer de relaparotomieé η moeten worden gestaakt. Intra-abdominale complicaties 
traden op bij 71% van de patiënten en frequenter bij patiënten die overleden. De 
complicaties stonden duidelijk in relatie met het aantal geplande relaparotomie ën. 
In de meeste patiënten was de intra-abdominale infectie onder controle (minder dan 
103 kolonie vormende eenheden micro-organismen per ml) na drie relaparotomieé'n. 
De mate van orgaanfalen, gemeten door middel van de MOF-score, veranderde niet 
gedurende de eerste week waarin geplande relaparotomie ën werden uitgevoerd. 
De conclusie luidt dat de methode van de "geplande relaparotomie" gepaard gaat 
met een hoge morbiditeit en dat de orgaanfunctie op korte termijn niet verbetert. Het 
criterium " minder dan 103 kolonie vormende eenheden micro-organismen per ml" 
is misschien van nut voor de beoordeling wanneer de relaparotomieën moeten worden 
gestaakt. 
In Hoofdstuk 7 doen wij verslag van de vroege en late resultaten van verwijdering 
van necrose, geplande reëxploraties en open drainage als behandelingsmethode bij 
10 patiënten met geïnfecteerde necrose van het pancreas. Drie patiënten stierven ten 
gevolge van meervoudig orgaanfalen. De helft van de patiënten had abdominale 
complicaties zoals een bloeding, necrose van het colon transversum en enterocutane 
fistelvorming. Bij geen van de patiënten werd een restabces in de buik gevonden. 
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Tijdens de follow-up ontwikkelde één patiënt een steatorrhoe en een andere patiënt 
een insuline afhankelijke diabetes mellitus. Alle niet-diabetische patiënten hadden op 
de lange termijn een gestoorde glucose tolerantie, gepaard gaande met significant 
hogere insuline en glucagon spiegels in het serum in vergelijking met gematchte gezonde 
vrijwilligers. 
Hoewel deze behandelingsmethode restabcessen in de buik voorkomt, gaat zij gepaard 
met een hoge morbiditeit. Zoals blijkt uit de verminderde glucose tolerantie en de 
verhoogde insuline en glucagon spiegels is het glucose metabolisme op langere termijn 
gestoord. 
In Hoofdstuk 8 wordt de activatie beschreven van stolling en fibrinolyse in het buikvocht 
en het plasma van patiënten met een bacterie Ie peritonitis. Bij 25 patiënten met een 
bacterie Ie peritonitis en zeven controle patiënten werden het trombine-antitrombine 
III (TAT) complex (maat voor de stollingsactivatie), tissue-type plasminogeen activator 
(tPA), urokinase-type plasminogeen activator (uPA), plasminogeen activator inhibitor 
(PAI), plasmine-o2-antiplasmine (PAP) complex (maat voor de stimulatie van de 
fibrinolysis) en de fibrine afbraakproducten (FbDP) gemeten in het buikvocht en het 
plasma. 
Het TAT complex in het buikvocht was significant hoger bij de patiënten met een 
peritonitis dan bij de controle patiënten. De buikvochtconcentraties van tPA en uPA 
waren 65 respectievelijk 10 maal verhoogd tijdens peritonitis; de PAI (remmer van 
tPA en uPA) concentratie was 400 maal verhoogd. Ondanks de hoge PAI spiegels 
was er, gezien de hogere PAP complex en FbDP concentraties, sprake van fibrinolyse 
in de buik. 
In het plasma van peritonitis patiënten waren in vergelijking met controle patiënten 
alleen het uPA en de FbDP significant verhoogd. 
Er mag worden gesteld dat zowel de stolling als het fibrinolytische systeem in het 
buikvocht van patiënten met een bacteriële peritonitis is gestimuleerd. Het lijkt er echter 
op dat de fibrinolytische activiteit onvoldoende is ten gevolge van de gelijktijdige remming 
van plasminogeen activatoren. 
Op zoek naar de oorzaak van adhesie- en abcesvorming in de buik worden in Hoofdstuk 
9 de activiteiten van tPA en PAI gemeten in het buikvocht van ratten met een faecale 
peritonitis en gerelateerd aan de mate van uitbreiding van de peritoneumbeschadiging. 
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Hoewel de tPA activiteit gedurende de hele studieperiode van 8 dagen laag was, bleek 
deze hoger in ratten met peritonitis. De PAI activiteit was significant hoger in ratten 
met een peritonitis dan in controle ratten. In beide groepen ratten was histologisch 
gezien de peritoneumbeschadiging hetzelfde. Er bestond geen verband tussen de 
mate van uitbreiding van de peritoneumbeschadiging en de tPA en PAI activiteit. 
Waarschijnlijk is de toegenomen PAI activiteit in het buikvocht van ratten met een 
faecale peritonitis de belangrijkste oorzaak van de afgenomen fibrinolyse in de buikholte. 
Andere bronnen dan het mesotheel zouden verantwoordelijk kunnen zijn voor deze 
tPA en PAI activiteit. 
Hoofdstuk 10 bevat gegevens over de in vitro interactie tussen humaan recombinant 
tPA (rtPA) en het fibrinolytische systeem van de rat. Er werden diverse kruisreacties 
tussen humaan rtPA en rattefactoren gevonden: humaan rtPA lost 'rattestolsels' op, 
humaan rtPA leidt tot piasmine gemedieerde afbraak van fibrinogeen en fibrine, en 
humaan rtPA wordt geremd doorratte-PAI. 'Rattestolsels' lijken echter meer resistent 
te zijn tegen afbraak door humaan rtPA dan humane stolsels. Bovendien is de 
laboratoriumtest, waarmee fibrine afbraakprodukten worden aangetoond, minder gevoelig 
voor ratte-FbDP dan humane-FbDP. Streptokinase was niet in staat rattestolsels op 
te lossen. 
Vanwege de interactie tussen humaan rtPA en delen van het fibrinolytische systeem 
in de rat, is de rat een goed proefdier om beïnvloeding van de fibrinolytische activiteit 
door middel van humaan rtPA tijdens peritonitis te bestuderen. 
In Hoofdstuk 11 wordt de pharmacokinetiek van intraperitoneaal toegediend humaan 
rtPA bij ratten met een faecale peritonitis beschreven. Allereerst werd de endogene 
tPA en PAI activiteit in het buikvocht en het plasma gemeten. Vervolgens werd zowel 
het tPA antigeen als de tPA activiteit gemeten na éénmalige intraperitoneale toediening 
van 0.5 mg/ml of 2.0 mg/ml humaan rtPA. 
Het bleek dat de endogene tPA activiteit in het buikvocht slechts licht verhoogd was, 
terwijl de PAI activiteit een sterke toename liet zien bij peritonitis, met een piek op 
16 uur na het ontstaan van de peritonitis. In het plasma was alleen de PAI activiteit 
verhoogd. 
Met beide doseringen humaan rtPA werd er gedurende de eerste 24 uur een aanzienlijke 
verhoging van de fibrinolytische activiteit bereikt in het buikvocht van alle ratten. In 
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ratten met een peritonitis was de gemeten tPA activiteit echter lager dan te verwachten 
was op basis van de gemeten tPA antigeen spiegels. Met beide doseringen bleef de 
plasma tPA activiteit relatief laag. Bij het gebruik van een gel als medium, waarin rtPA 
werd opgelost in plaats van Ringer's lactaat, was de tPA antigeen concentratie in het 
plasma lager. 
Een éénmalige toediening van 0.5 mg/ml of 2.0 mg/ml humaan rtPA is in staat de 
fibrinolytische activiteit in de buikholte gedurende 24 uur te verhogen. Het intra-
peritoneaal gebruik van humaan rtPA bij peritonitis wordt mogelijk nadelig beïnvloed 
door de hoge PAI concentraties in het buikvocht. Het risico van bloedingen bij gebruik 
van rtPA in de buik bij peritonitis is zeer waarschijnlijk laag. 
In Hoofdstuk 12 wordt verslag gedaan van het effect van verhoging van de fibrinolytische 
activiteit in de buikholte op het ontstaan van abcessen bij ratten met een faecale 
peritonitis door het intra-abdominaal toedienen van humaan rtPA (beschrijving peritonitis 
model in Hoofdstuk 9). 
Er kwamen minder intra-abdominale abcessen voor bij ratten behandeld met rtPA, 
opgelost in methyl hydroxy propyl cellulose (MHPC) gel (0.5 mg/ml) dan bij controle 
ratten, behandeld met MHPC alleen danwei met Ringer's lactaat oplossing. Uit de 
abcessen werd niet alleen de ingebrachte E. coli gekweekt, maar ook bacterën afkomstig 
uit de darm van de rat, hetgeen een aanwijzing is voor bacteriële translocatie. De 
mortaliteit van ratten behandeld met rtPA was hoger dan van controle ratten, hoewel 
tot onze verbazing een bacterie mie niet werd aangetoond. Indien de ratten werden 
blootgesteld aan een hogere dosis E. coli in het inoculum (10s kolonie vormende 
eenheden per ml) trad wel in een vroeg stadium een bacterie mie op. Echter dit kon 
niet worden gerelateerd aan een toegenomen sterfte. Er was geen relatie tussen het 
gebruik van rtPA en het optreden van bloedingscomplicaties. 
Recombinant tPA voorkomt de vorming van intra-abdominale abscessen in ratten met 
een faecale peritonitis. De vroeg optredende bacterie mie en de verhoogde mortaliteit 
zijn belangrijke nadelen van het intra-abdominaal gebruik van rtPA in dit rattemodel. 
In Hoofdstuk 13 wordt het effect van gentamicine bestudeerd op bacterie mie en 
mortaliteit, die worden veroorzaakt door het intra-abdominaal toedienen van rtPA bij 
ratten met een faecale peritonitis, zoals werd beschreven in het vorige hoofdstuk. 
Bij de hoge dosering E. coli (10e kolonie vormende eenheden per ml) leidde gentamicine 
195 
Samenvatting 
tot een significante verlaging van: (1) het aantal ratten met een bacterie mie, (2) de 
bacteriële concentratie in het bloed en (3) de mortaliteit. Gentamicine voorkwam sterfte 
door rtPA bij de lage dosering E. colico* kolonie vormende eenheden per ml), hoewel 
geen enkele rat een bacteriëmie ontwikkelde. Dieren die met rtPA waren behandeld 
hadden significant minder abcessen dan dieren die niet met rtPA waren behandeld. 
Gentamicine had geen invloed op het aantal abcessen. 
In conclusie: gentamicine verlaagt het aantal bacteriëmieën en de mortaliteit bij ratten 
met een faecale peritonitis, die intraperitoneaal rtPA krijgen toegediend om intra-
abdominale abcessen te voorkomen. 
Hoofdstuk 14 bevat de algemene beschouwing. Bij een intra-abdominale infectie is 
zowel de stollingscascade als het fibrinolytische systeem in de buikholte geactiveerd. 
Het lijkt er echter op dat de fibrinolytische activiteit onvoldoende is gestimuleerd ten 
gevolge van een gelijktijdige verhoging van remmers in het fibrinolytische systeem. 
Dientengevolge kan fibrine aanwezig blijven, zich organiseren en vervolgens een bron 
van restinfectie worden in de buik. In ratten met een faecale peritonitis kan restinfectie 
op een veilige manier worden voorkomen door het verhogen van de fibrinolytische 
activiteit in de buikholte met behulp van rtPA, in combinatie met antibiotica. 
De veranderingen in de tijd van het stollings- en fibrinolytische proces in de buikholte 
tijdens peritonitis en na het verwijderen van de bron van infectie moeten nader worden 
bestudeerd. De vraag waarom in sommige omstandigheden fibrine in de buikholte 
aanwezig blijft en leidt tot restinfectie, en er een indicatie bestaat voor fibrinolytische 
therapie, kan hiermee mogelijk worden beantwoord. 
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voor leken die leken lijken 
en niet-leken die leken blijken 
In dit proefschrift heeft fibrine een centrale rol. Fibrine is de 'weefsellijmstof in ons 
lichaam. Het is het eindproduct van het stollingsproces. Dit proces komt bijvoorbeeld 
op gang wanneer er een wond ontstaat of wordt gemaakt met letsel van bloedvaten. 
Een netwerk van fibrine dicht dan het gat in een bloedvat en zo komt de bloeding 
tot staan. Deze werking van fibrine is in principe tijdelijk. Na enige tijd wordt fibrine 
weer afgebroken en treedt definitieve wondgenezing op. 
Ook bij ontstekingen in het lichaam wordt fibrine gevormd. Zo wordt tijdens een operatie 
van patiënten met een blindedarmontsteking of een doorgebroken maagzweer meestal 
fibrine in de buik waargenomen. Deze fibrine vormt netwerken (verklevingen) en omsluit 
hiermee bacteriën en andere schadelijke stoffen die in de buik zijn gekomen. Zo kunnen 
deze niet in de bloedbaan komen en aanleiding geven tot een bloedvergiftiging. Dit 
is dus van groot voordeel voor de patiënt. 
Een nadeel is echter dat bacteriën worden afgeschermd van afweercellen van het 
eigen lichaam, die normaal gesproken bacteriën doden en afbreken. Ook werken 
antibiotica veel minder goed tegen bacteriën die in fibrine zijn 'gevangen'. Hierdoor 
zijn bacteriën in staat, in een min of meer beschermde omgeving van fibrine, zich te 
vermenigvuldigen en allerlei stoffen afte geven die schade toebrengen aan het lichaam. 
Op den duur ontstaat een abces in de buik. Patiënten hebben dan hoge koorts, last 
van zweten, buikpijn, verminderde eetlust en vermagering. Uiteindelijk kunnen ze zelfs 
overlijden aan een dergelijk abces. 
Dus: fibrine heeft zowel een gunstige werking als een ongunstige werking bij een infectie 
in de buik. 
De gunstige werking van fibrine -het voorkomen dat bacteriën via de bloedbaan schade 
aanrichten- kan tegenwoordig goed worden overgenomen door antibiotica. Deze zorgen 
ervoor dat de bacteriën die in de bloedbaan komen onmiddellijk worden gedood. 
Tegen de ongunstige werking van fibrine -het ontstaan van abcessen- is tot op heden 
nog geen afdoend middel gevonden. 
Er bevinden zich in de buik stoffen, afkomstig van cellen die de vrije buikholte bekleden, 
die fibrine kunnen oplossen (=tPA). Wij hebben aangetoond dat tPA in verhoogde 
hoeveelheden aanwezig is in de buikholte bij een buikvliesontsteking. Toch worden 
de fibrine-netwerken niet opgelost; enerzijds omdat er een continue aanmaak is van 
fibrine, anderzijds omdat de tPA wordt geremd. Tijdens een infectie bleken er namelijk 
ook grote hoeveelheden remmende stoffen'van tPA (=PAI) aanwezig te zijn in de 
buikholte. Er is dus een verstoring ontstaan in de balans tussen fibrine-aanmaak en 
-afbraak op een zodanige wijze dat deze fibrine-netwerken langdurig in de buik aanwezig 
blijven en zich zelfs verstevigen. 
'Breakthrough' by Marijke van Balen 
Dat fibrine de bron is van abcessen in de buikholte bij infecties, is al enige tijd geleden 
onderkend. Om deze reden zijn operatiemethoden ontwikkeld, die gericht zijn op het 
steeds maar weer verwijderen van fibrine-netwerken die verklevingen vormen tussen 
de diverse buikorganen. Deze methoden hebben als nadeel dat vaker dan één keer 
moet worden geopereerd en dat efl<e nieuwe operatie weer leidt tot nieuwe fibrinevorming. 
Ook kan het verwijderen van verklevingen met de hand, de schaar of het pincet gaatjes 
veroorzaken in de darm of bloedvaten, waardoor ontlasting in de vrije buikholte kan 
komen of bloedingen optreden en hierdoor de infectie wordt verergerd. Door deze 
complicaties hebben dergelijke operatiemethoden in het algemeen niet het gewenste 
resultaat opgeleverd. 
Een andere mogelijkheid om fibrine kwijt te raken is de locale verhoging van fibrine-
oplossende stoffen. Dit kan door bijvoorbeeld een dergelijke stof in de buik toe te dienen. 
Wij hebben de werking van een dergelijke fibrine-oplosser (=tPA) getest in ratten met 
een buikvliesontsteking. Het bleek inderdaad dat bij ratten die werden behandeld met 
tPA minder abcessen in de buikholte aanwezig waren. 
Naar verwachting nam wel het aantal bacteriën in de bloedbaan toe bij het gebruik 
van tPA. Dit ging ook gepaard met een verhoogde sterfte bij deze ratten. Echter zowel 
de hoeveelheid bacteriën in de bloedbaan alsmede de sterfte kon worden verminderd 
door het gelijktijdig gebruik van antibiotica. Waarschijnlijk krijgen bij gebruik van tPA 
de natuurlijke afweercellen (en antibiotica) de kans om de bacteriën in de vrije buikholte 
te doden. De combinatie van tPA en antibiotica lijkt dan ook doeltreffend in de strijd 
tegen het ontstaan van abcessen na een ernstige buikvliesontsteking. 
Natuurlijk moet een dergelijk fibrine-oplosmiddel eerst nog worden getest bij grotere 
proefdieren en bij mensen om uiteindelijk een adequaat middel in handen te hebben 
om abcessen na een buikvliesontsteking te kunnen voorkomen. 
Er is nog een lange weg van onderzoek te gaan... 

NAWOORD 
Doorgewinterde proefschriftlezers beginnen met het na- of dankwoord. Om deze reden 
is het nawoord vooral een voorwoord geworden. Bij dezen... 
Het idee achter dit proefschrift is ontstaan ¡n Wenen op een bankje voor paleis 
Schönbrunn (zie foto). tPA moest één van de ingrediënten worden van de 'ideale' 
spoelvloeistof voor 'vieze' buiken. Vol enthousiasme het concept uitgewerkt, onder 
genot van spinazie met knoflook (kok: Rob B.) en witte wijn, gevolgd door de tennismatch 
van het jaar. Na ruim vijf jaar het resultaat: geen 'ideale' spoelvloeistof, tPA werkt, 
maar hoe precies? Een nieuw Weens avontuur is wellicht noodzakelijk voor de 'juiste 
oplossing'. 
Enfin, beste Rob Bleichrodt, die grijze haren had ík je kunnen bezorgen. Je bezigde 
meermalen de term 'zelfrijzend bakmeel', maar vaak ontbrak het gist. Je bent meer 
dan de ideeënbedenker, de initiator en begeleider van dit proefschrift: een goede vriend 
met wie vele gezellige uurtjes zijn doorgebracht, waarbij er (onder andere) over het 
vak werd gepraat. Rob, zeer bedankt, je weet wel... 
Co-promotor dr. J. van der Meer, beste Jan, het is goed zaken doen met jou. Stagnatie 
in het onderzoek werd niet getolereerd. Je fibrinolytisch vermogen is ongekend, evenals 
je enthousiasme, efficiëntie, kennis van zaken en no-nonsense techniek van 
communiceren. Hartelijk dank! 
Promotor prof.dr. R.J.A. Goris, beste Jan, van mijn overstap van Groningen naar 
Nijmegen heb ik geen spijt. Er is een goede verstandhouding ontstaan. Dank voor 
de begeleiding bij het laatste deel van het proefschrift. De tweede set begint, zet je 
schrap! 
Dank ben ik verschuldigd aan dr. V.J.J. Bom. Beste Victor, jij was de bewaker van 
de assays en legde steeds genadeloos de zwakke plek in onze wetenschappelijke 
ideeën bloot. Discussiëren met jou was niet altijd even makkelijk, maar ik heb je bijdrage 
zeer gewaardeerd. 
Dr. W.J. Sluiter, beste Wim, sinds je de mathematische modellen hebt gemaakt van 
hetglucose-metabolisme bij portaal versus systemisch geschakelde pancreatica, ben 
ik niet meer van je losgekomen. Van het berekenen van CIR-waarden op een veredelde 
telmachine tot ingewikkelde statistische bewerkingen op een 486-er, je bent 
onnavolgbaar. Zonder jou had dit werk niet het predikaat 'statistisch relevant' gekregen. 
Wim....chapeau! 
Members of the manuscript committee, prof.dr. H. Wacha, prof.dr. H.M. Vemer and 
prof.dr. J.A.A. Hoogkamp-Korstanje, thank you for the speed in reviewing this manuscript 
during the warm summer of 1995. 
Een artikelenbevattend proefschrift heeft mede-auteurs. Een ieder heeft, op zijn of 
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in 'accepted'. Bedankt! 
Gedurende enkele jaren heb ik het stollingslaboratorium en de dependance van het 
streeklab onveilig gemaakt met buisjes bloed, buikvocht en pus. De flexibiliteit, waarmee 
medisch volk van allerlei pluimage tegemoet werd getreden, was opvallend. Haast 
ongewild ging ik me als chirurg thuisvoelen tussen agarplaten, erlenmeyers, -80-ers 
en ijklijnen. Dames en heren analisten en secretaresses, dit was een verdienste van 
jullie allemaal, houden zo! 
Gedurende de laatste anderhalf jaar heeft Myrna (Miranda) Verstegen zich gebogen 
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Marianne, van jou mocht ik geen hoogdravende woorden schrijven over'ontberingen', 
'gebrek aan gezinsleven', 'de verloren uurtjes inhalen', of 'dankzij' danwei 'ondanks'. 
Daarom houd ik het kort: ik hou van je. 
Tenslotte dank ik alle onderstaande personen die in de afgelopen jaren in meer of mindere 
mate betrokken zijn geweest bij dít proefschrift (in wording). Indien ik iemand heb 
vergeten...volgende keer beter! 
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STELLINGEN 
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FIBRINOLYTIC THERAPY IN 
GENERALIZED PERITONITIS 
TO PREVENT INTRAABDOMINAL 
ABSCESS FORMATION 
an experimental and clinical study 
Harm van Goor 
2 februari 1996 
1. De pathofysiologie van het ontstaan en 'oplossen' van adhesies is nog 
(lang) niet opgehelderd. 
2. De fibrinolytische activiteit in de buikholte berust niet op een aan-uit feno-
meen, maar op een nauwkeurige balans tussen remmers en stimulatoren 
van de fibrinolyse. 
3. Hoge PAI spiegels in het plasma tijdens peritonitis maken toepassing van 
hoge doseringen rtPA in de buik mogelijk, zonder dat systemische compli-
caties zullen optreden. 
4. Meer dan vier geplande relaparotomieé η bij 'septische' buiken biedt geen 
voordelen voor de patiënt. 
5. Na een acute necrotiserende pancreatitis is ook op de lange termijn een 
normale glucosetolerantie en een normale insuline-gevoeligheid niet te 
verwachten. 
6. Het 'systemisch schakelen' van een pancreastransplantaat is onlogisch. 
7. Zolang er een tekort bestaat aan orgaandonoren is er geen indicatie voor 
levertransplantatie bij patiënten met maligne tumoren van de lever of de 
galwegen. 
8. Congenital hypoplasia of the scaphoid bone must be regarded as a radial 
longitudinal hypoplasia, in which the limb is affected in a proximal-distal 
sequence, and not as an intercalary defect (JHand Surg i989,i4A:29i-4). 
9. NS 1996: eerste klas staat beter! 
10. Na een primaire traumatische schouderluxatie bij jonge mensen moet 
diagnostiek worden verricht naar het voorkomen van een afscheuring van 
het labrum glenoidale en indien aanwezig moet dit arthroscopisch worden 
gefixeerd. 
11. Gezien het stedelijk karakter van de recente (burger)oorlogen en de toene-
mende politieke bereidheid tot inzet van Nederlandse militairen daarbij, is 
het aan te bevelen in plaats van de mooiste natuurgebieden oude verval-
len stadswijken te gebruiken als militair oefenterrein. 
12. Een goede transplantatiecoó'rdinator is bij-de-hand. 
13. Het heffen van mannenbelasting onder het motto 'de vervuiler betaalt' 
geeft een nieuwe dimensie aan het begrip 'foute mannen'. 
14. In interviews met publieke media overschat de medicus vaak de kennis 
van het publiek, maar onderschat diens gezond verstand. 
15. Als in de operatiekamer de sfeer om te snijden is, is er geen sfeer om te 
snijden. 
16. Hoewel veel beproefd is de Nederlandse kookkunst een smakeloze vorm 
van kunst. 
17. Een echte omloop is nooit weg. 
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